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ABSTRACT 
Alpha ( 1,3)galactosyltransferase is the major xenoantigen associated with hyperacute 
rejection of xenotransplants. Tumor vaccines engineered to express this gene may show 
promise in breaking tumor tolerance. However there has been a lack of alternative tumor 
models to the highly published B16 with which to study the immunology associated with 
a(l,3) galactosyltransferase modified tumor vaccines. Moreover, limited in vivo models exist 
to study the basic biology of a(l,3) galactosyltransferase in xenotransplantation experiments. 
Therefore, we have developed a gastrointestinal stromal tumor, CA320M, derived from 
C57ZBL6 a(l,3)galactosyltransferase knock-out mice. Mice were subject to intraperitoneal 
injections of 9,10-dimethyl-1,2-benz-anthracene and 3-methylcholanthrene. Resultant tumors 
were harvested and characterized in vitro and in vivo. CA320M cells transduced with a 
herpes simplex virus amplicon vector (HE7agall) carrying the. murine a(l,3)GT gene 
resulted in significant agal epitope expression. CA320M cells expressing agal were 
incubated with normal human serum (NHS) or serum collected from a(l,3)GT KO mice 
immunized against agal (MS). Flow cytometric analysis of NHS exposed agal expressing 
cells demonstrated up to 97% complement lysis. Cells exposed to MS demonstrated up to 
35% cell killing. The approach, however, is based in part on the sensitivity of tumor cells to 
the effects of complement. Tumors expressing complement resistance factors such as 
membrane cofactor (CD46), decay accelerating factor (CD55) and protectin (CD59) have 
been shown to be more resistant to complement lysis. Anchored to the membrane by a 
glycosylphosphotidylinositol moiety (GPI-anchored), CD55 and CD59 can be cleaved by 
Bacillus thuringiensis phosphatidylinositol-specific phospholipase C (PIPLC). The PIPLC 
ix 
native signal sequence was replaced with the human epidermal growth factor signal 
sequence, EGFssPIPLC, to induce secretion from mammalian cells. Complement resistant 
A549 human lung carcinoma cells were engineered to express both the murine a(l,3)GT 
gene and the EGFssPIPLC gene, the latter to alleviate complement resistance and enhance 
agal-mediated cell killing. Expression of EGFssPIPLC resulted in complete removal of 
CD55 and CD59 while sparing the non-GPI-anchored CD46. Results demonstrated that 
secreted PIPLC did not affect agal epitope expression and that A549 cells expressing both 
the a(l,3)GT and EGFssPIPLC genes exhibited a 5-fold increase in sensitivity to anti-agal 
mediated complement lysis. 
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CHAPTER 1. GENERAL INTRODUCTION 
INTRODUCTION 
Gene Therapy 
Second to heart disease, cancer has become the leading cause of death in the United 
States. The American Cancer Society estimated in the year 2000 there would be 1.2 million 
new cases reported by the end of that year [1]. More staggering is that over 550,000 of those 
people would die of their disease, 6400 of whom reside here in Iowa. While progress in 
research on traditional chemotherapy is slow, new advances in non-traditional therapies such 
as the use of gene therapy and tumor vaccines shows great promise. 
Gene therapy developed out of the field of molecular and cell biology in the 1960's. 
Nobel Laureate Joshua Lederburg wrote in 1963: 
"We might anticipate the in vitro culture of germ cells and such manipulations as the 
interchange of chromosomes and segments. The ultimate application of molecular 
biology would be the direct control of nucleotide sequences in human chromosomes, 
coupled with recognition, selection and integration of the desired genes..." 
Nobel Laureate Edward Tatum stated on May 26,1966, at a symposium entitled "Reflections 
on Research and the Future of Medicine" held at Columbia University College of Physicians 
and Surgeons in New York City: 
"Finally we can anticipate that viruses will be used effectively for man's benefit, in 
theoretical studies concerning somatic cell genetics and possibly in genetic therapy.... 
We even can be somewhat optimistic about the long-range possibility of therapy 
based on the isolation or design, synthesis, and introduction of new genes into 
defective cells of particular organs." 
With the discovery of restriction endonucleases in the 1970's more sophisticated cloning 
tools were developed. Researchers hypothesized that the new technology could be applied to 
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correct somatic gene mutations responsible for human disease. It was further postulated that 
suicide genes could be transferred to cancer cells resulting in cell death. Questions arose as to 
how DNA could be efficiently transferred into cells. At that time genetic manipulation of 
viruses using modern molecular biology techniques was in its infancy. As molecular biology 
techniques improved, the possibilities of correcting monogenic defects by the introduction of 
a correct copy of the gene became more realistic. DNA plasmids derived from bacteria could 
be engineered to carry and express mammalian genes when introduced into cells. Early 
attempts were aimed at transacting DNA into cells using chemicals such as CaC^. Graham 
and van der Eb in 1973 postulated that in situ precipitation of calcium phosphate would occur 
when Ca+2 interacts with the negatively charge phosphate backbone of DNA[2, 3], They 
demonstrated uptake of adenovirus type 5 DNA by rat cells when the cells were mixed with 
the precipitate. Although the method was inefficient, researchers were, nonetheless, capable 
of introducing DNA into mammalian cells in the laboratory. Currently liposome mediated 
DNA delivery is an area of great interest due to the safety of the delivery system and the lack 
of viral antigens against which to mount an immune response [4], However, in vivo delivery 
still remains a limiting factor to successful use of non-viral vehicles. 
The delivery of DNA to cells was further improved upon with the use of viruses. Some of 
the earliest used were the Vaccinia virus [5], Shope papilloma virus [6], and retrovirus. 
Today, retroviruses such as the Moloney murine leukemia virus are still being used [7-9]. In 
addition, the human immunodeficiency virus, a Lentivirus, is being investigated for its use in 
infecting non-dividing cells [10-15], Other viruses include Adenovirus [16-18], Adeno-
associated virus [19-22], Herpes Simplex virus [23-27], Semiliki forest virus [28], and others. 
Much effort has been put into determining the characteristics of each delivery system. Figure 
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1 summarizes the profiles of a few of the viral and non-viral based systems used in gene 
therapy. In our work we used both the Herpes viral vector and the Moloney murine leukemia 
retrovirus to study the anti-cancer cell effects of a( 1,3)galactosyltransferase mediated 
hyperacute rejection. 
Alpha (1,3) Galactosyltransferase 
Alpha (1,3) galactosyltransferase (aGT) is a Golgi dependent enzyme that modifies 
glycoproteins and glycolipids. The aGT enzyme catalyzes the transfer of galactose from 
uridine diphosphate-galactose (UDP-Gal) to the penultimate acceptor N-acetyl-lactosamine 
(GlcNAc-R) of carbohydrate side chains in a gala 1—>3gal linkage (agal epitope) according 
to the following chemical equation [29, 30]: 
Gaip 1 -»4GlcNAc-R + UDP-Gal -> Galal->3Gal|3l->4GlcNAc-R 
The gene encoding a(l,3)galactosyltransferase, a(l,3)GT, is found in virtually all mammals 
[31]. However, mutations in both alleles of a(l,3)GT in humans, apes, and old world 
primates, such as baboons, render these species incapable of expressing a functional aGT 
enzyme (Figure 2) [32]. Clonal B-cell analysis suggests that in humans 1% of total 
circulating antibodies are directed against the agal epitope, presumably through constant 
antigenic stimulation from gastrointestinal normal flora [33-36]. Anti-agal antibodies from 
baboons have been shown to be responsible for inducing hyperacute rejection of agal 
positive porcine xenografts [37, 38]. These antibodies bind agal epitopes and activate the 
classical pathway of complement inducing cytolysis of the transplanted tissue (Figure 3) [11, 
39-42], 
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Alpha-gal knockout mice [0(1,3)01 KO] bred onto the C57/BL6 background have been 
developed by insertional inactivation of the a(l,3)GT gene [43, 44]. The mice lack functional 
aGT enzyme and do not express agal epitopes. Unlike humans, a(l,3)GT KO mice produce 
little or no natural anti-agal antibody [45]. When immunized by either injection of agal 
positive rabbit whole blood or oral administration of Escherichia coli 086:B7, anti-agal 
antibody titers are induced comparable to levels found in humans (Figure 4) [46, 47]. 
Therefore, these animals represent an excellent background in which to study agal mediated 
tumor therapies. 
Complement and Control of the Complement System 
Innate immunity consists of natural barriers to infection that do not require adaptation to 
an antigenic agent. Among these is the complement (C') system, a cascade of enzymatic 
steps that results in 1) the production of a pore in a cellular membrane causing osmotic lysis, 
2) the opsonization of infectious agents, and 3) the activation of proinflammatory mediators 
following infection. Complement components are produced by hepatocytes, as well as blood 
monocytes, tissue macrophages, and epithelial cells of the gastrointestinal and genitourinary 
tracts. Components are released into the blood or tissues as proenzymes to be sequentially 
activated. Two major pathways exist, each one distinct from the other by its activation steps 
but all resulting in lysis of the "target" cell. Classical C' is activated secondary to binding of 
antigen with IgM or at least 2 juxtaposed IgG (subclasses IgGl, IgG2, and IgG3 only) 
antibody (Figure 5). Binding of these antibodies induces a conformational shift in the Fc 
region exposing the CH2 domain to which CI may bind. CI exists in the serum as Clqr^, a 
Ca+2 bound complex where the sexameric Clq is stabilized by two molecules each of Clr 
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and Cl s. Bound Clqris? results in autoactivation of the serine protease Clr. Active Clr 
cleaves Cl s resulting in its activation. Cls then cleaves C4 into C4a and C4b. Once cleaved, 
C4b is rapidly hydrolysed unless it binds to the membrane next to the activation complex 
Clqr2S2. Cls has a second substrate, C2. Similar to C4, C2 is cleaved into C2a and C2b, 
however, C2a binds to C4b to make C4b2a, the active C3 convertase. C3 convertase cleaves 
up to 200 molecules of C3 into C3a and C3b, the latter binds to C4b2a to make the C5 
convertase C4b2a3b. The C5 convertase cleaves C5 into C5a and C5b both of which are 
active. The former is an anaphylatoxin and the latter deposits on the membrane as the initial 
step in the formation of the membrane attack complex. The membrane attack complex 
(MAC) is a macromolecular structure consisting of C5b, C6, C7, C8, and polymerized C9 
that results in the formation of a transmembrane channel. The channel formed in nucleated 
cell membranes is approximately 70-100 angstroms in diameter thus allowing ions and fluid 
to move freely causing osmotic lysis. 
A second cascade exists, the alternative pathway, which is similar to the classical pathway 
with the exception of how it is activated. The alternative pathway is activated by substrates 
found on many strains of gram positive (teichoic acid) and negative (lipopolysaccharide) 
bacteria, fungi, some viral envelopes, and some parasites (trypanosomes). In addition, 
antigen-antibody complexes consisting of human IgG, IgA and IgE, cobra venom factor, 
anionic polymers and carbohydrates such as inulin can all activate the alternative pathway. 
The pathway begins with the slow autodegradation of C3 into C3a and C3b. C3b may bind to 
molecules mentioned above resulting in the binding of the Mg+2 dependent Factor B. The 
interaction of these two molecules opens a cleavage site on Factor B for binding of Factor D. 
Factor D cleaves Factor B in to Ba and Bb resulting in the C3 convertase C3bBb. The 
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enzyme is capable of cleaving approximately 2 x 106 molecules of C3 thereby amplifying the 
amount of C3b deposition on the cell surface. Some of the C3b binds to C3bBb to make the 
C5 convertase. As in the classical pathway, C5 convertase initiates the MAC resulting in 
insertion of a pore in the membrane causing osmotic lysis of the cell. 
Control of C' by complement resistance molecules (CRMs) functions to protect host cells 
from the damaging effects of C' activation. Various C' inhibitors have been described which 
act on key players in the C' cascade. A family of proteins sharing a 60 amino acid repeating 
sequence called short consensus repeats is located on chromosome 1. These consist of 
membrane cofactor protein (CD46), decay accelerating factor (CD55), complement receptor 
type 1 and 2 (CR1 and CR2), C4b-binding protein (C4bBP) and factor H. Other protective 
proteins include S protein, homologous restriction factor (HRF), and membrane inhibitor of 
reactive lysis (MIRL also known as protectin or CD59) and CI inhibitor (Figure 6). 
CI inhibitor is a glycoprotein capable of complexing with Clr^ resulting in its 
dissociation from Clq thereby preventing further interaction with C4 and C2. The key 
amplification step in both pathways utilizes the C3 convertase to cleave C3 into C3a and 
C3b. This step can amplify the effects of C' several thousand times over, therefore regulation 
of the enzyme and its products is of importance to protecting host cells. Complement 
resistance molecules can act to prevent assembly of the C3 convertase or act on the C3 
convertase to dissociate it. In the classical C' pathway C4bBP, CR1, or MCP can act on 
membrane bound C4b preventing its interaction with C2a. Factor I then cleaves C4b into 
membrane bound C4d and soluble C4c. In the alternative pathway CR1, MCP, or Factor H 
can act on membrane bound C3b and prevent its interaction with Factor B. Factor I then 
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cleaves C3b into membrane bound C3bi and soluble C3f. Further action by Factor I results in 
the cleavage of C3bi into membrane bound C3dg and soluble C3c. 
In addition to the C3 convertase, the MAC is another target for CRMs. These molecules 
are both membrane bound and soluble due to the fact that C5b67 may be released from the 
membrane and affect neighboring cell resulting in "innocent bystander lysis". Here serum 
protein S can induce a conformational shift in C5b67 to make it more hydrophilic thus 
preventing it from inserting into the membrane. Protein S also prevents C9 polymerization on 
soluble C5b67 thereby reducing the insensible loss of serum C9. Further inhibition of MAC 
occurs by membrane bound HRF and MIRL (CD59). These molecules bind to C8 and 
prevent the polymerization of C9 and, therefore, its insertion into the membrane. 
Homologous reactive lysis and MIRL prevent cytolysis from allogeneic not from xenogeneic 
complement. 
Previous investigators have shown that human tumor cells express CD46, CD55, and 
CD59 [48, 49] that confer resistance to C'-mediated cytolysis [49-52], CD46 and CD55 
inhibit C3 while CD59 disrupts the formation of the membrane attack complex. Resistance to 
C lysis results in decreased tumor killing. Moreover, recruitment of antigen presenting cells 
and other phagocytes by the chemotactically active C cleavage product C5a, for example, 
would be diminished resulting in poor immune activation. Varsano et al, demonstrated 
increased expression of CRMs in the human lung tumor lines ChaGo K-l and NCI-H596 in 
comparison to normal human nasal epithelium in primary cultures [50]. These authors went 
on to show that ChaGo K-l and NCI-H596 tumor lines were highly resistant to C lysis 
unless treated with PIPLC prior to exposure to C. 
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Phosphatidylinositol-speciflc Phospholipase C 
The non-human phosphatidylinositol-speciflc phospholipase C (PIPLC) is a 35 kDa water 
soluble secreted enzyme produced by Bacillus thuringiensis, B. cereus, Listeria 
monocytogenes, L. ivanovii, Staphylococcus aureus, Clostridium novyi, and Rhodococcus 
equii [53]. Suspected to be a prokaryotic virulence factor [54, 55], PIPLC acts by cleaving 
membrane lipid phosphotidylinositol (PI), lyso-PI and glycosyl-PI [53]. GPI anchored 
complement resistance molecules, CD55 and CD59, are susceptible to PIPLC enzymatic 
cleavage, whereas, non-GPI anchored CD46 is not [52, 56]. Previous investigators have 
demonstrated the importance of CRMs in agal mediated tumor therapy of C' resistant tumor 
lines [52, 56]. However, their approach utilized exogenous application of PIPLC to agal 
expressing cells to alleviate the C' resistance. 
DISSERTATION ORGANIZATION 
The use of agal for cancer gene therapy has been investigated for its ability to cause 
hyperacute rejection of agal expressing tumors and its potential for eliciting anti-tumor 
immunity to tumor specific antigens. The a(l,3)GT KO mouse has played an important role 
in elucidating the effects of agal mediated tumor therapy in vivo. However, until this work, 
only one a(l,3)GT KO tumor model, the murine melanoma B16.BL6, existed to study agal. 
In chapter 1 we sought to develop a new tumor model in the a(l,3)GT KO mouse and 
evaluate its potential for use in agal tumor therapy. 
Breeding pairs of a(l,3)GT KO mice were procured and these mice were utilized in the 
studies described in the coming chapters. The mice were a cross between C57/BL6 (H-2b), 
129SV (H-2b), and DBA/2 (H-2d) backgrounds and were either H-2b/b, H-2d/d and H-2b/d 
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class I major histocompatibility complex haplotype. Mice were injected with varying 
concentrations of the polycyclic aromatic hydrocarbons 3-methylcholanthrene and 9,10-
dimethyl-1,2-benz-anthracene. Resultant tumors were harvested from mice, established in 
culture, sectioned for identification by standard pathology techniques, and characterized in 
vitro and in vivo. For in vivo studies, haplotyping the tumor was desirable. Therefore in 
chapter 2 we describe the development of a high-throughput screening technique to both 
confirm the a(l,3)GT KO phenotype and determine the haplotype of each mouse. The 
protocol allowed us to rapidly screen over 300 mice resulting in separation of the animals 
into H-2b/b and H-2d/d homozygotic colonies. Cultured tumor cells were haplotyped by 
immunofluorescence and matched to one of the homozygotic colonies for analysis of in vivo 
tumor growth kinetics. Of the tumors we harvested, CA320M demonstrated long term tumor 
growth mice and was used in our studies. 
While investigating human tumor cell lines for their susceptibility to agal mediated 
hyperacute rejection, we noticed that some tumor lines were more resistant to the effects of 
complement than others. One million agal expressing; A549 lung carcinoma, and IGROV 
ovarian adenocarcinoma, were compared for there susceptibility to C' lysis after incubation 
with 50% normal human serum (NHS) for 1 hr (Figure 7). IGROV cells were more 
susceptible to the effects of C' than A549 cells. One explanation may be the expression of C' 
resistance molecules CD55 and CD59. Flow cytometric analysis of IGROV cells 
demonstrated less expression of CD55 and CD59 that A549 (Figure 8). Other investigators 
had shown CD55 and CD59 conferred resistance to C' lysis of agal expressing fibrosarcoma 
cells, HT1080a. These authors incubated HT1080a cells with PIPLC to cleave the GPI-
anchored CD55 and CD59 prior to exposure to NHS. Following PIPLC treatment, C' killing 
of HT1080a was restored. In chapter 3 we sought to adapt this approach to a cancer gene 
therapy model by co-expressing the a(l,3)GT and PIPLC from retroviral vectors. We 
reasoned that engineering PIPLC to be secreted should result in cleavage of CD55 and CD59 
from the cell membrane rendering the cells more susceptible to C' lysis. 
Daniel Hellrang was the principle investigator for the work presented in each of the 
chapters in this dissertation. Co-major professors Dr. Charles Link and Dr. Mark Ackermann 
advised the work. 
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Figure î. The differences between various viral and non-viral DNA delivery vehicles. 
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Vector Class Expression Advantages Disadvantages 
Moloney Murine 
Leukemia Virus 
(retrovirus) 
Stable 
Low immunogenicity 
against viral vector, 
Integrates 
Only integrates into 
dividing cells, Relatively 
low titers 
Lentivirus (retrovirus) Stable 
Transduces non-dividing 
cells, Can target CD4+ 
cells, Integrates 
Unknown safety issues 
Adenovirus Transient 
High viral titer, 
Transduces most cell 
types 
Highly immunogenic, 
Transient expression 
Adeno-Associated Virus Stable 
Minimal immunogenicity 
against viral vector, 
Integrates 
Low transduction 
efficiency 
Herpes Simplex Virus Transient 
Ability to package large 
sequences, Transduces 
most cell types 
Non-integrating 
Vaccinia Virus Transient 
Ability to package large 
sequences, Transduces 
most cell types 
Induces strong T-cell 
response 
Cationic Lipids and 
Liposomes Transient 
No vector immune 
response Low transaction rates 
Compiled from : The Scientist 14[19]: 28, Oct. 2, 2000 
Figure 2. Various tumor cells expressing virally encoded (except MC38) agal and stained 
with fluorescein isothiocyanate labelled anti-agal IB4 isolectin. Upper panels are 
fluorescence alone and lower panels are fluorescence and bright field together showing that 
the B16F10 and human tumor lines do not naturally express agal. MC38, murine colon 
carcinoma naturally agal positive. B16F10, murine melanoma cells spontaneously agal 
negative. HCT15, human colon carcinoma. A549, human lung carcinoma. IGROV, OVCAR, 
and SKOV3 are human ovarian carcinoma's. 
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Figure 3. Anti-agal antibody mediated complement lysis of cells engineered to express agal 
epitopes. Cancer cells are infected with a herpes simplex virus containing the a(l,3)GT gene. 
Expression of the a(l,3)GT gene results in modification of glycoproteins and glycolipids to 
contain gala(l,3)gal carbohydrates epitopes. Anti-agal antibodies bind inducing the classical 
complement pathway causing the formation of the membrane attack complex. The formation 
of the complex in the cell membrane results in osmolysis. 
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Figure 4. Enzyme linked immunosorbent assay results demonstrating anti-agal titer of 
pooled sera from six human donors (IRB and IACUC approved protocol) compared to 
pooled sera from three a(l,3)GT KO mice. Mice were immunized twice with 2 x 107 agal 
expressing rabbit red blood cells prior to collecting blood for analysis. Titer from human and 
mouse sera are similar at about 1:3200. 
26 
Human 
Mouse 
Figure 5. Classical complement pathway. The cascade begins with antibody (2 IgG or IgM) 
bound to membrane antigen. ClqrzS2 complex binds to the antibody resulting is activation of 
the Cl s serine protease. The pathway continues with the deposition of C3b on the membrane 
followed by C5b which is marks the beginning of the membrane attack complex (C5b-9). 
The membrane attack complex produces a pore in the membrane resulting in osmolysis. 
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Figure 6. Complement resistance molecules (CRMs) target several steps in the classical 
pathway. These CRMs protect nucleated and non-nucleated cells from the actions of 
complement. Some tumor cells have enhanced expression of these molecules making them 
more resistant to cytolysis. 
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Figure 7. Susceptibility of various tumor cell lines to complement killing. Cells were 
transduced with three multiplicity of infection of herpes simplex virus amplicon vector 
carrying the a(l,3)GT gene. 1 x 106 cells were exposed to 50% normal human serum 
(Serum) or heat inactivated serum (HI) for 1 hr and subsequently co-stained with fluorescein 
isothiocyanate (FITC) labeled anti-agal IB4 isolectin (green bars) and propidium iodide (PI) 
indicating cell death (red bars). CI are untreated cells, C2 are no vector cells subject to FITC 
and PI staining. Y-axis is percent positive cells expressing agal (green bars) or agal and PI 
(red) indicating the percent of agal cells that were killed by complement lysis. The lack of 
cell killing in A549 may be due to high level expression of complement resistance molecules. 
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Figure 8. Flow cytometric analysis of IGROV, A549, and CA320M using antibodies 
detecting the complement resistance molecules, membrane co-factor protein (CD46), decay 
accelerating factor (CD55), and protectin (CD59). 
Events Events 
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ABSTRACT 
Background: Gastrointestinal malignancies represent 20% of newly diagnosed cases 
of cancer each year and 132,300 deaths from these tumors. Our group is exploring the use of 
a(l,3)galactose epitopes (agal) to induce hyperacute rejection of tumors. Results: Towards 
this goal, we developed and characterized a gastrointestinal stromal tumor line, CA320M, 
derived from agal knockout [a(l,3)GT KO] mouse. Mice were injected with the carcinogens 
9,10-dimethyl-1,2-benz-anthracene, 3 -methylcholanthrene, or 6a-methyl-17 a-hydroxy-
progesterone acetate. CA320M was harvested from the small intestine of a female mouse and 
established in cell culture. Flow cytometric analysis demonstrated these cells to be 
homozygous H-2b/b haplotype with a normal diploid genome which replicated every 12 hr. 
CA320M cells demonstrated no detectable cell surface agal epitopes. Cells transduced with a 
herpes simplex virus type 1 amplicon vector (HE7agall) carrying the murine a(l,3)GT gene 
resulted in significant agal epitope expression. CA320M cells, transduced with HE7agall, 
were incubated with normal human serum or serum collected from a(l,3)GT KO mice 
immunized against agal. Flow cytometric analysis of serum exposed a(l,3)GT expressing 
cells demonstrated up to 97% anti-agal antibody mediated complement lysis. Female H-2b/b 
mice were subcutaneously injected with CA320M (5xl06) cells which resulted in a mean 
tumor volume of 500 mm3 within 30 days. Histopathological examination of the resulting 
tumors demonstrated morphologies consistent with a poorly differentiated sarcoma. 
Conclusions: These data suggest that CA320M, a model specifically designed for small 
animal studies, may be useful to clinical and basic science researchers investigating 
gastrointestinal tumors and the future development of tumor vaccines. 
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BACKGROUND 
In the United States, 250,600 patients were newly diagnosed with gastrointestinal 
malignancies in 2002 and 132,300 died [1]. These statistics provide great impetus to design 
novel therapies for gastrointestinal tumors. One approach that shows some promise is the use 
of tumor vaccines to stimulate cell mediated immunity to native tumor antigens. Clinical 
trials involving the use of cytokine expressing cancer vaccines such as GM-CSF are currently 
being investigated to treat colorectal carcinomas [2], Another immunotherapy includes the 
use of a(l,3)galactose epitopes (agal) to induce antibody-mediated hyperacute rejection of 
tumor cells [3-5]. a(l,3)galactosyltransferase (aGT) is a Golgi dependent enzyme that 
modifies cell surface glycoproteins and glycolipids. The aGT enzyme catalyzes the transfer 
of galactose from uridine diphosphate-galactose (UDP-Gal) to the penultimate acceptor N-
acetyl-lactosamine (GlcNAc-R) of carbohydrate side chains in a gala 1—>3gal linkage (agal 
epitope) [6, 7], The gene encoding a(l,3)galactosyltransferase, a(l,3)GT, is found in 
virtually all mammals [8], However mutations in both alleles of a(l,3)GT in humans, apes, 
and old world primates, such as baboons, render these species incapable of expressing a 
functional aGT enzyme [9], Clonal B-cell analysis suggests that in humans 1% of total 
circulating antibodies are directed against the agal epitope, presumably through constant 
antigenic stimulation from gastrointestinal normal flora [10-13]. Anti-agal antibodies from 
baboons have been shown to be responsible for inducing hyperacute rejection of agal 
positive porcine xenografts [14, 15]. These antibodies bind agal epitopes and activate the 
classical pathway of complement inducing cytolysis of the transplanted tissue [16-20]. 
Alpha-gal knockout mice [a(l,3)GT KO] bred onto the C57/BL6 background have been 
developed by insertional inactivation of the a(l,3)GT gene [21, 22]. The mice lack functional 
aGT enzyme and do not express agal epitopes. Unlike humans, a(l,3)GT KO mice produce 
little or no natural anti-agal antibody [23]. When immunized by either injection of agal 
positive rabbit whole blood (RWB) or oral administration of Escherichia coli 086:B7, anti-
agal antibody titers are induced comparable to levels found in humans [24, 25]. Therefore, 
these animals represent an excellent background in which to study agal mediated tumor 
therapies. 
Using the murine agal negative melanoma line, B16.BL6, previous investigators have 
demonstrated that agal expressing B16.BL6 tumor vaccines can potentiate immunity 
resulting in protection from subsequent lethal tumor challenge from parental B16.BL6 [3], In 
those experiments 30% of the mice survived lethal tumor challenge. However, the 
B16.BL6/agal model may not predict the outcome of other tumor types including 
gastrointestinal malignancies. Currently no other a(l,3)GT KO tumor models have been 
reported for other tumor types. Therefore, in order to investigate tumor therapies potentially 
relevant for gastrointestinal cancers an additional tumor model is needed. Towards that end, 
a(l,3)GT KO mice were administered 9,10-dimethyl-1,2-benzanthracene, 3-
methylcholanthrene, and 6a-methyl-17a-hydroxy-progesterone acetate to induce tumors. A 
population of chemically treated mice were followed for up to two years. Here we 
characterize a new gastrointestinal stromal tumor (GIST), CA320M, derived from the small 
intestine of a female mouse treated with 9,10-dimethyl-1,2-benzanthracene and 3-
methylcholanthrene and show its usefulness in an in vitro tumor cell killing model. This 
work sets the stage for future study of agal tumor vaccine therapies. 
RESULTS 
Chemical Carcinogens 
One hundred twenty cx(l,3)GT KO mice aged 8-16 weeks were subject to two 
intraperitoneal injections of various combinations of 9,10-dimethyl-1,2-benz-anthracene and 
3-methylcholanthrene or 6a-methyl-17a-hydroxy-progesterone acetate alone, all dissolved in 
250 |il olive oil each (table 1). Tumors were observed as early as 4 months post-injection. 
Animals were followed for up to 24 months. A total of 44 tumors were harvested with an 
average tumor volume of 2.76 cm3. Most tumors were confined to the abdominal quadrant. 
Twenty-four of the 44 tumors were successfully cultured through passage ten. 
Histopathology of Isolated Tumors 
Tumors were fixed for a minimum of 3 days in 4% formaldehyde and subject to 
dehydration in 25% sucrose for another 3 days. Tumors were frozen and sectioned on a 
cryostat at 5-10 gm. CA320M was isolated from the intraperitoneal cavity associated with 
the small intestine of a female mouse. Histopathological examination of both frozen and 
paraffin sections of the primary and transplanted tumors, respectively, demonstrated 
morphologies consistent with a poorly differentiated sarcoma (Figs, la, lb). Actin probes 
specific for muscle and smooth muscle as well as a myoglobin probe failed to stain either the 
primary tumor or tumor sections derived from transplanted tumor cells. These data taken 
together with the primary histopathology eliminate leiomyosarcoma or rhabdomyosarcoma 
and indicate that CA320M is a poorly differentiated sarcoma of the small intestine. 
Other tumors of interest (not shown) consisted of a subcutaneous nodule isolated from the 
mammary area of a female mouse. Histochemical analysis revealed cellular morphology 
consisting of acinar structures with several mitotic figures indicative of an adenocarcinoma 
of the breast. Another tumor was isolated from the dermis of a female mouse and appeared 
fibrous upon excision from the animal. Microscopic analysis revealed "pearls" - diagnostic 
hallmarks of a squamous cell carcinoma of the dermis. Finally, another fibrous tumor was 
located in the intraperitoneal cavity of a female mouse. Histochemical analysis revealed a 
fibrosarcoma with several mitotic figures throughout the tumor. 
Haplotyping of Parental Mice and CA320M Tumor Line 
Tumors were developed in outbred a(l,3)GT KO mice. The genetic background of these 
mice were determined to be a cross between C57/BL6 (H-2b), 129SV (H-2b)and DBA/2 (H-
2d) [21]. Possible haplotypes were, therefore, limited to homozygous H-2b/b or H-2d/d or 
heterozygous H-2b/d [29]. Antibodies specific for these haplotypes were used to identify the 
haplotype of both the parental mice and the CA320M tumor. Three hundred mice were typed 
and matching haplotypes were bred for further use. Flow cytometry using these same 
antibodies demonstrated that CA320M was homozygous H-2b/b (Fig. 2). Mice of the same 
haplotype were bred resulting in two colonies representing both H-2b/b and H-2d/d haplotypes. 
Because CA320M was isolated from a female mouse and determined to be H-2b/b haplotype, 
all subsequent in vivo experiments were conducted in female H-2b/b a(l,3)GT KO mice. 
Determination of Cell Cycle and Proliferation Rate in Normal and Serum Starved 
Conditions 
To determine the "putative tumorigenic" potential of the diploid CA320M tumor line, cell 
cycle and proliferation rate analysis was performed following culture in normal serum 
conditions and serum starved conditions. As a reference point B16.BL6 was used as it is a 
well characterized murine agal negative tumor line. Cells were cultured for up to 48 hr in 
normal (D10) or serum starved (D0.1) conditions. The percent CA320M cells in S phase 
began to decline at 36 hr and by 48 hr reached 18.4% (Fig 3a). By contrast the percentage of 
cells in the G1 phase steadily increased to 80%. (Fig. 3b). Similarly, B16.BL6 demonstrated 
growth arrest after 48 hr culture in D0.1 (Fig. 3c, 3d). Proliferation rate was determined by 
incorporation of the die CFSE into cells cultured with D10 or D0.1 for up to 48 hr (Fig. 3e). 
When grown in D10, cells doubled every 12 hr resulting in approximately 3-4 doublings 
during a 48 hr period. Cells cultured in serum starved conditions followed a similar pattern 
for the first 24 hr and over 48 hr, 3 doublings were observed (Fig. 3f). These data correlate 
well with the variations in cell cycle noted above in murine tumor cells cultured in similar 
conditions. 
HSV-1 Gene Transfer and Analysis of agal Expression 
CA320M cells induced in a a(l,3)GTKO mouse failed to bind fluorescein isothiocyanate 
(FITC) labeled IB4 isolectin (Fig. 4a), that specifically detects agal epitopes, verifying that 
this murine tumor is, as expected, devoid of functional aGT enzyme and, therefore, agal 
epitopes. CA320M cells were susceptible to infection by an HSV-1 based vector and 
expressed agal epitopes after transduction with HE7agall. HE7EGFP was used as a control 
for transduction efficiency. Eight hours post transduction agal epitopes were detected on the 
cell surface by IB4 isolectin and GFP was detected by fluorescent microscopy (Fig. 4b, 4c). 
Susceptibility of agal Expressing CA320M to Anti-agal Serum 
CA320M cells expressing agal epitopes were exposed to pooled normal human serum 
(NHS) and pooled a(l,3)GT KO mouse serum collected after two immunizations with RWB 
(MS). Serum was collected and quickly frozen to preserve complement components. Human 
and mouse sera were found to have similar anti-agal antibody titer as determined by ELI SA 
(Fig. 4, Chapter 1). MC38 murine colon carcinoma cells, naturally express agal, and 
CA320M cells transduced with 3 MOI of HE7agal or HE7EGFP were incubated with 50% 
NHS for 1 hr. MC38 (98%) and CA320M agal expressing cells (97%) both bound anti-C3c 
antibody and were killed by serum as detected by incorporation of 7 A AD (Fig. 5a). EGFP 
expressing cells (40%) were killed (data not shown) which may represent an anti-HSV 
antibody response or a component of direct HSV viral toxicity. Moreover non-transduced 
CA320M (33%) cells were also killed suggesting the presence of a xenoreactive component 
of NHS against the parental tumor line alone. Incubation with heat inactivated NHS resulted 
in 1.7% cell death showing that cytolysis was complement dependent. CA320M agal 
expressing cells incubated with 50% MS for 1 hr resulted in 35% cytolysis (Fig. 5b.). By 
contrast only 6% of EGFP cells and 5.5% parental CA320M cells were killed. Therefore, 
cells expressing agal are killed by human serum 3 fold more than cells not expressing agal 
when incubated with NHS compared to at least 7 fold more agal specific killing by MS. 
These data demonstrate that CA320M may be useful for studying hyperacute rejection as a 
tumor therapy in a(l,3)GT\LO mice. 
Tumor Growth Kinetics In Vivo 
Tumor growth in vivo was assessed by subcutaneous injection of either lxl06 or 5x10* 
cells into parental mice. Resulting tumors were measured for length, width, and height and 
the calculated volume was plotted against time. Approximately 90% of the mice permitted 
tumor growth when challenged with 5xl06 cells (Fig. 6a). Tumor growth kinetics vary 
between female haplotype matched mice with an average tumor volume of approximately 
200 mm3 within 14 days, which increased to approximately 500 mm3 by day 30 (Fig. 6b). 
With an end point of 30 days approximately 63% of the animals had lethal tumor volumes of 
over 400 mm3 and had to be euthanized due to tumor size or ulceration of the skin overlaying 
the tumor (Fig. 6c). These data indicate that this tumor model would be useful in studying 
agal mediated therapies for gastrointestinal malignancies in vivo. 
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DISCUSSION 
Gastrointestinal malignancies represent a significant contributor to the overall death rates 
due to cancer each year. In 2002 alone, 132,300 people died of these cancer's representing 
24% of the overall fatalities from cancer [1]. Treatments using tumor vaccines are being 
explored in an attempt to induce an immune response to native tumor antigens. One of the 
approaches consists of inducing hyperacute rejection of tumor vaccines using 
a(l,3)galactosyltransferase gene therapy. With this approach it may be possible to use agal 
modified tumor vaccines to education the immune system to recognize native tumor antigens. 
Alpha ( 1,3)galactosyltransferase (aGT) modifies glycoproteins and glycolipids to express the 
agal epitope, gal a(l-»3)gal [6, 7]. Humans fail to express agal epitopes due to mutations in 
both alleles of the a(l,3)GT gene but have high titer antibody directed against this epitope 
[9-13]. The presence of anti-agal antibody primes the immune system to respond to agal 
epitopes resulting in complement mediated lysis of tissue expressing these epitopes. It has 
been shown that human and murine tumor cells engineered to express the agal epitope are 
sensitized to agal mediated complement lysis when incubated for 1 hr with 50% NHS. [3-5, 
30]. However, few small animal tumor models exist to study this vaccine approach, 
particularly with respect to gastrointestinal malignancies in vivo. 
LaTemple et al., used the B16.BL6 line as a model for agal mediated tumor therapy of 
melanoma [3]. In their experiments, animals where immunized with RWB, vaccinated with 
either agal expressing B16.BL6 or parental B16.BL6, followed fourteen days later by 
challenge with parental B16.BL6 tumor cells. They demonstrated that approximately 30% of 
the animals survived lethal challenge and raised the question as to whether cell mediated 
immunity against native tumor antigens had developed in those animals. One of the 
drawbacks of using the B16 model is that it has been reported to be highly metastatic [31] 
and variable in its immunogenic properties [32-35]. Moreover, in that study the animals used 
were outbred resulting in a variable background of H-2d and H-2b haplotypes and B16.BL6 
was derived from C57/BL6 and therefore is H-2b haplotype. Therefore, the predictive 
capacity of B16.BL6/agal model in those studies may be suboptimal for other tumor types 
including gastrointestinal malignancies. 
Studies by Unfer et al., using the murine agal positive colon carcinoma, MC38, have 
shown protection from lethal tumor challenge in haplotype matched a(l,3)GT KO mice [5]. 
Mice were immunized against the agal epitope using RWB followed by lethal challenge with 
MC38 cells. In that study, 100% of the animals were protected as compared to controls. 
However, since the MC38 model endogenously expresses agal, the syngeneic agal negative 
melanoma model, B16.BL6, was used as a negative control. A limitation of this approach is 
the inability to study how agal induces the education of cell mediated immunity to native 
tumor antigens. Therefore, a murine tumor line devoid of agal expression would provide a 
model with which to study the immunological aspects of agal tumor therapies for 
gastrointestinal malignancies. 
Due to the limitations of the current in vivo models for studying agal tumor vaccines we 
developed a gastrointestinal stromal tumor, CA320M. Histopathology of both frozen and 
paraffin embedded sections demonstrated morphologies consistent with a sarcoma (Fig. la, 
lb). The cells failed to stain positive for actin or smooth muscle specific actin indicating that 
CA320M likely either did not arise from muscle tissue or lost muscle specific actins during 
its evolution. An anti-myoglobin probe used to detect muscle specific myoglobin was also 
negative. Therefore, CA320M appears to represent a poorly differentiated gastrointestinal 
sarcoma. 
The a(l,3)GT KO mice, from which CA320M was derived, were an outbred strain. In 
order to use this model for immunological studies both the mice and the tumor haplotypes 
were determined. The a(l,3)GT KO mice were developed from a C57/B16 x DBA/2 x 129SV 
background resulting in H-2b or H-2d haplotypes. Using a rapid screening method, 
antibodies against H-2Kb, H-2Kd, H-2Db, and H-2Dd were used on blood samples of several 
hundred animals in order to separate homozygotes from hétérozygotes. Homozygous H-2b/b 
and H-2d/d haplotype colonies were established for use in this and future studies. CA320M 
cells were also probed with the same antibodies and determined to be homozygous H-2b/b 
haplotype (Fig. 2). The haplotype matched colonies of a(l,3)GT KO mice may facilitate 
investigation into innate and adaptive immune responses against agal mediated tumor 
therapies. In addition, these animals could help elucidate the role tumor cell minor antigens 
may play in developing an immune response to these therapies. 
To further characterize CA320M cell cycle was analyzed after culture in complete media 
containing 10% FBS and complete media containing 0.1% FBS (serum starvation) for up to 
48 hr. As a reference point, B16.BL6 murine agal negative melanoma cells were used for 
comparison. Both CA320M and B16.BL6 began to arrest in G1 by 48 hr in serum starved 
conditions (Fig 3a through 3d) as compared to normal serum. Also, it became evident that 
CA320M cell doubling slowed through 48 hr incubation in serum starved conditions 
resulting in only 3 divisions (Fig. 3f) as compared with up to 4 doublings in normal serum 
culture conditions. Therefore CA320M appears to be following a similar growth pattern 
established for other tumor lines. 
To evaluate the use of CA320M as a gene therapy model of hyperacute rejection, it was 
necessary to demonstrate that mutations associated with chemical carcinogenesis or the 
method of developing the a(l,3)GT KO background from which this tumor was derived 
didn't interfere with a(l,3)GT gene expression and resulting enzyme function. Also, since 
gene therapy relies on gene delivery systems, we sought to determine if CA320M was 
susceptible to infection by herpes simplex virus type 1 (HSV-1) amplicon vectors. Among 
the many gene transfer techniques available, HSV-1 amplicons are attractive because they 
can carry large fragments of DNA, have greater than 90% tropism, infect nondividing cells, 
and can be prepared in high titers [27, 28]. Therefore, we used an amplicon vector system to 
deliver the murine a(l,3)GT gene or EGFP. The virus successfully infected CA320M as 
detected by EGFP fluorescence within 8 hr (Fig 4c). Also, a(l,3)GT expression resulted in 
the modification of cell surface molecules to present agal epitopes as detected by FITC 
labeled IB4 isolectin binding (Fig. 4b). These results indicate that CA320M is capable of 
being infected by HSV-1 vectors and cellular mutations have not inhibited the functional 
expression of aGT enzyme. 
Previous investigators have demonstrated lysis of agal expressing human tumor cells such 
as A3 75 melanoma [4], ALL-1 pre-B leukemia [36] as well as murine tumor cells such 
MC38 colon carcinoma and B16.BL6 [3, 5]. To evaluate the efficiency of hyperacute 
rejection of agal expressing CA320M, cells were infected with HE7agall for 8 hr followed 
by incubation with 50% normal human serum (NHS) or serum collected from mice primed 
with RWB (MS). Ninety-seven percent of agal expressing CA320M cells bound anti-C3c 
antibody and stained with 7AAD demonstrating cell death when incubated with NHS (Fig. 
5a). By comparison, 98% of MC38 cells, derived from wild-type C57/B16 mice that are 
naturally agal positive, were killed. To determine if this was a response to a xenoantigen 
independent of agal epitopes or a component of the viral toxicity, CA320M cells alone or 
infected with HE7EGFP, expressing the enhanced green fluorescent protein, were incubated 
with NHS as above. Thirty-three percent of parental CA320M compared to 40% of EGFP 
expressing cells were killed demonstrating that NHS can recognize other epitopes on 
CA320M independent of the virus. However, agal expression increased the killing of these 
cells 3-fold indicating that the increase in cell lysis was due to the expression of agal 
epitopes. Moreover since complement is easily destroyed by heat, these cells were incubated 
with heat inactivated serum and only 2% of the cells were killed. 
Incubation with MS killed 35% of agal expressing cells (Fig. 5b), however the majority 
of the cells bound C3c but not 7AAD. These results suggest that either the terminal 
complement components had degraded or that the expression of complement resistance 
molecules, such as homologous restriction factor, on the membrane of the tumor cells 
resulted in inhibition of the membrane attack complex of complement. Still, these data 
correlate well with NHS results by showing up to a 7-fold increase in agal specific killing 
over controls. Moreover, these results suggest that the CA320M tumor model would be well 
suited for studying hyperacute rejection as a cancer therapy strategy in vivo as anti-agal 
mouse serum is capable of killing these cells. 
Finally, CA320M growth kinetics was studied to establish parameters to use for in vivo 
tumor vaccine studies. One and five million cells were injected subcutaneously into 8-14 wk 
old mice. Tumors grew in 90% of the animals reaching a mean tumor volume of 164 mm3 
and 471 mm3, respectively, by day 30. In the latter group, 63% of the animals had to be 
euthanized due to tumor size or ulceration of the skin overlying the tumor. By contrast, a 
dose of between 1x10s and 5x10s B16.BL6 cells has been reported to kill 100% of a(l,3)GT 
KO mice in 2-3 wks [3, 5], In addition, Unfer et al, reported as little as 2.5xl05 cells killed 
100% of a(l,3)GT KO mice within 18 days post challenge [5]. Comparatively, CA320M is 
not a highly aggressive tumor line and therefore, should be good for immunological studies 
where death of the animal is not required or where a less aggressive tumor model is 
desirable. Moreover, the variability observed in tumor growth between animals may have to 
do with the outbred nature of the a(l,3)GT KO mice. Although the mice were haplotype 
matched for these experiments, minor antigens may play a role in tumor survival. Therefore, 
this tumor model may be important in studying the role of minor antigens in tumor immunity. 
Human gastrointestinal stromal tumor (GIST's) models have been developed from 
primary tumors to study genetic abnormalities in this class of tumors. Mutations in the proto-
oncogene c-KIT (CD 117) have been reported to correlate with malignancy of GIST's [37]. In 
addition, Debiec-Rychter et al., reported that chromosomal losses of 14q32 and 22ql 1 loci 
correlated with the most malignant GIST's from human primary and recurrent tumors [38]. 
CA320M, therefore, may allow investigators to study the genetics of this tumor model in an 
analogous fashion to human GIST's. Importantly, in vivo studies can be conducted utilizing 
the a(l,3)GT KO mouse background allowing for the evaluation of tumor biology in a small 
animal model that may more closely approximate human responses. 
An additional potential advantage over existing naturally agal positive mouse models is 
elucidation of the role that agal epitopes play in tumor biology or its response to cancer 
therapies. This is important considering that the a(l,3)GT gene in humans and old world 
primates was mutated through evolution but remained intact in lower mammals. An area 
under active investigation is whether or not the presence or absence of a(l,3)GT effects 
immune responses or aspects of tumor biology. Prior research demonstrated that expression 
of agal epitopes on B16.BL6 cells unmasked cell surface carbohydrates that react with 
soybean agglutinin, peanut agglutinin, and vicia villosa lectin. Furthermore, metastasis of the 
agal expressing B16.BL6 was reduced in agal positive C57/BL6 mice as compared to 
unmodified parental cells [39, 40]. Therefore, the CA320M model may provide a tool to 
gather further evidence that agal epitopes may play a role in tumor biology. 
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CONCLUSION 
We have developed and characterized a new gastrointestinal stromal tumor line derived from 
an a(l,3)GT KO mouse and evaluated its use as a gene therapy model for treating cancer. 
Although future work in establishing an in vivo agal mediated tumor vaccine is ongoing, this 
model should provide a valuable addition to further studying treatments for gastrointestinal 
malignancies and in many areas of cancer therapy. 
MATERIALS AND METHODS 
Mice 
Two female and one male a(l,3)GT KO mice were procured from Michigan State 
University animal facility [21]. After an adjustment period mice were harem bred. The 
resulting outbred colony was amplified to sufficient numbers for use in this study in our 
AAALAC accredited animal facility. 
Chemical Carcinogens 
Lipid soluble 9,10-Dimethyl-1,2-Benz-Anthracene, 3-Methylcholanthrene were acquired 
(Sigma, St. Louis, MO) and dissolved in olive oil (Sigma) at various concentrations. 6a-
methy 1-17a-hydroxy-progesterone acetate (Sigma) was dissolved in olive oil at 1 mg/250 |il 
Mice aged 8-16 wks were injected twice with 250 (il of chemical/olive oil solution 
intraperitoneal^ (i.p.) at two-week intervals. 
Isolation of Tumors 
Mice presenting with tumors were euthanized and necropsied. Tumors were removed and 
bisected; one half was fixed in 4% formaldehyde (Sigma) lx phosphate buffer saline (PBS, 
Invitrogen-Life Technologies Inc., Carlsbad, CA) for histopathological analysis. The second 
half was digested for 1 hr at 37°C with shaking in a cocktail of 880 U/ml collagenase 
(Sigma), 6.08 U/ml hylaronidase (Sigma), and 456 KUnits/ml DNase (Sigma) diluted in 
Hanks Balanced Salt Solution (HBSS, Invitrogen-Life Technologies, Inc.). The cocktail was 
further diluted 1:1 in Dulbecco's Modified Eagles Medium (DMEM) supplemented with IX 
L-glutamine, 20% heat inactivated (30 min at 56°C) fetal bovine serum (FBS), 6X 
penicillin/streptomycin, and 2X fungizone (all media components from Invitrogen-Life 
Technologies, Inc.). Cellular debris was removed by gauze filtration, followed by 
centrifugation and established in culture with DMEM supplemented with 20% heat 
inactivated FBS, lx penicillin/streptomycin, lx L-glutamine, lx fungizone for 1 week. 
Subsequent passages were made in DMEM with 10% FBS and lx L-glutamine (D10). 
Histopathology of Isolated Tumors 
Fixed tumors were dehydrated with 25% sucrose dissolved in PBS, for 3 days. Thin 
sections were obtained by snap freezing with PBS to a stage and sectioning at 5-10 |xm on a 
Leica CM1850 cryostat. Sections were allowed to air dry overnight and then stained with 
hematoxylin/eosin according to standard procedures [26]. Paraffin embedded sections of 
transplanted CA320M tumors were obtained by standard techniques (Iowa State University 
Immunohistochemistry Services, Ames, IA). Sections were stained with hematoxylin/eosin 
and probed for the presence of actin (smooth muscle specific and muscle specific) and 
myoglobin. 
Haplotyping of Parental Mice and CA320M Tumor Line 
Phycoerythrin (PE) labeled Anti-H-2Db, fluorescein isothiocyanate (FITC) labeled anti-H-
2Kb, PE labeled anti-H-2Dd and FITC labeled anti-H-2Kd antibodies with isotype controls 
(BD Pharmingen, San Diego CA) were used to haplotype both the parental mice and the 
CA320M tumor. Blood was drawn from the saphenous vein of up to 300 mice and each 
sample was washed in HBSS and approximately 106 cells were stained with 1 gg of each of 
the antibodies above in a 96-well plate (Coming, Coming NY). Labeled leukocytes were 
positively identified under fluorescent microscopy. Haplotype matched mice were bred and 
used for the remainder of this work. Approximately 106 CA320M cells were labeled with 
each of the antibodies above and analyzed by flow cytometry (Beckman Coulter Epics Altra). 
Determination of Cell Cycle and Proliferation Rate in Normal and Serum Starved 
Conditions 
Adherent CA320M or B16.BL6.2 cells were harvested from tissue culture flasks by 
incubating with 0.4% trypsin 0.05 mM EDTA (Invitrogen-Life Technologies, Inc.) for 2 min 
at 37°C. Cells were then seeded in 8 flasks and cultured in D10. Twenty-four hours later 
media of 4 flasks was replaced with DMEM supplemented with 0.1% FBS (D0.1) and 
cultured for 12, 24, 36, and 48 hr. Cells from 0 hr and each subsequent time point were 
harvested as above and analyzed for cell cycle by flow cytometry after staining with Coulter 
DNA-Prep Reagents Kit (Coulter Co, Miami, FL). Cell ploidy was determined by using the 
0 hr time point. Proliferation rate was determined by culturing cells stained with carboxy-
fluorescein diacetate, succinimidyl ester (CFSE) in similar conditions as above for 0, 24, and 
48 hr time points. Cells (lxlO6) for each time-point were incubated with 5 p,m CFSE at 37°C 
for 2 min and the reaction was terminated by the addition of iced D10. Cells were washed in 
HBSS and plated in either D10 or D0.1 for the duration of the time point. Each flask was 
trypsinized as above and cells were analyzed by flow cytometry. 
Detection of agal epitopes on isolated tumor cells 
Tumor cells and blood drawn from the haplotyped mice above were stained with Griffonia 
simplicifolia FITC labeled IB4 isolectin (Vector Laboratories, Burlingame, CA). Alpha-gal 
epitopes are specifically bound by the IB4 isolectin. Tumor cells were cultured overnight in a 
24 well plate (Coming Co.) whereas 10 jul of fresh blood from each animal was transferred 
into a well of a 96-well plate. Each well was washed with HBSS and incubated for 10 min at 
room temperature with 200 fil of a 10 gl/ml solution of IB4 isolectin diluted in lx Opti-MEM 
(Invitrogen-Life Technologies, Inc.). Cells were washed with HBSS and analyzed by either 
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flow cytometry and/or viewed microscopically (Nikon Diaphot) under 488 nm wavelength 
light. 
a(l,3)GT Gene Transfer and Expression 
The herpes simplex virus type 1 amplicon, pHE700, was engineered to carry either the 
murine a(l,3)GT gene or enhanced green fluorescent protein (eGFP) gene by standard 
cloning techniques [27]. DNA sequence analysis of the a(l,3)GT transgene, post-cloning 
verified the correct sequence. pHE700agal and pHE700EGFP amplicons were transfected 
into E5 (African Green Monkey Kidney) cells as previously described [27]. Briefly, E5 
carries the ICP27 gene required for initiation of replication and packaging of the HSV-1 
genome and amplicon [27, 28]. Transduction of E5 cells, containing either amplicon, with 
the helper virus CgalA3 (derived from dl20 and expressing the lacZ marker gene) results in 
packaged HE7agall and HE7EGFP1 virions. CA320M cells were infected with 3 MOI of 
either virus. Eight hours post-transduction agal epitopes were detected by IB4 staining as 
described above. 
Susceptibility of agal Expressing CA320M Cells to Anti-agal Serum 
a(l,3)GT KO mice were immunized against the agal epitope by subcutaneous injection of 
2x1 (f female NZW rabbit whole blood cells (CoCalico Biologicals Inc, Reamstown, PA) 
diluted in HBSS. Two injections were performed 14 days apart. On day 28, sera was 
collected and analyzed by enzyme linked immunosorbant assay (ELI SA) for anti-agal 
antibody titer [5]. Briefly, 96-well plates (Falcon, Becton Dickinson Labware, Franklin, NJ) 
were coated with 50 |il of 5 jig/ml agal-BSA conjugate (Vector labs) in carbonate buffer (pH 
9.5) overnight at 37°C in a humidified chamber. Plates were blocked with 150 |xl of 1% BSA 
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Fraction V (Sigma) in carbonate buffer for 2 hr at 37°C in humidified chamber. Sera was 
serially diluted in wash buffer (lx PBS/0.05% Tween 20 pH 7.2) to a final volume of 50 
(il/well and incubated at room temperature for 2 hr. Wells were washed 5x in wash buffer 
followed by incubation with 50 jxl/well of 1:3000 dilution of goat anti-mouse IgG conjugated 
to horseradish peroxidase (Dako A/S, Denmark) in wash buffer for 1 hr at room temperature. 
Wells were washed 5x followed by addition of 100 gl/well 3,3',5,5'-tetramethylbenzidine 
(Sigma) liquid substrate. The reaction was allowed to develop for 30 min at room 
temperature where upon it was terminated by the addition of 100 (j,l/well of 1 M H2SO4 and 
the results read at 450 nm. 
CA320M cells were transduced with 3 MOI of either HE7agall or HE7EGFP1 virus and 
incubated 8 hr at 37°C. Pooled sera from normal human donors or primed mice (described 
above) were incubated at a concentration of 50% with 2x10? cells for 1 hr at 37°C. Cells were 
washed in HBSS and tri-labeled with 1 jig/ml biotinylated anti-agal IB4 (Vector Labs) 
1:2000 dilution anti-C3c FITC labeled IgG (Dako A/S) and 1 gg/106 cells of 7-
aminoactinomycin D (7-AAD, Sigma) in HBSS containing 1% BSA for 30 min room 
temperature. The biotinylated IB4 was detected with 0.5 gg/ml streptavidin conjugated PE. 
Cells were washed in HBSS and analyzed by flow cytometry. 
Tumor Growth Kinetics In Vivo 
Cultured cells were disassociated, pelleted, and resuspended in 10 ml HBSS. Cells were 
washed as above and pellets were resuspended in 5 ml HBSS and counted by trypan blue 
exclusion. Each of eight 8-14 wk old female haplotype matched animals received either 
lxlO6 or 5x10* CA320M cells diluted in 100 fil HBSS via subcutaneous injection on the 
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shaved ventral surface of the abdomen and followed for 60 days. Tumor volumes were 
calculated by multiplying the length, width, and height of each measured tumor and plotted 
over time. 
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Table 1. Various combinations of chemicals used to induce tumors in a(l,3)GT KO mice. 
Mice were injected i.p. twice fourteen days apart with 250 gl of drug dissolved in olive oil. 
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Table 1. Drug Combinations and Resulting Tumors 
No. of 
DMBA (mg) 3-MC (mg) MHP (mg) Tumors* 
* 44 tumors harvested from 120 animals 
$ Group from which CA320M was derived 
DMBA ; 9,10-dimethyl-1,2-benz-anthracene 
3-MC; 3-methylcholanthrene 
MHP; 6a-methyl-17a-hydroxy-progesterone acetate 
Chemicals dissolved in 250 |J,1 olive oil injected twice i.p. 
0.5 
1.0 
*2.0 
2.0 
2.0 
n/a 
1.0 
1.0 
1.0 
0.1 
0.5 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
1.0 
8 
8 
9 
6 
8 
5 
Figure 1. Photomicrographs of CA320M tumor. A. Frozen section of primary tumor, 
CA320M, derived from the gastrointestinal tract of a female mouse, 16x. Inset shows 
morphologies consistent with a sarcoma, 40x. B. Paraffin section of tumor arising from 
subcutaneous transplanted CA320M cells, 16x. Inset shows mitotic figures at 40x 
magnification. 
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Figure 2. Flow cytometric analysis of CA320M haplotype. Antibodies against H-2Kb, H-
2Kd, H-2Db, and H-2Dd were used on 106 cells. The histogram in the left panel shows dual 
labeled cells for the H-2d haplotype. The histogram in the right panel shows dual labeled 
cells for the H-2b haplotype. These data indicate that CA320M was derived from à 
homozygous H-2b/b mouse. 
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Figure 3. Cell cycle analysis of nonsynchronized CA320M and B16.BL6 cultured in normal 
serum (DIO) or serum starved conditions (D0.1). A. The change in S phase of CA320M in 
both culture conditions from 0 to 48 hr. B. The changes in G1 of CA320M for the same 
conditions. C. The changes in S phase of B16.BL6 D. The changes in G1 phase of B16.BL6 
for the same conditions. [•] Cells cultured in DIO, [•] Cells cultured in D0.1. Both 
CA320M and B16.BL6 appear to arrest in G1 by 48 hr in D0.1 as indicated by an increase in 
percent G1 with a concomitant decrease in S phase. E. Modeling the proliferation rate of 
CA320M. [O] Theoretical curve of 2 cell divisions in 24 hr, [•] Cells cultured in DIO, [•] 
Cells cultured in D0.1, [A] Theoretical curve of 3 cell divisions in 24 hr. Cells double 
approximately every 12 hr in DIO. F. Percent CFSE positive cells per doubling time in 48 hr 
in DIO and D0.1 cultures. Cells cultured in DIO cycled 3-4 times versus 2-3 times in D0.1. 
Results are representative of several experiments. 
72 
B 
90% 
m 30% 
12 24 36 
Hours in Culture 
90% 
70% 
U 50% -
= 30% 
12 24 36 
Hours in Culture 
QJ l/l (0 
_c 
CL 
10 
C 
VI 
60% 
50% 
40% 
= 30% 
U 
20% 
12 24 36 
Hours in Culture 
48 
u 60% 
= 50% 
12 24 36 
Hours in Culture 
10000 
<u 
u 
c O) 
% 
2 
o 3 
C (0 O) 
V) 
1000 - u 
> 
—
f 
§ 
—
f 
§ 
100 • 4—' 40% -
O 
10 - ! % 20% • 
1 • , , s u 0% -• 
80% 
12 24 36 
Hours in Culture 
48 
nD10 eDO.1 
0 12 3 4 
Nurriber of Cell Doublings 
Figure 4. A. CA320M unmodified cells stained with FITC labeled IB4 lectin specific for 
agal epitopes. B. Cells transduced with HE7agall for 8 hr showing the presence of cell 
surface agal epitopes. C. Cells transduced with HE7EGFP as a control of efficiency of viral 
infection showing GFP fluorescence. D. Bright field of a representative culture of CA320M. 
40x magnification. 
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Figure 5. Serum killing analysis with A. normal human serum (NHS) (density plots on the 
right are of HE7agall expressing cells gated on 7AAD and C3c staining) or B. serum 
collected from mice (MS) primed against the agal epitope by 2 injections of RWB (density 
plots on the right are similar to above). Two hundred thousand cells were incubated with 
50% serum for lhr at 37°C and tri-labeled for agal epitope, C3c complement, and cell death 
discrimination by 7AAD. Results are plotted as percent agal positive C3c bound dead cells 
except for the non-transduced CA320M cells that were only C3c/7AAD positive. HIS, Heat 
inactivated serum. Experiments were performed in triplicate. 
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Figure 6. In vivo tumor growth kinetics of CA320M in a(l,3)GT KO female H-2b/b mice. 
Mice (n = 8 per group) were injected subcutaneously with cells suspended in 100 |il HBSS. 
A. Mean (± SEM) tumor volume over time, [•] lxlO6 or [•] 5xl06 cells per animal. B. 
Percentage of mice permitting tumor growth through day 30. C. Percentage of mice with 
lethal tumor volume (defined as an end-point tumor volume > 400 mm3) by day 30. 
Experiments were performed in triplicate. 
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CHAPTER 3: HIGH-THROUGHPUT FLUORESCENT SCREENING OF 
TRANSGENIC ANIMALS: PHENOTYPING AND HAPLOTYPING 
A paper accepted by the journal Cytometry, 2006 
Daniel J. Hellrung1'2, Gabriela Rossi1, Charles J. Link1'2 
'iowa Cancer Research Foundation, Urbandale, IA 
2Iowa State University, Ames, IA 
Key Words: high-throughput, screening, phenotyping, genotyping, transgenic, knockout, 
a( 1,3)galactosy transferase 
Abbreviations: 
WBC: white blood cells IB4: isolectin B4 
PE: phycoerythrin agal: a(l,3)galactosytransferase epitope 
a(l,3)GT: a(l,3)galactosytransferase gene 
a(l,3)GTKO: a( 1,3)galactosytransferase gene knockout mouse 
Background: Methods for genotyping transgenic animals currently consist of extracting 
genomic DNA from blood or tissue followed by PGR or Southern blot analysis. These 
methods when used to screen large numbers of animals can be time consuming and 
expensive. Therefore, we developed a novel microscopy method that allows high-throughput 
screening of phenotypic changes on leukocytes resulting from the transgenic genotype. This 
technique allows investigators to quickly screen a large number of animals without the need 
to extract DNA from each one. Moreover, since blood is collected for the initial screening, 
putative homozygotes can be confirmed by conventional methods using the same blood 
samples. Methods: We collected blood from wild-type mice expressing the 
a(l,3)galactosytransferase gene [a(l,3)GT] positive and a(1,3)GTknockout [a(l,3)GTKO] 
mice and probed for the presence of gala(l—>3)gal (agal) epitopes. Also, alloantigen specific 
antibodies were used to determine the haplotype of our outbred mouse colony in order to 
develop an inbred line. Results: agal epitopes were detected in wild-type but not a(l,3)GT 
KO samples. To validate these results PGR was used to demonstrate the native a(l,3)GT 
gene in wild-type and the pGKneo construct in a(l,3)GT KO mice. Furthermore, haplotypes 
were determined and mice divided for backcrosses. Conclusions: This screening method is 
useful for both preliminary screening of transgenic mice and the development of an inbred 
mouse colony by rapid determination of MHC I haplotype. Here we demonstrate the use of 
this technique and show how it can be a valuable tool saving time and resources in both 
investigator effort and animal husbandry. 
The development of transgenic animals, including both knockin and knockout types, has 
enhanced the studies of many disciplines including immunobiology and transplant biology. 
For example, porcine organs have been investigated for transplantation into humans due to 
the many similarities between species (7). However, efforts have been hampered by the 
existence of the xenoantigen gala(l—>3)gal (agal epitope) on the transplant tissue. To 
address this problem Lai et al., recently developed an a(l,3)galactosyltransferase knockout 
[a(l,3)GT KO] pig thereby paving the road for organ transplantation in the future (6). 
Examples like this are numerous in the literature however production and screening of 
transgenic animals still remain a laborious, time consuming, and expensive process 
regardless of the method employed. Several protocols exist for the production of transgenic 
animals depending on the investigators' goal (3). In most cases a genomic copy of the gene 
of interest is cloned and transferred into recipient cells where random integration or 
homologous recombination between a wild-type allele occurs. Offspring are screened to 
isolate those animals with homozygous genotypes by methods such as PGR or Southern blot 
analysis using DNA isolated from whole blood, tail tissue, or saliva (1,4,5,8,9,11). These 
screening steps can often be time consuming and expensive not only in reagents but also in 
animal husbandry costs. Here we describe a novel high-throughput method of phenotyping 
transgenic animals by microscopy that allows the investigator to quickly determine which 
animals require further genotyping. Moreover, since the technique employs the use of blood 
samples the investigator can validate initial phenotypic findings by extracting genomic DNA 
for analysis by PGR or Southern blot without the need to collect additional samples from the 
animals. Finally, blood samples can further be used to determine class I major 
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histocompatibility complex haplotype of the animals thereby allowing the investigator to 
begin the process of developing an inbred strain or to conduct haplotype specific 
experiments. 
RESULTS AND DISCUSSION 
Detection of agal Epitopes on White Blood Cells 
Mice, transgenic knockout of the CD1 gene but agal positive (hereby referred to as wild-
type) were procured from the University of Chicago animal facility (2) and a(l,3)GT KO 
(agal negative) mice were procured from Michigan State University animal facility (10). 
After an adjustment period, mice were bred in our AAALAC accredited animal facility and 
all procedures were approved by the IACUC prior to being used in this study. The left leg of 
wild-type and a(l,3)GT KO mice were shaved to expose the saphenous vein. Heparinized 
Microvette CB300 tubes (Sarstedt Inc, Newton, NC) were filled with approximately 200 (il 
of blood collected after the vein was transected with a 25-gauge needle (Becton Dickinson, 
Franklin Lake, NJ). Fifteen microliters of blood was transferred to a round-bottom 96-well 
plate (Corning Co, Corning, NY) and diluted with 85 |xl Hanks Balanced Salt Solution 
(HBSS, Invitrogen-Life Technologies Inc., Carlsbad, CA). Samples were stained by adding 
100 |ll of 1 gg/ml biotinylated anti-agal Griffonia simplicifolia IB4 isolectin (Vector 
Laboratories, Burlingame, CA) diluted in HBSS and incubated at room temperature for 30 
min. Binding of the biotinylated IB4 isolectin was detected with 0.5 fig/ml avidin conjugated 
phycoerythrin (PE, BD Pharmingen, San Diego CA). Cells were pelleted by centrifugation 
for 5 min at 423 x g using a 96-well plate holder followed by washing with 200 |J,1 HBSS, 
and pelleted as before. Cells were resuspended in 200 pil HBSS and 50 p.1 were transferred to 
a flat-bottom 96-well plate (Coming Co). The plate was centrifuged as above and 
microscopically analyzed (Nikon Diaphot) using a Cy3 (532 nm) fluorescent filter (Table 1). 
IB4 isolectin successfully detected agal epitopes on white blood cells (WBC) of blood 
samples collected from wild-type but not a(l,3)GT KO mice (Fig. la and lb, respectively). 
Figure lc is a bright field photomicrograph of a representative blood sample demonstrating 
the number of cells used in this assay. 
Validation of the agal Phenotype 
Genomic DNA was isolated from wild-type and a(l,3)GT KO blood samples. Polymerase 
chain reaction (PGR) screening of a(l,3)GT KO was performed using the forward primer 
(GALFDJH) 5'-GAG GAG ATC CTG GCC GAG ATC GAG GAG GAG-3', which binds 
upstream of the Sail site in exon 9 of the agal gene, and the reverse primer (NeoU) 5'-GGT 
GGA GAG GCT ATT CGG CTA TGA -3' which binds the 5' region of the NeoR gene. To 
screen the wild-type, PGR was performed with the GALFDJH primer and the reverse primer 
(BGLGAL#2) 5'-AGA TCT TGA GAG ATT ATT TCT AAC CAA ATT ATA CTC-3' 
which binds 481 bp downstream of the Sail site. To construct the a(l,3)GT KO strain, Thall 
et al., inserted the pGKneo construct into the Sail site of exon 9 of the a(l,3)GT gene (10). 
Therefore, 751 bp and 481 bp PGR products from a(l,3)GT KO and wild-type mice, 
respectively, was expected. A PGR program of 94°C for 30 sec, 55°C for 90 sec, and 68°C 
for 60 sec for a total of 40 cycles was used. Results from the a(l,3)GT KO blood samples 
yielded the expected 751 bp fragment (Fig. Id, lanes 1 and 2). By comparison, the same 
primers failed to amplify a band in the wild-type samples demonstrating absence of the NeoR 
gene in exon 9 of a(l,3)GT gene (Fig. Id lanes 3 and 4). To confirm the presence of exon 9 
of the a(l,3)GT gene in the wild-type mice, a primer downstream of the Sail site was used to 
successfully amplify a 481 bp fragment (Fig. Id lanes 5 and 6). A cDNA clone of the 
a(l,3)GT gene was used as a positive control with the same primers as the wild-type 
demonstrating the expected 481 bp fragment (Fig. Id lane 7). No fragment was amplified in 
the control reaction where all three primers were used without DNA template (Fig. 2 lane 8). 
Techniques designed to enhance the process of production and screening of transgenic 
animals that save the investigator time and resources are in demand. Therefore, we have 
developed a novel high-throughput phenotyping technique that allows the investigator to 
determine putative knockin or knockout homozygotes from WBCs using direct or indirect 
fluorescent microscopy. Either a primary labeled fluorescent probes such as an antibody or 
lectin, or an unlabeled probe followed by a secondary detection system can be used to screen 
large numbers of samples in a microtiter plate within a short period of time. Moreover, this 
technique allows for the analysis of both cell surface and intracellular expression of antigens, 
the latter requiring the cell to be incubated in a membrane permeablizing agent prior to 
staining. By contrast, other phenotyping methods, such as flow cytometry, may be 
suboptimal for many reasons. First this method requires a larger volume of blood to be 
collected from the animal which can be particularly difficult in mice. Subsequent sample 
collection may be needed to complete the validation steps. Second, sample analysis is slower 
due to the necessity of handling individual tubes for each blood sample and acquiring the 
flow data for each tube. Finally, a highly trained staff member must be capable of calibrating 
the machine and acquiring the data for each sample including controls. Using flow 
cytometry, therefore, may be useful for some specialized applications, but for large scale 
screening, may be less efficient. In our lab, we found the limiting step using flow cytometry 
was the number of samples that could be analyzed in a day. Using our high-throughput 
screening technique, we found that the limiting factor was how many animals could be bled 
in a day, rather than analyzed. For example, using flow cytometry, at least 2 days of sample 
preparation and analysis were required to phenotype approximately 30 animals. By 
comparison our rapid screening method required only 1 day for sample preparation and 
analysis of over 80 animals. Moreover, unlike the flow cytometry method, we could use the 
remaining blood samples of putative homozygotes to extract genomic DNA from the WBCs 
to validate the phenotype without having to collect more tissue from the animals. 
As with many phenotyping protocols, problems exist when attempting to discern between 
homozygotes and hétérozygotes, particularly for knockin genotypes. For example 
hétérozygotes resulting from the integration of a marker gene such as green fluorescent 
protein (GFP) would have a green fluorescent phenotype. However this technique would still 
remain valuable for screening the null phenotype resulting from aberrant or non-integrated 
GFP. 
We have used this method in our lab to screen for the agal null phenotype in 363 F1 
offspring from F0 heterozygote CD1 KO x a(I,3)GT KO crossed mice. In these experiments 
we collected blood from each of the animals and used a variation of the protocol in table 1 
that allowed us to store blood samples long term. Samples were fixed and simultaneously the 
red blood cells were lysed prior to fluorescein isothiocyanate (FITC) conjugated IB4 isolectin 
labeling. Seventy-nine animals were found to be agal negative and 27 of those were tested 
for the double knockout phenotype of CD1~'~ and a(l,3)GT1'. Results of genotyping these 
mice by PGR using genomic DNA extracted from the blood samples validated the phenotype 
observed using the fluorescent screening technique. 
The sensitivity and specificity of the assay will depend on the marker selected, the quality 
of the fluorescence reagent, affinity for the ligand and number (or concentration) of ligands 
on or within target cells. For experiments like the one above, the agal epitopes were present 
in high concentration on the cell surface and easily detected by light microscopy using the 
agal-specific isolectin. Therefore, we found with this application the technique was 95% 
sensitive and 100% specific. However, in another experiment to detect CD1 molecules in 
non-CD/ KO mice we were not able to convincingly use this assay since the level of 
expression of these molecules on the cell surface of PBLs was not sufficient. It is noteworthy 
that flow analysis of the same cells was unreliable thereby requiring more intensive genetic 
analysis. 
Many protocols require the use of a variety of genetic backgrounds from which to produce 
transgenic animals. For example, the a(l,3)GT KO mice were a cross between C57/BL6 (H-
2b), 129SV (H-2b), and DBA/2 (H-2d) backgrounds. For immunological studies, haplotype 
matched mice are desirable. Therefore, in addition to phenotyping transgenic mice, we used 
this protocol to haplotype our cross-bred colony of mice. We employed multiple antibodies 
against the H-2b and H-2d haplotypes corresponding to the possible combinations of class I 
major histocompatibility complex expressed by these mice. With PE labeled anti-H-2Db, 
FITC labeled anti-H-2Kb, PE labeled anti-H-2Dd and FITC labeled anti-H-2Kd antibodies 
with isotype controls we screened 300 mice and were able to divide them into colonies of 
homozygous H-2b/b and H-2d/d animals for use in both inbreeding the colony and studies 
requiring haplotype matched animals. Utilizing multiple antibodies allowed for satisfactory 
control thereby avoiding having to isolate DNA from each of these animals for either PCR or 
Southern blot analysis. 
Techniques designed to facilitate the researcher in achieving results quickly and cost 
effectively are valuable, especially when they involve production of transgenic animals. We 
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have described a novel protocol that has vastly decreased our time, effort, and expense in 
developing transgenic colonies of mice for our lab. 
89 
ACKNOWLEDGEMENTS 
The authors thank Dawn Bertrand and Robin Helton for expertise in maintaining the 
animal colony. This work was funded by a grant from the Department of Defense Army 
Breast Cancer Foundation (#DAMD 17-00-1 -0292) and the Susan G. Komen Breast Cancer 
Foundation (#99-3215). 
REFERENCES 
1. Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith 
and K. Struhl. 1995. Current Protocols in Molecular Biology. Current Protocols 
John Wiley & Sons, Inc 7:Unit 2.9A. 
2. Chen, Y.H., N.M. Chiu, M. Mandai, N. Wang and C.R. Wang. 1997. Impaired 
NK1+ T cell development and early IL-4 production in CD 1-deficient mice. 
Immunity 5:459-467. 
3. Clarke, A. 2002. Transgenesis Techniques: Principles and Protocols 2nd Ed. 
Methods in Molecular Biology, Humana Press Inc. 180. 
4. Gross, M. and E. Rotzer. 1998. Rapid DNA extraction method for genetic 
screening. Eur J Med Res 3:173-175. 
5. Henneberger, C., R. Grantyn and T. Rothe. 2000. Rapid genotyping of newborn 
gene mutant mice. J Neurosci Methods 700:123-126. 
6. Lai, L., D. Kolber-Simonds, K.W. Park, H.T. Cheong, J.L. Greenstein, G.S. Im, 
M. Samuel, A. Bonk, A. Rieke, B.N. Day, C.N. Murphy, D.B. Carter, R.J. 
Hawley and R.S. Prather. 2002. Production of alpha-1,3-galactosytransferase 
knockout pigs by nuclear transfer cloning. Science 295:1089-1092. 
7. Lai, L. and R.S. Prather. 2002. Progress in producing knockout models for 
xenotransplantation by nuclear transfer. Ann Med 34:501-506. 
8. Ohhara, M., Y. Kurosu and M. Esumi. 1994. Direct PCR of whole blood and hair 
shafts by microwave treatment. Biotechniques 17:726, 728. 
9. Sandford, A.J. and P.D. Pare. 1997. Direct PCR of small genomic DNA fragments 
from serum. Biotechniques 23:890-892. 
91 
10. Thall, A.D., P. Maly and J.B. Lowe. 1995. Oocyte Gal alpha 1,3Gal epitopes 
implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required 
for fertilization in the mouse. J Biol Chem 270:21437-21440. 
11. Zimmermann, K., H P. Schwarz and P L. Turecek. 2000. Deoxyribonucleic acid 
preparation in polymerase chain reaction genotyping of transgenic mice. Comp Med 
50:314-316. 
Table 1. High-throughput phenotyping/genotyping protocol designed for analysis of samples 
by microscopy. Peripheral blood cells are labeled with a fluorescence labeled probe specific 
for the antigen corresponding to the transgenic genotype and viewed under fluorescence 
microscopy. 
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Table 1. High-Throughput Phenotyping Protocol 
1. Collect ~ 200 |jl whole blood in heparinized tubes. 
2. Dilute 15 fxl blood with 85 |il HBSS in 96-well round bottom 
microtiter plate. 
3. Mix samples with 100 (il of fluorescence labeled probe or 
unconjugated probe*. Incubate 30 min RT. 
4. Pellet cells by centrifugation 5 min @ 423 x g, wash with 200 
jjlI HBSS, Repeat 3 with secondary fluorescence labeled 
probe (or go to step 5), pellet cells again and wash. 
5. Raise in 200 gl HBSS, transfer 50 jllI to 96-well flat bottom 
microtiter plate, cytospin as in step 4 and view with 
fluorescence microscopy. 
* For primary labeled probes such as antibodies or lectins, do not repeat step 3. 
For some applications cells may need to be fixed and/or permeabilized for the 
probe to bind. To increase the number of blood cells or to detect more rare targets 
lyse RBCs prior to staining. 
Figure 1. Photomicrographs of results obtained from the microtiter plate protocol. A. 
Phycoerythrin labeled anti-agal IB4 isolectin successfully detected agal epitopes on CD1 KO 
[a(l,3)GT wild-type] mouse white blood cells (WBC) from whole blood samples. B. 
a(l,3)GT KO mice do not express the a(l,3)GT gene as confirmed by the lack of anti-agal 
IB4 isolectin staining of WBCs from whole blood samples. C. Bright field photomicrograph 
of whole blood representing the number of cells used in the final analysis step of the 
protocol. Red blood cells (RBC) were not lysed in these photomicrograph's. However, to 
increase the number of WBCs for analysis, the RBCs may be lysed, filtered and the 
remaining WBCs may the used for detection of the antigen of interest. 

Figure 2. PGR results after amplifying a region of exon 9 from the a(l,3)GT gene using 
genomic DNA extracted from whole blood samples. 1 Kb DNA ladder was used as the 
marker. Lanes 1 and 2 are from a(l,3)GT KO mice showing the expected 751 bp fragment 
corresponding to the a(l,3)GT specific amplification of the NeoR gene (green and blue 
primer pair) used to disrupt the a(l,3)GT gene. Lanes 3 and 4 are from CD1 KO mice 
demonstrating the absence of NeoR in the a(l,3)GT gene (green and blue primer pair). Lane 
5 and 6 demonstrate wild-type exon 9 of the a(l,3)GT gene showing the expected 481 bp 
band (green and red primer pair). Lane 7 is the positive control from a cDNA clone of the 
a(l,3)GT gene showing the expected 481 bp fragment. Lane 8 is the negative control where 
all three primers were used in the reaction without template DNA. X denotes an empty lane. 
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CHAPTER 4: CO-EXPRESSION OF a(l,3)GALACTOSYLTRANSFERASE AND 
BACILLUS THURINGIENSIS PIPLC ENHANCES HYPERACUTE REJECTION OF 
TUMOR CELLS 
A paper accepted to the journal Cancer Immunology, Immunotherapy, 2006 
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Running Title: Co-expression of agal and PIPLC enhances tumor killing 
Keywords: a( 1,3)galactosyltransferase, phosphatidylinositol-specific phospholipase C, 
complement, complement resistance molecules, immunotherapy, cancer 
The use of a( 1,3)galactosyltransferase (aGT) as a method of inducing hyperacute 
rejection of tumors has been gaining interest recently. However, the approach is based in part 
on the sensitivity of each tumor line to the effects of complement mediated lysis. Tumors 
expressing complement resistance factors such as membrane cofactor (CD46), decay 
accelerating factor (CD55) and protectin (CD59) have been shown to be more resistant to 
complement mediated lysis than cells not expressing these surface molecules. Anchored to 
the membrane by a glycosylphosphoinositol moiety (GPI-anchored), CD55 and CD59 can be 
cleaved by Bacillus thuringiensis phosphatidylinositol-specific phospholipase C (PIPLC). 
Complement resistant A549 human lung carcinoma cells were engineered to express both the 
murine aGT gene and the B. thuringiensis PIPLC gene to alleviate complement resistance 
and enhance antibody dependent agal-mediated cytotoxicity. The PIPLC native signal 
sequence was replaced with the human epidermal growth factor signal sequence, 
EGFssPIPLC, to induce secretion from A549. Expression of EGFssPIPLC resulted in 
complete removal of CD55 and CD59 while sparing the non-GPI-anchored CD46. Results 
demonstrated that A549 cells transduced with two recombinant retroviral vectors carrying the 
a(l,3)GT and EGFssPIPLC genes expressed high levels of agal epitope and exhibited a 5-
fold increase in sensitivity to anti-agal mediated complement lysis (hyperacute rejection). 
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INTRODUCTION 
Use of the xenoantigen gal a(l,3)gal has been gaining attention for its potential to induce 
tumor killing [19, 39]. a(l,3)galactosyltransferase (aGT) is a Golgi dependent enzyme that 
modifies membrane bound glycoproteins and glycolipids. aGT catalyzes the transfer of 
galactose from uridine diphosphate-galactose (UDP-Gal) to the penultimate acceptor N-
acetyl-lactosamine (GlcNAc-R) of carbohydrate side chains in a galal—>3gal linkage (agal 
epitope) [21, 24]. Virtually all mammalian cells possess a functioning a(l,3)GT gene [12], 
however mutations in both alleles of a(l,3)GT gene in humans, apes, and old world primates, 
such as baboons, render these species incapable of expressing a functional aGT enzyme [20]. 
Clonal B-cell analysis suggests that 1% of total circulating antibodies are directed against the 
agal epitope, presumably through constant antigenic stimulation from gastrointestinal normal 
flora [10, 11, 13, 16]. Anti-agal antibodies from baboons have been shown to be responsible 
for inducing hyperacute rejection of agal positive porcine xenografts [32, 33]. These 
antibodies bind agal epitopes and activate the classical pathway of complement inducing 
cytolysis of transplanted tissue [7, 14, 35, 36, 41]. 
Hyperacute rejection of agal expressing tumor cells has been studied and is the basis for 
allogeneic vaccine tumor therapy [25, 26, 39]. In addition, intratumoral injection of a(l,3)GT 
encoding viral vectors provides another avenue of cancer immunotherapy, however, a 
significant problem may exist with these approaches. Previous investigators have shown that 
human tumor cells express the complement resistance molecules (CRM); CD46 (membrane 
cofactor protein), CD55 (decay accelerating factor), and CD59 (protectin) [3, 4] that confer 
resistance to complement (C') mediated cytolysis [3, 19, 23, 40]. The classical pathway of C' 
activation is secondary to antibody binding of antigen. Binding of Clq to the Fc region of 
membrane bound antibody results in a series of proteolytic events ending with the activation 
of terminal C' components C5-C9 (membrane attack complex). The membrane attack 
complex produces a pore in the lipid bilayer resulting in cytolysis. CD46 and CD55 inhibit 
C3, an early C' component, while CD59 disrupts the formation of the membrane attack 
complex. Resistance to C' mediated lysis results in decreased tumor killing. Moreover, 
recruitment of antigen presenting cells and other phagocytes by the chemotactically active C' 
cleavage product C5a, for example, would be diminished resulting in poor immune 
activation. Varsano et al., demonstrated increased expression of CRMs in the human lung 
tumor lines ChaGo K-l and NCI-H596 in comparison to normal human nasal epithelium in 
primary cultures [40]. These authors went on to show that ChaGo K-l and NCI-H596 tumor 
lines were highly resistant to C' mediated lysis unless treated with PIPLC prior to exposure 
toC'. 
The non-human phosphatidylinositol-specific phospholipase C (PIPLC) is a 35 kDa water 
soluble secreted enzyme produced by Bacillus thuringiensis, B. cereus, Listeria 
monocytogenes, L. ivanovii, Staphylococcus aureus, Clostridium novyi, and Rhodococcus 
equii [15]. Suspected to be a prokaryotic virulence factor [9, 27], PIPLC acts by cleaving 
membrane lipid phosphotidylinositol (PI), lyso-PI and glycosyl-PI [15]. 
Glycosylphosphoinositol anchored CRMs, CD55 and CD59, are susceptible to PIPLC 
enzymatic cleavage, whereas, non-GPI anchored CD46 is not [19, 42]. Previous investigators 
have demonstrated the importance of CRMs in antibody-dependent agal mediated cell lysis 
of C' resistant tumor lines [19, 42]. However, their approach utilized exogenous application 
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of PIPLC to agal expressing cells to alleviate the C' resistance. For in vivo therapy, 
exogenous application of this enzyme would not be a feasible approach. 
The Bacillus thuringiensis PIPLC and the a(l,3)GT genes were engineered to be 
delivered to cells in two separate retroviral vectors. Results presented here show activity of 
PIPLC, secreted from transduced A549 human lung tumor cells, and demonstrate a 
synergistic increase in agal mediated complement killing in an in vitro assay. When applied 
to in vivo agal mediated therapy of solid tumors, this approach may enhance anti-tumor 
immune responses. 
MATERIALS AND METHODS 
Construction of a secretable PIPLC enzyme 
Plasmid pET21b-PLC encoding the PIPLC gene isolated from the gram positive bacteria 
Bacillus thuringiensis was obtained (kindly provided by Dr. Ming Tsai of Ohio State 
University). Analysis of the PIPLC and human epidermal growth factor (EGF, NM_001963) 
signal sequences (SS) were performed using SignalP-HMM software[17]. Polymerase chain 
reaction (PCR) primers (PAGE purified, Sigma-Genosys, St. Louis, MO) were designed to 
replace the PIPLC SS with the EGF SS in a two step PCR reaction. The 51 bp forward 
primer, EGFssF, corresponds to the first 15 amino acids of the EGF SS (an Xhol restriction 
enzyme cut site was engineered at the 5' terminal): 5'-ctc-gag-ATG-CTG-CTC-ACT-CTT-
ATC-ATT-CTG-TTG-CCA-GTA-GTT-TCA-AAA-TTT-3 '. The 52 bp reverse primer, 
EGFssR2: 5-CAA-GCT-CAT-TAA-CAG-AGC-TAG-CTG-CTG-AGA-GAC-TAA-CAA-
AAC-TAA-ATT-TTG-A-3' annealed to both the 5' region of the PIPLC gene immediately 
downstream the native SS and the 3' end of EGFssF primer with a 9 nt overlap. In the first 
step, 2 gg of EGFssF and EGFssR2 were annealed and filled-in using a PCR thermocycler. 
Eighty nanograms of the product was used along with 2 fig of EGFssF and NEWPLCR2 (37 
bp with Xhol engineered into the primer: 5 '-ctc-tcg-AGT-TAT-TCT-TTT-ATT-AAT-GAC-
TTA-TTC-GCT-C-3 ') primers to amplify the PIPLC gene with the new signal sequence, 
EGFssPIPLC. The following program was used: 95°C for 3min, 95°C for 30 sec, 50°C for 45 
sec, 68°C for 1 min, 35 cycles, 68°C for 10 min. The 990 bp PCR product was confirmed by 
agarose gel electrophoresis. The product was gel isolated through Spin-X Plastic Centrifuge 
Tube Filters (Coming Life Sciences, Corning, NY) and ethanol precipitated. Five min room 
temperature ligation using the pCRXL-TOPO (Invitrogen-Life Technologies Inc„ Carlsbad, 
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CA) plasmid was performed and DH5a (Invitrogen-Life Technologies Inc.) were 
transformed by heat shock. Kanamycin resistant colonies were screened by PCR using the 
EGFssF and NEWPLCR2 primers using the above program. Plasmid DNA was isolated from 
PCR positive colonies and cut with Xhol restriction enzyme. The EGFssPIPLC gene was gel 
isolated as above and ligated to an Xhol digested and dephosphorylated Moloney murine 
leukemia viral plasmid pLXSN [28] resulting in the plasmid pLPSN. The 
oc(l,3)galactosyltransferase gene, a(l,3)GT was PCR amplified from pHE700-aGal vector 
using a 36 bp forward primer AgalKoz-F, 5'-ACA-AAA-GCT-TGA-CAT-GGA-TGT-
C A A-GGG-AAA-AGT - AAT-3 % which contains a Kozack consensus sequence for effective 
translation of the native murine a(l,3)GT, and, a 28 bp reverse primer, AgalD, 5'-AAT-
TAT-CGA-TTC-AGA-CAT-TAT-TTC-TAA-C-3 '. The amplified DNA fragment was 
digested by Hind III and Clal restriction enzymes and cloned into similarly prepared 
Moloney murine leukemia viral plasmid pLNCX [28]. 
Plasmids pLXSN, pLPSN and pLNCKG were packaged into infectious retroviral particles 
by transaction into the pAM3-IRES-Zeo expressing NIH-3T3 retroviral packaging cell line 
[43]. Viral supernatant, LXSN, LPSN and LNCKG were used to infect A549 cells giving rise 
to the cell lines: A549LXSN, A549LPSN, A549LNCKG. Cells lines were selected with 
neomycin for use in this study. An aliquot of neomycin selected A549LPSN cells was co-
transduced with LNCKG giving rise to A549LNCKG-LPSN. Alpha-gal positive cells were 
selected by fluorescence activated cell sorting (FACS, Beckman Coulter Epics Altra). 
Detection and cleavage of CRMs on A549 human lung tumor cells 
Detection of the complement resistance molecules CD46 (membrane cofactor protein), 
CD55 (decay accelerating factor), and CD59 (protectin) on A549 human lung tumor cells 
was performed using either fluorescein isothiocyanate (FITC) or phycoerythrin (PE) labeled 
anti-CD46 (clone E4.3), anti-CD55 (clone IA10), and anti-CD59 (clone H19) antibodies as 
per the manufacturer's recommended protocol (BD Pharmingen, San Diego, CA). Isotype 
control antibody (clone G155-178) was used where appropriate. Briefly, cells were labeled 
with 50 |il/ml/106 cells of each antibody for 30 min at room temperature (RT). Cells were 
washed twice in Hanks Balanced Salt Solution (HBSS, Invitrogen-Life Technologies Inc.), 
resuspended in 1 ml HBSS and analyzed by flow cytometry. Recombinant PIPLC (Sigma 
Aldrich) was resuspended in Phosphate Buffered Saline (PBS, Invitrogen-Life Technologies 
Inc.) and 0.1U/106 A549 cells was incubated for 1 hr at 37°C. Expression of membrane 
bound CRMs was analyzed as above. Finally, A549LPSN cells were cultured for 72 hr in D5 
media consisting of Dulbecco's Modified Eagles Medium (DMEM) supplemented with 5% 
fetal bovine serum (FBS) and lx L-glutamine with lx HEPES buffer solution (Invitrogen-
Life Technologies Inc.) 
Cleavage of membrane bound CRMs over time 
A549 no vector (NV) and A549LXSN membrane expression of CRMs were compared to 
A549LPSN over culturing periods of 24, 36, 48, 72 hrs. Cells were seeded at a density of 105 
in a T-25 culture flask (Nalge Nunc International, Rochester, NY) in D5 media. At each time 
point, cells were released from the flask with 0.4% Trypsin-EDTA (Invitrogen-Life 
Technologies Inc), washed twice in HBSS, and labeled with anti-CD59 PE labeled antibody 
and isotype PE labeled control as above. Cells were analyzed by flow cytometry. 
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Detection of Secreted PIPLC 
In the absence of a suitable antibody to analyze secreted PIPLC, we compared co-cultured 
A549LNCKG:A549NV cells to co-cultured A549LNCKG-LPSN:A549NV cells in both 
barrier and non-barrier culture plates. Cells were cultured approximately 1:1 over a 72 hr 
period followed by flow cytometric analysis of CD55 and CD59 membrane expression using 
either PE labeled CD55 or CD59 antibodies as above. To detect agal membrane expression 
cells were counter-staining with Griffonia simplicifolia FITC labeled anti-agal IB4 isolectin 
(Vector Laboratories, Burlingame, CA). After antibody labeling, cells were washed with 
HBSS and incubated in 1 |il/ml FITC labeled IB4 isolectin for 10 min at RT. Cells were 
washed twice in HBSS and analyzed by flow cytometry. 
Effect of PIPLC on agal Expression 
Alpha-gal expression was compared in A549LNCKG and A549LNCKG-LPSN cells. 
After 72 hrs culture in D5 and lx HEPES, as above, cells were stained with anti-CD59 PE 
labeled antibody and anti-agal FITC labeled IB4 isolectin. Cells were washed twice with 
HBSS and analyzed by flow cytometry. 
Increased susceptibility of agal-PIPLC co-expressing A549 cells to anti-agal serum 
Sera from six human donors (NHS) was collected, and frozen in aliquots at -70°C to 
preserve complement factors until use. Anti-agal antibody titer was determine by ELISA as 
described elsewhere [39]. Briefly, 96-well plates (Falcon, Becton Dickinson Labware, 
Franklin, NJ) were coated with 50 |xl of 5 (ig/ml agal-BSA conjugate (Vector Laboratories) 
in carbonate buffer (pH 9.5) overnight at 37°C in a humidified chamber. Plates were blocked 
with 150 fil of 1% BSA Fraction V (Sigma Co., St. Louis, MO) in carbonate buffer for 2 hr at 
37°C in humidified chamber. Sera was serially diluted in wash buffer (lx PBS/0.05% Tween 
20 pH 7.2) to a final volume of 50 (il/well and incubated at room temperature for 2 hr. Wells 
were washed 5x in wash buffer followed by incubation with 50 |il/well of 1:3000 dilution of 
goat anti-mouse IgG conjugated to horseradish peroxidase (Dako A/S, Denmark) in wash 
buffer for 1 hr at room temperature. Wells were washed 5x followed by addition of 100 
(il/well 3,3 ',5,5'-tetramethylbenzidine (Sigma Co.) liquid substrate. The reaction was 
allowed to develop for 30 min at room temperature where upon it was terminated by the 
addition of 100 |0,l/well of 1 M H2SO4 and the results read at 450 nm. 
Concentration of complement factors, Clq, C3 and C4 were determined in each serum 
sample by immunoprecipitation (Iowa- Methodist Medical Center, Des Moines, IA). 
Furthermore, we used a functional assay to assess C' activity. One million agal expressing 
murine colon carcinoma cells, MC38, were incubated with 6.25%, 12.5%, 25%, and 50% 
pooled NHS for 1 hr at 37°C. Cells were washed in HBSS and stained with 1 (il/ml anti-agal 
FITC labeled IB4 isolectin for 30 min at RT. Next, cells were washed twice in HBSS, 
counter-stained with 10 |Xg/ml propidium iodide for 10 min at RT, and analyzed by flow 
cytometry. 
A549 NV, A549LXSN, A549LPSN, A549LNCKG, and A549LNCKG-LPSN were 
cultured for 72 hrs in D5 media. One million cells from each group were incubated with 
12.5% pooled NHS, or 12.5% heat inactivated pooled NHS (HIS) for 1 hr at 37°C. Cells were 
washed in HBSS and tri-labeled with 1 (ig/ml biotinylated anti-agal IB4 (Vector Labs) 1:150 
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dilution of mouse anti-C5b-9 FITC labeled IgG (Dako A/S) and 1 jJ.g/106 cells of 7-
aminoactinomycin D (7-AAD, Sigma Co.) in 1% BSA and HBSS for 30 min at room 
temperature. The biotinylated IB4 was detected with 0.5 jlg/ml streptavidin conjugated PE. 
Cells were washed in HBSS and analyzed by flow cytometry. 
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RESULTS 
Construction of a secretable PIPLC enzyme 
The PIPLC gene isolated from the gram positive bacteria B. thuringiensis was engineered 
to be secreted from eukaryotic cells by replacing the native SS (nSS) with the human 
epidermal growth factor signal sequence (EGF SS). Signal sequence prediction software 
specific for gram positive bacteria localized the SS to the first 31 residues of the PIPLC gene 
(fig. la), confirming the published sequence (Genbank accession number X14178). Similar 
analysis of the human EGF SS was performed, using parameters specific for eukaryotes, 
localized the SS to the first 22 residues (fig. la) confirming the published sequence (Genbank 
accession number NM 001963). Primers were developed to replace the nSS with the EGF 
SS by PCR. Two overlapping primers, EGFssF (fig. lb primer A) and EGFssR2 (fig. lb 
primer B) corresponding to the EGFss and a region immediately downstream the PIPLC nSS, 
were annealed and used with a third primer, NEWPLCR2 (fig. lb primer C) to amplify the 
full length PIPLC containing the EGFss. DNA sequence analysis along with PCR 
amplification of the cloned fragment using EGFssF and NEWPLCR2 confirmed the 
successful switching of the SS giving rise to EGFssPIPLC (data not shown). 
The EGFssPIPLC gene was cloned into Moloney murine leukemia retroviral vector, 
pLXSN, giving rise to pLPSN (fig. lc). To demonstrate the effect of secreted PIPLC on agal 
mediated C' cell killing, the murine a(l,3)GT gene was cloned into the Moloney murine 
leukemia retroviral vector, pLNCX, giving rise to pLNCKG (fig. Id). Viral vectors pLXSN, 
pLPSN and pLNCKG were packaged into infectious retroviral particles by transaction into 
the pAM3-IRES-Zeo expressing NIH-3T3 retroviral packaging cell line [43]. Viral 
supematants, LXSN, LPSN and LNCKG were used to transduce A549 human lung tumor 
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cells giving rise to the cell lines: A549LXSN, A549LPSN, A549LNCKG. Transduced cells 
were selected with neomycin prior to use in these experiments. An aliquot of selected 
A549LPSN cells was further transduced with LNCKG viral supernatant and the resulting co-
transduced cells were selected by fluorescent activated cell sorting for agal expression giving 
rise to A549LNCKG-LPSN. 
Detection and cleavage of CRMs on A549 human lung tumor cells 
Expression levels of complement resistance molecules (CRMs); CD46 (membrane 
cofactor protein), CD55 (decay accelerating factor), and CD59 (protectin) were determined 
on A549 cells. Antibodies directed against the CRMs demonstrated high level expression of 
CD59 and moderate levels of CD46 and CD55 expression (fig. 2a). Incubation of cells with 
0.1U B. cereus PIPLC (same specific activity as the related B. thuringiensis PIPLC) resulted 
in cleavage of CD55 and CD59 GPI anchored glycoproteins from the cells' membrane while 
the non-GPI anchored CD46 remained surface bound (fig. 2a). A549LPSN cells cultured for 
up to 72 hr resulted in 92% reduction of membrane bound CD55 and 96% reduction of CD59 
when normalized against A549NV control by calculating percent difference. Membrane 
bound CD46 levels remained virtually unchanged (fig. 2b). A consistent but small decrease 
in membrane expression levels of all three were noted with the A549LXSN cells. Results in 
figure 2b were expressed as a percent of control. All flow results are representative of several 
experiments. 
Cleavage of membrane bound CRMs over time 
I l l  
Time course analysis of A549LPSN membrane expression of CD55 and CD59 was 
performed with comparison to A549NV and A549LXSN. As expected with a secreted 
enzyme, the effect of PIPLC on a monolayer of cells is time dependent. Early culture periods 
(up to 24 hr) demonstrated a decline of 59% in membrane CD59 expression levels (fig. 3) 
whereas increased incubation periods of 36 hr and 48 hr resulted in further decreases of 69% 
and 72% respectively. By 72 hr, we observed a 97% decline in membrane CD59 expression 
levels. By comparison, A549LXSN cells demonstrated CD59 expression levels comparable 
to A549NV parental control with a standard deviation of ±5% (data not shown). Results were 
based on percent difference from A549NV control and representative of several experiments. 
Detection of secreted PIPLC 
Secretion of PIPLC was determined by co-culturing of A549NV cells with A549LNCKG-
LPSN co-transduced (CoTD) cells (co-culture 1) in both barrier and non-barrier culture 
plates. Membrane expression of CD55 and CD59 were analyzed and compared to a co-
cultured control of A549LNCKG with A549NV (co-culture 2). Alpha-gal expression served 
as a distinguishing marker for flow cytometric analysis. In co-culture 1, membrane 
expression of both CD55 (fig. 4a) and CD59 (fig. 4b) on both cell lines were reduced to 
levels observed with A549LPSN control. In co-culture 2 total expression levels of CD55 and 
CD59 were similar to A549NV and A549LXSN controls. These data indicates, i) expression 
of EGFssPIPLC gene results in secretion of the PIPLC enzyme and, ii) that CD55 and CD59 
molecules expressed on parental cells are susceptible to cleavage when cultured in the 
presence of a PIPLC secreting cell line. When parental cells are cultured with cells which 
only express the a(l,3)GT gene, levels of CD55 and CD59 remain unchanged suggesting 
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either there was little spontaneous release of endogenous human PIPLC or the human PIPLC 
had little effect on the membrane bound GPI anchored molecules. 
Effect of PIPLC on agal expression 
Since PIPLC cleaves GPI-anchored glycoproteins and glycolipids, and 
a(l,3)galactosyltransferase modifies these membrane molecules, the effect of PIPLC 
enzymatic activity on agal epitope density was analyzed. Alpha-gal expression was 
compared in A549LNCKG and A549LNCKG-LPSN cells. After 72 hr cultured cells were 
analyzed for CD59 and agal membrane expression. Alpha-gal expression (mean fluorescence 
of 150) in A549LNCKG control cells (fig. 5) was similar to co-transduced A549LNCKG-
LPSN (mean fluorescence of 130). Expression of CD59 (mean fluorescence of 106) in 
control cells (fig. 5) was significantly higher than the co-transduced cells (mean fluorescence 
of 3.4). These data indicate that PIPLC expression had little effect on agal epitope density. 
Increased susceptibility of agal-PIPLC co-expressing A549 cells to anti-agal serum 
Sera from six human donors (NHS) was collected, and frozen in aliquots at -70°C to 
preserve complement factors until use. Anti-agal antibody titer was determined by ELIS A 
with a mean of 1:5600 (table 1). Concentration (mg/dl) of complement factors, Clq, C3 and 
C4 were determined in each serum sample by immunoprecipitation (table 1). Using a 
functional assay to assess C' activity murine colon carcinoma cells, MC38, naturally 
expressing the agal epitope were incubated with various concentrations of pooled NHS to 
generate a standard curve. Concentrations of 6.25%, 12.5%, 25%, and 50% pooled NHS 
incubated with 106 cells each resulted in 18%, 42%, 75%, 88% cell death (fig. 6). These data 
demonstrate the presence of high titer anti-agal antibody with well preserved complement 
activity in the sera. Moreover, at a cell density of 106 per sample, C' factors are exhausted as 
evidenced by increased percentage of killing at lower cell densities of 5x10s and lxlO5 per 
sample (data not shown). 
To demonstrate specifically that decreased expression or CD55 and CD59 resulted in 
increased sensitivity of cells to agal mediated hyperacute rejection, A549 NV, A549LXSN, 
A549LPSN, A549LNCKG, and A549LNCKG-LPSN were each incubated with 12.5% 
pooled NHS (NPS) or heat inactivated pooled NHS (HIS). Cells were labeled with anti-agal 
IB4 isolectin and co-labeled with anti-C5b-9 antibody to detect the membrane attack complex 
of terminally activated C' which correlates to cell killing. Flow cytometric analysis gated on 
cells co-labeled with the anti-agal isolectin and anti-C5b-9 demonstrated a significant 
increase in agal mediated serum killing of cells co-expressing PIPLC. A549LNKG 
(expressing agal only) incubated with pooled NHS resulted in 12% cell killing compared to 
6% cell killing when cells incubated with HIS (fig. 7). However, A549LNCKG-LPSN 
(expressing agal and secreting PIPLC) demonstrated nearly five fold increase in serum 
killing (58%) compared to A549LNCKG control cells. By comparison to the functional 
complement assay, the same number of MC38 cells were incubated with 12.5% pooled NHS 
resulting in 42% cell death. These data demonstrate that A549 cells virally co-expressing the 
EGFssPIPLC gene together with the a(l,3)GT gene result in a synergistic sensitizing effect 
to NHS. 
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DISCUSSION 
Innate human immunity to the xenoantigen gal a(l,3)gal (agal) may provide a means for 
cancer therapy. aGal modified tumor cell vaccines, or direct intratumoral injection of viral 
vectors containing the a(l,3)GT gene, will elicit an immune response to agal and potentially 
native tumor antigens. aGT modifies glycoproteins and glycolipids to express the agal 
epitope, gal a(l—>3)gal [21, 24]. Humans fail to express agal epitopes due to mutations in 
both alleles of the a(l,3)GT gene but produce high titer antibodies directed against this 
epitope [10, 11, 13, 16, 20]. The presence of anti-agal antibody primes the immune system to 
respond to agal epitopes resulting in complement mediated lysis of tissue expressing these 
epitopes. Both human tumor cells engineered to express the agal epitope, and murine tumor 
cells naturally expressing agal are subject to anti-agal antibody mediated C' lysis when 
incubated for 1 hr with 50% normal human serum. [19, 25, 26, 39]. However, resistance to 
C' mediated lysis by tumor cell lines expressing complement resistance molecules (CRM) 
represents a major hurdle for in vivo agal tumor therapy. Jager et al., demonstrated HT 1080 
fibrosarcoma cells expressing the agal epitope were resistant to C' lysis due to membrane 
expression levels of CRMs CD46, CD55, and CD59 [19]. Specifically, they found that the 
GPI-anchored CRMs CD55 and CD59 conferred resistance to anti-agal antibody mediated 
C' lysis. Following treatment with PIPLC enzyme, which cleaves GPI-anchored membrane 
molecules, sensitivity to C' lysis was restored. 
Tumor antigen-antibody complexes enhance the immune response by recruiting antigen 
presenting cells (APC) to the local environment. Chemotaxis in response to C' cleavage 
product C5a has been shown to recruit dendritic cells [37]. Tsuji et al., demonstrated C5a 
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dependent T-cell recruitment, concluding that C5a played a crucial role in the generation of 
T-cell immunity [38]. Other investigators have shown that C5a together with the membrane 
attack complex (MAC) act synergistically to generate chemokines such as CXC and CC in 
response to immune complexes resulting in increased neutrophil accumulation [8], 
Therefore, eliciting robust C' activation by eliminating CRMs may lead to more potent 
immune responses to antibody mediated tumor therapies. 
The B. thuringiensis PIPLC was cloned and modified for secretion by eukaryotic cells. 
The modified enzyme, EGFssPIPLC was cloned into a retroviral vector, designated LPSN, 
and used in this study. The A549 human lung tumor line is resistant to C' mediate lysis and 
demonstrates high level CD59 and moderate level CD55 expression. We infected this cell 
line with LPSN and the null vector LXSN resulting in A549LPSN and A549LXSN, 
respectively. The goal of this work was to show enhanced anti-agal mediated C' killing 
through co-expression of EGFssPIPLC gene. The LNCKG, retroviral vector encoding 
a(l,3)GT gene was constructed to transduce both A549 cells and A549LPSN cells, resulting 
in A549LNCKG and A549LNCKG-LPSN, respectively. 
A549LPSN and A549LNCKG-LPSN cells demonstrated nearly complete reduction of 
GPI anchored CD55 and CD59, expression (fig. 2b, 4a, 4b). However, little change was 
observed in the expression level of CD46, a non-GPI anchored membrane molecule (fig. 2b). 
We used the empty vector LXSN to control for variations in transgene expression due to the 
influence of either viral infection and/or expression of the NeoR gene. The influence of 
virally encoded NeoR on expression of either viral or non-viral genes is uncertain, however, 
Hlavaty et al., demonstrated a 17 fold decrease in eGFP expression in constructs containing 
SV40 driven NeoR [18]. In our study, LXSN infected A549 cells demonstrated a minor 
reduction in CRM expression (fig. 2b) which may in part be explained by expression of the 
NeoR gene. The authors further found that changing the selection marker to puromycin 
alleviated the suppression of eGFP expression. Therefore, in adapting this approach for 
future experiments, using a selection system other than neomycin may improve the 
expression of both the a(l,3)GT and PIPLC. Reduction in membrane expression of these 
molecules was similar when A549NV cells were incubated with 0.1U PIPLC (fig. 2a). Taken 
together, these data indicate the reduction in membrane levels of CD55 and CD59 in 
A549LPSN cells is a direct result of EGFssPIPLC expression. 
To determine if cells expressing EGFssPIPLC were secreting the enzyme, A549LNCKG-
LPSN cells were co-cultured with A549NV cells. Secreted PIPLC was expected to reduce 
membrane levels of CD55 and CD59 on A549NV cells similar to that of A549LNCKG-
LPSN cells alone. A549NV membrane levels of CD55 and CD59 were reduced to 
background levels, lower than levels seen in the control co-culture of A549LNCKG with 
A549NV cells (fig. 4). These data indicate the PIPLC was secreted from cells and was 
capable of cleaving CRMs of neighboring cells not expressing the enzyme. This is important 
with respect to sensitizing tumor cells to post-intratumoral injection of therapeutic agents. 
Because humans have preformed antibodies against the agal epitope use of both a(l,3)GT 
and EGFssPIPLC may elicit a response from the immune system to promote efficient 
complement mediated cytolysis and may help in establishing an immune response to tumor 
specific antigens through an antigen presenting cell intermediate. Generation of an immune 
response against tumor specific antigens may result in cell mediated immunity directed 
against non-transduced tumor cells thereby alleviating the necessity of a 100% tumor cell 
infection. Moreover, cells expressing EGFssPIPLC after intratumoral injection may 
potentiate neighboring tumor cells to the effects of C' and reduce the number of gene vector 
doses required for clinical efficacy. Pathophysiological evidence of this effect may be found 
in paroxysmal nocturnal hemoglobinuria where decreased membrane levels of CD55 and 
CD59 sensitize red blood cells to complement lysis in the absence of antibody[31]. 
The effect of co-expressing EGFssPIPLC with a(l,3)GT on the sensitivity of A549 cells 
to anti-agal mediated C' lysis was assessed using pooled NHS incubated with agal 
expressing A549LNCKG cells and agal/PIPLC co-expressing A549LNCKG-LPSN cells. 
Incubation of A549LNCKG with 12.5 % serum resulted in 12% cytolysis, whereas, 
A549LNCKG-LPSN cells saw a 5 fold increase (58%) in cytolysis (fig. 7). Previous 
investigators have shown similar results with human fibrosarcoma cells engineered to 
express a(l,3)GT followed by incubation with PIPLC enzyme prior to serum exposure [19]. 
HT1080 was transduced with a retrovirus contain the oc(l,3)GT gene and assessed for 
susceptibility to anti-agal mediated hyperacute rejection. The authors noted that no cytolysis 
occurred when incubated with pooled NHS prior to treatment with PIPLC. Following 
incubation with PIPLC enzyme 75-80% of cells were lysed upon incubation with the pooled 
NHS. 
Flow cytometric analysis demonstrated complete removal of CD55 and CD59 from A549 
cells expressing both the EGFssPIPLC and a(l,3)GT. Cell killing increased by 5 fold over 
agal expressing controls. These results may be due to C' depletion at the cell density used in 
these experiments. The functional assay using control agal positive murine MC38 cells to 
test the ability of NHS to lyse demonstrated 42% cytolysis at 106 cells. However, these 
experiments don't exclude the possibility that other complement regulatory molecules such 
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as the soluble Factor H, CD46 or C1INH may have an influence on cell lysis. Junnikkala et 
al., demonstrated constitutive expression of soluble Factor H in the human ovarian tumor 
lines SKOV-3 and CAOV-3 suggesting that tumors can modulate complement activation 
independent of CD55 and CD59 [22]. Normal and tumor cells both express the mammalian 
variant of PIPLC which is an intermediate used in the PLC 2nd messenger system. Naturally 
encoded and virally delivered enzyme released upon lysis of these cells may undergo 
dilutional effects or enzymatic degradation. Phagocytosis of cells containing the enzyme may 
prevent a large release of soluble PIPLC, however, release of some PIPLC onto neighboring 
un-transduced tumor cells may sensitize them to complement killing thereby further 
enhancing the effect of this approach. 
In this study we have demonstrated that it is possible to express the B. thuringiensis 
PIPLC in mammalian cells. Moreover, after modification of its signal sequence, PIPLC is 
secreted and is effective in removing CD55 and CD59 from the cell membrane without 
affecting CD46, a non-GPI anchored molecule, expression. Co-expression of a(l,3)GT and 
EGFssPIPLC leads to a synergistic increase in anti-agal antibody mediated C' cytolysis. 
This novel approach may enhance antibody mediated therapies involving either tumor cell 
vaccines or intratumoral injection of agents designed to elicit an immune response. 
Adaptation of in vitro models to in vivo studies has been difficult. This is due in part to a lack 
of efficient gene transfer and poor gene expression from viral vectors such as Moloney 
murine leukemia virus and non-viral vectors[l, 5, 6]. Transgene expression is often transient, 
and immune responses against the vector are frequently observed[29]. Retroviruses integrate 
into transcriptionally active sites in the chromosome which requires the cell to be in an active 
stage of the cell cycle. In this proof of principle study retroviruses were used as delivery 
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vehicles, however, this approach may be adapted for use with other viral vectors such as 
herpes simplex virus or adenovirus. Both of these viruses have high infectivity and high level 
gene expression independent of cell cycle. Moreover these vectors can support the use of a 
bicistronic construct containing both the oc(l,3)GT and EGFssPIPLC genes under the control 
of highly active promoters such of the immediate early pCMV. Royal et al., successfully co-
expressed, in human PBLs, two genes linked to the SV40 promoter by an internal ribosome 
entry site (1RES) [34]. Expression of the downstream gene was further enhanced by 
incorporation of a splice acceptor motif in the construct. In vivo gene delivery may be further 
enhanced by the use of receptor/ligand and transcriptional targeting such as that studied in 
adenoviral vectors [2, 30]. These modifications may help to reduce the non-specific infection 
of normal cells. 
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Table 1. Analysis of pooled normal human sera 
Mean Std Dev Reference Range 
Antibody Titer* 5600 ±4800 N/A 
Complement* 
C1q 13.2 ±2.6 9-17 
C3 115.3 ±8.0 95-163 
C4 20.1 ±49 7-40 
* Anti-agal titer was determined by ELISA, (1/x) 
# C factors assessed by immunoprecipitation (mg/dl) 
Figure 1. Construction of EGFssPIPLC and the viral vectors used in this study. A. Signal 
sequences of B. thuringiensis PIPLC and human epidermal growth factor. | indicates 
identical amino acids and * indicates amino acids of the same family. B. Overlapping primers 
containing the EGFss were developed to replace the nSS of PIPLC through a two-step PGR 
protocol. Arrows on primers indicate direction of polymerization. Primer A corresponds to 
EGFssF (the first 15 aa of the EGFss) and Primer B corresponds to the latter 7 aa of the 
EGFss and the first 7 aa of the PIPLC adjacent to the nSS. The EGFss was constructed by 
annealing Primer A to Primer B through a 9 nt overlap and extending the primers. Primer C 
was a reverse primer used with EGFssF to amplify the entire PIPLC after swapping the nSS 
with the EGFss. C. Retroviral vector constructs of EGFssPIPLC expressing vector pLPSN, 
and D. the a(l,3)GT expressing vector pLNCKG. Not pictured is the viral vector pLXSN, 
the empty virus used to construct pLPSN, and used in experiments to control for the effects 
of the NeoR gene. 
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Figure 2. Effect of PIPLC on A549 CRM expression. A. Flow cytometric analysis of A549 
CRM expression before and after incubation with 0.1U B.cereus PIPLC enzyme. (IC, Isotype 
Control Antibody; A, anti-CD46 after PIPLC treatment; B, anti-CD46; C, anti-CD55 after 
PIPLC treatment; D, anti-CD55; E, anti-CD59 after PIPLC treatment; F, anti-CD59). B. 
A549LXSN control, and A549LPSN (expressing EGFssPIPLC) cells were incubated for 72 
hr followed by flow cytometric analysis of CRMs. Results were calculated as a percent 
difference from A549NV control and experiments were performed in triplicate. 
1«% Decrease in Expression 03  
Figure 3. Effect of PIPLC on CRMs over time. A549LPSN cells were incubated for 24, 36, 
48, and 72 hr followed by analysis of membrane expression levels of CRMs. Increased 
culture periods resulted in further decreases in CRM membrane expression levels. Results 
were calculated as a percent difference from to A549NV control. 
1-% Decrease In CD59 Expression 
3  8  8 * 2  
S 
* 
1 —r- { 
1 i 1 
1 i 1 
1 i 1 
1 i 1 
I i 
1 i 
1 i 
j l i 
À  
/ '  
1 I 1 / « 
i r i 
i i I / i 
1 i / i 
« l / « 
I / I 
I «y I 
I 
if 
« ; 
i 
i 
1 
1 I A f t  l 
1 h  l 
1 
1 
f t  
I  i 
l 
i 
1 
1 
i It 
/ i 
i 
i 
1 1 I 1 JF I 1 
1 / 1 
1 / 1 i 
1/ I i 
I / 
f  1 
t 
l 
i 
1 / 1 
1 
i 
t 
1 / 1 
t l 
s  1 1 
# 1 Î i 
1 1 i 
1 1 
1 1 i 
I 1 1 
1 1 l 
W Ui 
Figure 4. Analysis of secreted PIPLC. A549NV cells were co-cultured with either 
A549LNCKG or A549LNCKG-LPSN (CoTD) for up to 72 hr. Total populations were 
analyzed by flow cytometry for A. CD55 expression and B. CD59 expression. In co-cultures 
with A549LNCKG, no difference was seen in either CD55 or CD59 levels compared to 
controls. However, in co-cultures of A549LNCKG-LPSN, CD59 expression levels fell below 
background. 
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Figure 5. Effect of PIPLC on gala(l,3)gal epitope density. aGal epitope expression was 
compared in A549LNCKG-LPSN cells to A549LNCKG 72 hr incubation. A small expected 
difference (130 versus 150, respectively) was noted in mean fluorescence intensity between 
the two populations after staining with FITC labeled IB4 isolectin. This may represent 
cleavage of some membrane GPI-anchored agal modified molecules. 
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Figure 7. Enhanced tumor cell killing in cells co-expressing a(l,3)GT and EGFssPIPLC. 
One million cells of each group were incubated with 12.5% pooled NHS for 1 hr. Cells were 
stained with FITC labeled IB4 isolectin, PE labeled C5b-9 antibody corresponding to the 
membrane attack complex of C', and 7AAD (not shown on y-axis label), an indicator of cell 
death. NV = A549NV, LXSN = A549LXSN, LPSN = A549LPSN, LNCKG = A549LNCKG, 
CoTD = A549LNCKG-LPSN. NPS = pooled NHS, HIS = heat inactivated pool NHS. 
Experiments were performed in triplicate. 
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CHAPTER 5. GENERAL CONCLUSIONS 
GENERAL CONCLUSIONS 
The use of agal for cancer gene therapy has been investigated for its ability to cause 
hyperacute rejection of agal expressing tumors and its potential for eliciting anti-tumor 
immunity to tumor specific antigens. The a(l,3)GT KO mouse has played an important role 
in elucidating the effects of agal mediated tumor therapy in vivo. However, prior to these 
studies, only one a(l,3)GT KO tumor model, the murine melanoma B16.BL6, was used to 
study agal mediated cancer therapies. We sought to develop a new tumor model in the 
a(l,3)GT KO mouse and evaluate its potential for use in agal tumor therapy. 
a(l,3)GT KO mice were procured and amplified into a working colony. The mice were a 
cross between C57/BL6 (H-2b), 129SV (H-2b), and DBA/2 (H-2d) backgrounds and were 
either H-2b/b, H-2d/d and H-2b/d class I major histocompatibility complex haplotype. Mice 
were injected with varying concentrations of the polycyclic aromatic hydrocarbons 3-
methylcholanthrene and 9,10-dimethyl-1,2-benz-anthracene. Resultant tumors were 
harvested from mice, established in culture, and sectioned for pathological identification. For 
further studies with these tumors, haplotype matching the tumor to mouse was desirable. 
Therefore we developed a high-throughput screening technique to both confirm the a(l,3)GT 
KO phenotype and determine the haplotype of each mouse. The protocol allowed us to 
rapidly screen over 300 mice resulting in separation of the animals into H-2b/b and H-2d/d 
homozygotic colonies. Cultured tumor cells were haplotyped by immunofluorescence and 
matched to one of the homozygotic colonies for analysis of in vivo tumor growth kinetics. Of 
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the tumors we harvested, CA320M demonstrated long term tumor growth mice and was used 
in our studies. 
CA320M was identified as a gastrointestinal sarcoma tumor of H-2b/b haplotype. Cell 
cycle analysis revealed G1 arrest and an increase in doubling time in serum starved 
conditions which was similar to the B16.BL6. CA320M was capable of expressing agal 
epitopes upon transduction with an HSV-1 viral vector carrying the a(l,3)GT gene, 
HE7agall, as determined by binding of the FITC labeled IB4 isolectin. 
To evaluate the use of CA320M as a gene therapy model of hyperacute rejection, cells 
were infected with HE7agall followed by incubation with NHS or serum collected from 
mice primed with RWB (MS). Ninety-seven percent of agal expressing CA320M cells 
bound anti-C3c antibody and stained with 7AAD demonstrating cell death when incubated 
with NHS. Incubation with MS killed 35% of agal expressing cells. These results suggest 
that the CA320M tumor model would be well suited for studying hyperacute rejection as a 
cancer therapy. 
CA320M growth kinetics was studied to establish parameters to use for in vivo tumor 
vaccine studies. Tumors grew in animals reaching a mean tumor volume of 471 mm3 within 
30 days. Compared to B16.BL6, CA320M is not a highly aggressive tumor line. Some 
variability in tumor growth between animals was observed which may have had to do with 
minor antigens incompatibilities. CA320M growth kinetics suggest that this tumor line would 
be suited to study cancer vaccines or tumor therapies utilizing direct intratumoral injection. 
While investigating human tumor cell lines for their susceptibility to agal mediated 
hyperacute rejection, we noticed that some tumor lines were more resistant to the effects of 
complement than others. One million agal expressing; A549 lung carcinoma, and IGROV 
ovarian adenocarcinoma, were compared for there susceptibility to C' lysis after incubation 
with 50% NHS for 1 hr (Chapter 1, figure 7). IGROV cells were more susceptible to the 
effects of C' than A549 cells. One explanation may be the expression of C' resistance 
molecules CD55 and CD59. Flow cytometric analysis of IGROV cells demonstrated less 
expression of CD55 and CD59 that A549 (Chapter 1, figure 8). Other investigators had 
shown CD55 and CD59 conferred resistance to C' lysis of agal expressing fibrosarcoma 
cells, HT 1080a. These authors incubated PIPLC with HT1080a to cleave the GPI-anchored 
CD55 and CD59 prior to exposure to human serum. Following PIPLC treatment, C' killing 
of HT1080a was restored. We sought to adapt this approach to a cancer gene therapy model 
by co-expressing the a(l,3)GT with PIPLC from one retroviral vector. Engineering PIPLC to 
be secreted would result in the cleavage of CD55 and CD59 from the cell membrane 
rendering the cells susceptible to C' lysis. 
B. thuringiensis PIPLC was modified with the EGF SS for secretion from transduced 
A549 cells. A549LPSN and A549LNCKG-LPSN cells demonstrated nearly complete 
reduction of GPI anchored CD55 and CD59, expression. Reduction in membrane expression 
of these molecules was similar when A549NV cells were incubated with 0.1U PIPLC. 
Secreted PIPLC has greater effect on CD55 and CD59 over time up to 72 hrs in culture. 
Moreover, mixed co-cultures of A549LNCKG-LPSN cells with A549NV cells demonstrated 
complete reduction of CD55 and CD59, which was not seen in the control co-culture 
A549LNCKG with A549NV cells. 
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Although PIPLC cleaves GPI-anchored glycolipids and aGT modifies cellular 
glycoproteins and glycolipids, no decrease in agal expression in cells co-expressing the two 
genes was observed. The effect of co-expressing EGFssPIPLC with oc(l,3)GT on the 
sensitivity of A549 cells to anti-agal mediated C' lysis was assessed using pooled NHS 
incubated with A549LNCKG and A549LNCKG-LPSN cells. Incubation of A549LNCKG-
LPSN cells saw a 5 fold increase (58%) in cytolysis over A549LNCKG demonstrating a 
synergistic increase in sensitivity to anti-agal antibody mediated C' cytolysis in the absence 
of CD55 and CD59. 
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RECOMMENDATIONS FOR FUTURE RESEARCH 
Alpha-gal mediated cancer therapy has been investigated in the murine melanoma model 
B16.BL6. Tumor cell vaccines have been developed and direct intratumoral injection of 
established tumors studied to determine if this approach can protect mice from lethal tumor 
challenge. The CA320M model was developed to determine if agal mediated cancer 
therapies can successfully be applied to other tumor models. Therefore, several studies may 
be conducted to investigate these questions. Of particular interest is the use of tumor 
vaccines. These consist of modifying autologous tumor cells by the introduction of genes that 
activate an immune response against the primary tumor upon reintroduction of the modified 
cells into the patient (Figure 1). 
An important step in breaking tumor tolerance is educating T cells to recognize tumor 
specific antigens (TSA). Previous studies using tumor vaccines to treat melanoma have been 
successful at generating anti-melanoma specific CTL [1], However, these early vaccines 
have failed primarily due to lackluster recruitment of APC in vivo. Kusumoto's group has 
conducted clinical trials in which melanoma cells are engineered to express the granulocyte-
macrophage colony stimulation factor (GM-CSF) gene [2], Here the genetically engineered 
melanoma can recruit APCs to the site of vaccination to enhance the potency of the vaccine. 
In these trials, tumor-specific CTL assays showed that the levels of CTLs in the peripheral 
blood of 5 of 9 patients increased following vaccination. Immunohistochemical examination 
of the vaccination sites of one patient, biopsied after the 3rd and 4th vaccination, showed an 
infiltration of inflammatory cells such as T cells (CD3+, CD8+), macrophages and dendritic 
cells (CD83+) for a period of up to about 8 days. Taken together, these data suggest that the 
immune system can be educated following vaccination with an immunostimulatory vaccine. 
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Alpha-gal modified tumor vaccines possibly represent an even more effective means by 
which to educate the immune system to recognize tumor specific antigens. 
Anti-agal antibodies from baboons have been shown to be responsible for inducing 
hyperacute rejection of agal+ porcine xenografts [3, 4]. These antibodies bind agal epitopes 
and activate the classical pathway of complement inducing cytolysis in the transplanted 
tissue [5]. In our lab, using a murine MC38 agal colon adenocarcinoma cell line, we have 
demonstrated as little as 1% viability after incubating these cells with 50% human serum for 
1 hour. Similar to the results using GM-CSF, Galili et al, have demonstrated that a melanoma 
tumor vaccine engineered to express the immunostimulatory carbohydrate agal can augment 
the recognition melanoma antigens leading to an enhanced immune response to subsequent 
tumor challenge in mice [6], Furthermore, preliminary results in our lab have shown that 
agal knockout mice vaccinated with an agal expressing CA320M tumors and subsequently 
challenged with the parental tumor resulted in up to 93% of the animals remaining tumor free 
at 60 days post-injection (Figure 2). 
The mechanism of tumor protection has not been elucidated. However immune complexes 
(IC) and complement components may play an important role in the recruitment and 
activation of antigen presenting cells such as M0 and DC. In part, APC recruitment, uptake, 
and activation is based on the hyperacute rejection model whereby binding of an antigen with 
its cognate antibody is followed by deposition of complement components that result in lysis 
of the target cell, i.e. tumor vaccine [3, 4], Complement components such as C3a and C5a are 
effective proinflammatory agents that capable of recruiting APCs. Moreover, the interaction 
of the agal epitope with the anti-agal antibody results in IC formation. Immune complexes 
are efficiently internalized by APCs through binding of the Fc receptors to the Fc domain of 
the antibody. Classically it was thought that internalization of ICs would follow the 
exogenous pathway of antigen processing and give rise to a humoral response. However it 
was observed that this pathway could yield presentation of antigens in the context of MHC 
class I yielding CD8+ Tc cells. Work by Bevan and others has demonstrated that cross-
priming is important in initiating CDS restricted responses to tumors, peripheral self, viral, 
and bacterial antigens [7, 8]. Experimental evidence exists to quite elegantly show that cross-
priming with ICs leads to dendritic cell maturation and activation and gives rise to both class 
I and class II presentation of antigens. In one study by Schuurhuis, a well characterized 
murine dendritic cell line, Dl, was shown to efficiently internalize ICs through its FcyR 
which induced activation of the DC's as shown by an increase in expression of CD86 (B7.2), 
CD40, and MHC Class I [9], Moreover, expression of the Thl promoting cytokine IL-12 
was shown to be induced as well as improved efficiency of MHC class I restricted Ag 
presentation. In another study ICs were shown to promote maturation of DCs and 
presentation on both MHC class I and II which would allow for priming of both CD4+ helper 
and CD8+ cytotoxic T lymphocytes in vivo [10]. 
Currently there is a lack of conclusive experimental evidence to show that agal 
expressing vaccines can generate a CTL response to native tumor specific antigens in vivo. 
An important point in this process, however, is to show that agal expressing cells can be 
internalized by APCs, a crucial step towards constructing a successful vaccine. Previous 
studies by LaTemple and Tanemura, demonstrated that opsonized agal expressing tumor 
cells by anti-agal IgG lead to internalization of the complex by APCs [11, 12]. These studies 
support the idea that CA320M expressing agal epitopes should bind anti-agal antibody in 
vivo resulting in ICs that would be efficiently recognized by FcyRs and internalized by APCs. 
Finally, presentation of antigens to CD4+ Thl cells as well as cross presentation of tumor 
specific antigens to CD8+ cytotoxic T cells may result in their activation into immune 
effector and memory cells. Tumor tolerance may be overcome as effector CTLs home to the 
primary tumor and recognize native tumor specific antigens and elaborate their cytolytic 
effects. Studies to elucidate these points are ongoing and should be beneficial to 
understanding the role that agal may play in tumor vaccines of the future. 
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Figure 1. Schematic of autologous tumor vaccine approach using agal modified cells. Cells 
harvested from a patient are cultured and transduced with a virus carrying the a(l,3)GTgene. 
Cells are irradiated and reintroduced to the patient. Anti-agal antibody and complement 
promote a local immune response resulting in the recognition of tumor specific antigens. The 
aim is to develop a cell mediated immune response to neoantigens. 
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Figure 2. Kaplan-Meier survival plot of agal tumor vaccine trial. Alpha-GT KO mice (n=15 
per group) were primed twice with 2 x 107 rabbit red blood cells to raise their anti-agal titer. 
One thousand CA320M cells alone (null) or transduced with an HSV viral vector carrying 
either the oc(l,3)GT gene (HDKgal) or a Sail mutant of a(l,3)GT (HDKgal mutant, which 
failed to express agal epitopes) were irradiated with 25Gy of ionizing radiation and injected 
subcutaneously into mice. Mice were subsequently challenged with a lethal dose (1 x 107) 
live CA320M and followed for 60 days. 
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Immunity to the «(l,3)Galactosyl Epitope Provides Protection in Mice Challenged 
with Colon Cancer Cells Expressing a(l,3)Galactosyl-transferase: A Novel 
Suicide Gene for Cancer Gene Therapy1 
Robert C. Unfer, Daniel Hellrung, and Charles J. Link, Jr.2 
Stoddard Cancer Research Institute, Iowa Methodist Medical Center, Des Moines, Iowa 50309, and Department of Immtmobiohgy, Zona State University, Ames, Iowa 5003} 
ABSTRACT 
Human immunity to «(l,3)Galactosyl epitopes («Gai) may provide the 
menus for a successful cancer gene therapy that uses the immune system 
to identify and to destroy tumor cells expressing the suicide gene 
«(1.3)GalsctosyItransferase («GT). Innate antibody specific for cell sur­
face «Gai constitutes a high percentage of circulating IgG and IgM 
immunoglobulins In humans and Is the basis for complement-mediated 
hyperacute xenograft rejection and antibody-dependent cell-mediated cy­
totoxicity. In humans, the gene for «GT is mutated, and cells do not 
express the «Gal moiety. We hypothesized that human tumor ceils in­
duced to express the «Gal epitope would be killed by the hosts* innate 
immunity. Previous in vitro work by our group has demonstrated com­
plement-mediated lysis of «Gal-transduced human tumor cells in culture 
by human serum. To induce antibodies to «Gat in this in vivo study, «GT 
knockout mice were used to determine whether immunization with «Gal 
could provide protection from challenge with «Gal-expressing murine 
MC38 colon cancer cells. Knockout mice were immunized either a single 
time, or twice, with rabbit RBC. Antibody titers to «Gal measured by 
Indirect ELISA were significantly higher in mice immunized twice and 
approached the titers observed in human serum. Anti «Gal antibodies 
were predominantly of the IgGl and IgG3 subtype. Immunized knockout 
mice were challenged i.p. with varying doses of «Gai* MC38 colon 
carcinoma cells. Noniinimmized control groups consisting of «GT knock­
out mice, and wild-type C57BL/6 mice were challenged as well with MC38 
cells. Immunized mice survived and exhibited slower tumor development 
in comparison to nonimmunized knockout and control mice. This study 
demonstrates, in vivo, the protective benefit of an immune response to the 
«Gal epitope. Oar results provide a basis to pursue additional develop­
ment of this cancer gene therapy strategy. 
INTRODUCTION 
Cancer gene therapy offers a potential replacement or augmentation 
of traditional cancer treatments, which use invasive or toxic protocols. 
Suicide genes that encode an enzyme that activates a prodrug into a 
toxic molecule, or genes that induce apoptosis, have been or are 
currently being tested in clinical trials for their efficacy in cancer 
therapy (1-3). Gene therapy vaccine technology is under development 
for several malignancies. Melanoma lias been the favored target 
because it is a veiy immunogenic tumor. However, the more common 
and important forms of cancer have minimal or 110 immunogenicity. 
We are developing a novel approach to cancer gene therapy that uses 
a patient's innate immunity against xenoantigens to identify and 
destroy tumor cells. The key aspect of this work is to determine 
whetlier colon cancer cells tliat express a xenoantigen can be rejected 
by an immune response to the antigen. Colon cancer is the third most 
common form of cancer and third leading cause of death (4) and 
provides a good target for a successful cancer gene therapy. 
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Humans possess specific humoral immunity to aGal,3 a major 
xenotransplant antigen. Although human cells do not caiiy a func­
tional enzyme for the expression of «Gal epitopes because of a 2-base 
frameshift gene mutation (5), there is evidence that suggests that high 
titer natural antibody to aGal is produced in humans because of 
continuous antigenic stimulation by gastrointestinal bacteria (5-7). 
Clonal B-celi analyses estimated that —1% of circulating B cells 
produce anti-aGal antibody (8). The aGT catalyzes the transfer of 
galactose from UDP galactose to the JV-acetyl-lactosamine acceptors 
on carbohydrate side chains of glycoproteins and glycolipids to create 
the aGal moiety. The anti-aGal immune response is responsible for 
initiating hyperacute rejection of vascularized xenotransplants, a se­
vere immunological reaction observed in primates. When aGal and 
specific antibody form immune complexes, complement is activated 
via the classical pathway (9-13). 
Our interest in «Gal-mediated destruction of tumor cells was in­
spired by studies describing lysis of murine retroviral VPCs after 
exposure to human peritoneal fluid. VPCs have been used for m vivo 
gene delivery in several cancer gene therapy studies (14, 15). Our 
laboratory and others have demonstrated that antibody and comple­
ment in human serum binds aGal within 30 mill of exposure and 
induces complement-mediated lysis of VPCs and the viral vectors 
they produce (16-20). Additionally, Collins et al. (21) showed that 
human fibroblast cells expressing porcine «GT were destroyed by 
antibody and complement. To test whether this gene could be used to 
induce destruction of tumor cells, a truncated version of the murine 
aGT was cloned into a retroviral vector backbone and used to trans­
duce human A375 melanoma cells (22). During m vitro experiments. 
>90% of transduced A375 cells expressing aGal were killed after 
exposure to human serum. «Gal-expressing A375 cells were treated 
for 30 mm with human serum and then injected in vivo into athymic 
nude mice. All experimental mice remained tumor free, whereas 
control groups developed tumors (22). Lysis of «Gal-expressing 
murine cells by human sernm can be blocked by the addition of 
complement inhibitors (heparin, enoxaparin) or soluble complement 
receptor 1 (20). These data demonstrate the key role that complement 
has in destruction of targets expressing the aGal xenoantigen. 
Transgenic knockout mice that lack the aGT gene («GT KO) have 
been produced (23, 24) and provide au ideal small animal model to 
study the in vivo immune response against aGal epitopes. While not 
expressing detectable cell surface aGal epitopes, these mice can 
produce low detectable titers of natural anti-aGal, possibly from 
bacterial stimulation (25, 26). Immunization with RKBCs results in 
the production of anti-aGal antibody with titers and specificity similar 
to those observed in humans (27). In this report we present in vivo data 
that shows clear protective benefits of an anti-aGal immune response, 
when RRBC-immtinized aGT KO mice are challenged with aGal+ 
tumor cells. These findings have implications for generation of a 
system to deliver the «Gal suicide gene to human tumor cells, and 
3 The abbreviations used are: «Gai, a(l,3XMactosyl epitope; aGT, a(l,3)Galaetonyl-
transferasc enzyme; aGT KO. c^t,3)Galacto5yltrattsfera5e knockout: VPC, vector pro­
ducer ceîl; RRBC, rabbit RBC: IB4, isoîeetin B4: PL propidiiim iodide. 
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making them susceptible to destraction by natural human immunity 
to aGal 
MATERIALS AND METHODS 
Cells and Media, MC38 colon carcinoma cells are syngeneic for C57BL/6 
mice and express the «Gal antigen mi their cellular surface. BI6.BL6-2 
melanoma cells, a metastatic nonimmunogenic derivative of the B16.F1Ô cell 
line, are also syngeneic for C57BL/6 mice and are «Gal-negative. Ail cells 
were maintained at 37°C m a 5% C02 incubator. The growth medium con­
sisted of DMEM (Invitrogen-Life Technologies. Inc., Carlsbad, CA) supple­
mented with 10% FBS (D-10; Ihvitrogen-Life Technologies, Inc.). 
Animal Model, Knockout mice for aGT (aGT KO) were received for 
establishing a breeding colony from Dr. John B. Lowe of the University of 
Michigan (23). C57BL/6 mice were obtained from Harlan Sprague Daw ley. 
Inc. (Indianapolis, IN), and were used as control mice during minor implan­
tation studies. All animals were cared for under Institutional Animal Care and 
Use Committee-approved protocol and housed in a contained facility. 
Lectin Staining for «Gal Epitopes. MC38 and B16.BL6-2 cells were 
seeded into 30-mm dishes in D-IQ, incubated at 37*C in 5% CO,. and grown 
to confluent monolayers. Cell monolayers were washed twice with HBSS and 
incubated for 15 miu at room temperature with a 1:50 dilution in Opli-MEM 
(Invitrogen-Life Technologies, Inc.) of FITC-labeled Griffonta simplicifolia 
XB4 (Vector Laboratories, Inc., Burlingame. CA). This lectin lias previously 
been shown to bind specifically to «Gal epitopes (28, 29). Hie lectin solution 
was removed, monolayers were washed twice with HBSS, and fresh Opti-
MEM was added to cells. Monolayers were observed for lectin binding using 
a Nikon Diaphot 300 fluorescent microscope (Nikon» Inc.. Melville, NY) and 
photographed using Fuji 1600 Previa color film (Fuji Photo Film Co.. Tokyo, 
Japan). 
Complement-media ted Cell Death. MC38 cells in culture were 
trypsinized for 2-3 min at 3?0C. The trypsin was inactivated with complete 
culture media (D-10), and cells were collected by centrifugation at 3000 rpm 
for 5 miu at 4°C. Cells were suspended in 200 iû of one of three possible 
treatment solutions: 50% DMEM and 15% FBS (D-15) in Opti-MEM; 50% 
fresh human serum in Opti-MEM; or 50% heat-inactivated human serum in 
Opti-MEM. In addition, cells were incubated at 37*C for 1 h. Treated cells 
were collected, resuspended in 100 fil of FITC-labeled IB4 lectin (diluted 
1:100 in Opti-MEM), and incubated at room temperature for 10 min. One 
hundred /il of a PI solution (25 £ig/inl) diluted in HBSS were added to the cells 
and incubated for 5 min at room temperature. Cells were collected, resus-
pended in Opti-MEM, and analyzed by flow cytometry (Coulter Epics Altra 
Flow Cytometer, Miami, FL). 
«Gal Antigen Immunization. Eight to 12-week-old «GT KO mice were 
used in this study and cared for under an approved animal protocol using 
American Association of Laboratory Animal Care guidelines. Mice were 
immunized i.p., with 107 aGal+ female NZW RRBCs (Cocalico Biologicals. 
Inc., Reamstown, PA) suspended in 100 jxl of HBSS. Immunizations were 
given either a single time 14 days before MC38 and B16.BL6-2 tumor cell 
challenge or twice at 28 days and 14 days before MC38 tumor cell challenge. 
Control QGT KO and control C57BL/6 mice were mock immunized with 
100 of HBSS t.p. 
Antibody Titration and Snbtyping. Antibody specific for the «Gal 
epitope was detected, and end point was titrated using an indirect ELISA. aGal 
antigen («Gal-BSA; V-Labs, Inc., Covington, LA) was diluted to 5 jig/ml in 
carbonate buffer (pH 9.5) and coated onto polyvinyl chloride (PVC) ELISA 
plates (Falcon 3912; Becton Dickinson Labware, Franklin Lakes, NJ) over­
night at 37°C in a humidified chamber. Nonspecific binding sites in assay 
wells were blocked for 2 h with a solution of 1% BSA (Fraction V; Sigma) in 
carbonate buffer. Two-fold serial dilutions of primary sera were made in wash 
buffer [IX PBS (pH 7,4), 0.05% Tween 20), added to antigen-coated wells, 
and incubated for 1 h at 37*C. Wells were washed five times, and a secondaiy 
antibody, horseradish peroxidase-Iabeled goat antimouse IgG H+L diluted 
1:5000 in wash buffer (Pierce Chemical Co., Roekfbrd. IL), was added to assay 
wells and incubated 1 h at room temperature. Wells were washed five times, 
and 100 p»l of 3,3 ', 5 \ 5-tetramefhy^benzidine liquid substrate (Sigma) was 
added. After a 15-min incubation at room temperature, the substrate reaction 
was stopped with 0.5 N H2S04, and the absorbance at 450 nm for each well was 
determined using a Molecular Dynamics SpectraMax 250 Plate reader (Sunny­
vale, CA). 
The murine immune response to aGal was measured over time. Serum from 
immunized mice was diluted 1:100 in wash buffer before detection by ELISA 
as before. Anti-aGal antibody class and subtype was determined from serum 
collected 14 days after the last RRBC immunization, using a Zymed MonoAb 
ID ELISA kit (Zymed Laboratories, Inc., San Francisco, CA). orGal-BSA 
antigen was coated onto PVC ELISA plate wells as before, and nonspecific 
binding sites were blocked using 1% BSA. Diluted primary sera were added 
and incubated with antigen. Secondaiy rabbit antimouse isotype horseradish 
peroxidase-Iabeled antibodies and 3,3'$5',5-tetramethylbenzidine substrate 
were used for detection. 
Tumor Cell Challenge. In the first experiment, 15 aGT KO mice were 
immunized i.p. a single time with 10? RRBC in 100 fx\ of HBSS 14 days before 
tumor cell challenge. As experimental controls, 15 «GT KO mice and 15 
syngeneic C57BL/6 mice were mock immunized with HBSS. In a blinded 
experiment, all mice were divided into three sets, with each set comprised of 
5 immunized aGT KO mice, and 5 mice each of the two control groups. Each 
set of mice was challenged i.p. with a different dilution of MC38 colon 
carcinoma cells suspended in Plasma-Lite (Baxter Healthcare Corp., Deerfield, 
IL). Mice in set A were challenged with 2.5 X 104 MC38 cells. Mice in sets 
B and C were challenged with 5.0 X 194 and 1.0 X 105 MC38 cells, 
respectively. Separately, 8 aGT KO mice were immunized a single time as 
before with 107 RRBC in HBSS 14 days before i.p. challenge with 1.0 X 10s 
B16.BL6-2 melanoma cells suspended in Plasma-Lite. A second experiment 
was designed in which 15 aGT KO mice were immunized twice with 107 
RRBC 28 and 14 days before MC38 tumor cell challenge. Fifteen aGT KO 
mice and 15 syngeneic C57BL/6 mice were mock immunized with HBSS and 
served as experimental controls. All RRBC-immunized and mock-immunized 
control mice were challenged i.p. with 2.5 X 104 MC38 colon carcinoma cells. 
In all experiments, mice were observed daily for animal morbidity and pal­
pated for tumor growth. 
RESULTS 
FITC-Lectin Staining. MC38 colon carcinoma and B16.BL6-2 
melanoma cells were incubated with a solution of FITC-labeled IB4 
lectin to identify the differences between the two cell lines in expres­
sion of the aGal epitope. FITC staining is prominent along the outer 
surface membrane of cultured MC38 cells (Fig. 1) because this cell 
line has a functional aGT gene and expresses the surface aGal moiety 
that is detected by IB4 lectin binding. B16.BL6-2 melanoma cells do 
not express the aGal moiety because they lack a functional aGT gene 
mid are not stained with ÎB4 lectin-FITC. 
Complement-mediated Cell Death. aGal-positive MC38 cells 
were incubated with culture medium containing no human serum, 
50% normal human serum, or 50% heat-inactivated human serum. 
Flow cytometry of FITC-lectin-stained cells provided total cell 
counts. In addition, PI uptake by dead cells as a percentage of total 
cell numbers was used to measure cell death after incubation with the 
test media. Flow cytometry of cells treated with the three test media 
demonstrated killing of 98% of aGal-positive MC38 cells by media 
containing human serum with active complement (Fig. 2). Cells that 
were incubated with media containing heat-inactivated human serum 
exhibited a 30% cell death by PI uptake, whereas background uptake 
by untreated cells was 22%. 
Antibody Titers and Subtyping. Antibody titers to the aGal 
epitope from immunized «GT KO mice and mock-immunized control 
aGT KO and C57BL/6 mice were determined by indirect ELISA. Fig. 
3 shows the results of antibody titration in serum from mice that wer e 
immunized either a single time 14 days before serum collection (Fig. 
3,4), or mice that were immunized twice, 28 and 14 days, before serum 
collection (Fig. 3B). Senmi from mock-immunized aGT KO and 
C57BL/6 mice exhibited an average A450 absorbance of <0.05 at a 
1:50 dilution and was considered negative. This serum was pooled and 
used to determine background antibody binding. Immune sera with mi 
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Fig. 1. Visualization of «Gal expression in MC38 colon carcinoma cells and lack of expression in «Gal-negative B16.BL6-2 melanoma cells using FITC-IB4 lectin staining. Cells 
were incubated with a 1:50 dilution of FITC-IB4 lectin in Opti-MEM at room temperature for 15 min. A and S show MC3S cells, and C and D show B16.BL6-2 cells. FITC-lectin 
staining of the u-Gal moiety in the outer cell surface membrane demonstrates the activity of the «GT gene in MC3S cells and lack of gene expression in B16.BL6-2 cells. A and C 
were photographed using a Nikon DM505 FITC cube, and B and D were photographed under brightfieid light using the same FITC cube. 
v-f450 absorbance of >0.1 above background were considered positive. 
The average titer of anti-aGal antibody in mice immunized one time 
with RRBC' was 1:1600 (Fig. 3.4). Mice that were immunized twice 
with RRBC had an average titer of 1:8000 (Fig. 35). The immune 
response ill aGT KO mice to aGal was determined by collecting 
serum from mice at various times after RRBC immunization on days 
14 and 28. An anamnestic IgG immune response to aGal that peaks 
at 7 days after the second immunization was observed (Fig. 44). 
Serum samples collected on day 0 from «GT KO mice immunized 
once on day —14 (14 mice) or twice on days —28 and —14 (8 mice) 
were assayed for their antibody isotype. An.4450 absorbency > 0.2 for 
an individual antibody isotype was considered positive. Serum was 
negative for an antibody isotype and subclass if the. j450 absorbance 
was <0.2. RRBC immunization stimulated the production of IgM, 
IgGl. and IgG3 antibodies (Fig. 45). The predominant subclass was 
IgG3. which developed in 50% (11 of 22 immunized mice). The IgGl 
subclass was observed with higher frequency (36%) then either IgG2a 
or IgG2b (5 and 13%). All mice immunized regardless of schedule 
demonstrated high levels of IgM antibody, and no immunized mice 
demonstrated any IgA antibody isotype. Interestingly, all immunized 
mice developed antibody with K light chain, and no A light chain was 
found in these mice. 
Tmnor Cell Challenge. Fourteen days after RRBC immunization 
of aGT KO mice and mock immunization of «GT KO and C57BL'6 
controls, the mice were divided into three groups and implanted i.p. 
with different dilutions of MC38 colon carcinoma cells in a blinded 
experiment. Tumor cell dilutions were made, coded, and randomized 
before injection into mice. All mice were observed daily for tumor 
development and were euthanized when tumors reached - 1200 mnr\ 
exhibited ascites fluid production, or when the mice were moribund. 
Inactivated 
Human 
Fig. 2. «Gal-positive MC'jS colon carcinoma ceils aie killed when exposed to serum 
containing active human complement. MC38 cells were stained with FITC-IB4 lectin and 
suspended in test media containing no human serum. 50% human serum, and 50% 
heat-inactivated human serum- After 1-h incubation at 37*C. cells were incubated with a 
suspension of PI for 5 min at room temperature. Flow cytometry demonsttated that only 
serum containing active complement was able to kill aGal expressing MC3S cells. 
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Survival curves of RRBC-immunized and mock-immunized control 
mice challenged with the three doses of MC38 tumor cells (2.5 X 104, 
5.0 X 10 ', or 1.0 X 10s) are presented (Fig. 5). Immunized aGT KO 
mice were observed to develop tumors more slowly regardless of the 
amount of MC3S cells used for challenge. Immunized and mock-
immunized mice challenged with the three dilutions of MC38 cells 
were pooled and analyzed as a group. The percentage of mock-
immunized control «GT KO mice (47%) that survived challenge with 
the three dilutions of MC38 cells was lower than the percentage of 
RRBC-inmiunized aGT KO mice (87%) that were challenged 
(P = 0.031). All three dilutions of MC3S cells were able to rapidly 
establish tumors in mock-immunized C57BLZ6 control mice, and all 
C57BL/6 control mice were euthanized by 18 days after tumor cell. In 
a separate experiment, the survival cur ve for RRBC-iuimunized aGT 
KO mice challenged with 1 X 105 B16.BL6-2 cells demonstrates that 
immunity to «Gal does not protect against challenge with oGaT 
melanoma cancer cells (Fig. 6). In this experiment, all 8 immunized 
«GT KO mice developed tumors rapidly and were euthanized by 
day 25. 
The challenge experiment was repeated using a single dilution 
(2.5 x I04) of MC38 tumor cells to challenge aGT KO mice immu­
nized twice with RRBC to increase their antibody titers and mock-
immunized control mice. After tumor cell challenge, all mice were 
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Fig. 3. High anti-aGal antibody titers are induced in aGT KO mice after immunization 
with RRBC. An indirect ELISA using an ocGal-BSA conjugate as the antigen was used to 
titrate scrum collected from <xGT KO mice that were immunized (4) one time with 10' 
RRBC or (S) twice with $i 14-day interval with Î07 RRBC. Serum was collected 2 weeks 
after completion of immunization. Serum from mock-imtmarized mice was pooled and 
used to determine background antibody binding. Immune sera with an^i450 absorbance of 
>0.1 above background were considered positive. The average titer of anti-orGal antibody 
in mice immunized one time with RRBC was 1:1600 6i), Mice thai were immunized twice 
with RRBC had an average liter of 1:8000 (B). 
A 
1.5 
10 20 5 0 
B 
Mouse anti-aGal Antibody lsotypes Determined by Indirect ELISA 
IgGi Ig02a Ig02b JgGS IgA IgM K X 
Mice immunized once 6 .1 2 6 0 14 14 0 
(n= 14) 
Mice immunized twice 2 0 1 5088ft 
(n - 8) 
Fig. 4. Immune response to aGal epitopes peaks at 7 days after a second immunization 
with aGal-positive RRBC. Â, mice were immunized with 10' RRBC on days 0 and 14 
(indicated by aircnvs), Blood was collected from the saphenous vein at various times from 
4 to 26 days after umnunizations were initiated. Serum was analyzed using an indirect 
ELISA to measure the presence of anti-aGal antibodies. An anamnestic response to aGal 
was observed after the second immunization. B, serum from RRBC-imimmized mice was 
used to determine anti-aGal antibody isotypes by indirect ELISA. Mice immunized once 
or twice all produced IgM heavy chain and K light chain antibodies. The predominant IgO 
subtypes for both sets of immunized mice were IgGl and IgG3. 
closely monitored and palpated for tumor growth (Fig. 7). None of the 
mock-immunized C57BL/6 control mice (0%) survived beyond 17 
days after tumor cell challenge. Only 9 of 15 (60%) mock-immunized 
«GT KO mice survived beyond 32 days after challenge. In contrast, 
all of the immunized aGT KO mice (100%) survived MC38 challenge 
(P - 0.0069). and palpated tumors were smaller and developed much 
more slowly when compared with mock-immunized «GT KO mice. 
DISCUSSION 
The role of aGal epitopes in xenograft rejection has been well 
studied (9-13, 30). Rapid immune recognition of aGal epitopes on 
the surface of foreign cells results in antibody-mediated cell cytotox­
icity and complement-mediated lysis of targeted cells. This immunity 
is a barrier to the use of nonhuman organs and tissue for transplant 
purposes. Recent advances in transplant science have resulted in the 
development of aGT KO pigs that may overcome immune obstacles 
to successful xenotransplantation in humans (31). Cancer gene ther­
apy protocols that rely upon murine VPC for delivery of genes can 
also be limited by the potent human immune response to «Gal 
epitopes. Both VPC and the vectors they produce are destroyed by 
anti-aGal immune mechanisms (16-20). Clonal B-cell analysis esti­
mated that ~ 1% of circulating B cells produce anti-aGal antibody (8), 
and an estimated 1-2.4% of circulating IgG and 3.9-8% of IgM aie 
specific anti-aGal antibodies (32, 33). We hypothesize that innate 
anti-aGal immunity that is disadvantageous for xenograft transplan­
tation and VPC therapies could be used as an advantageous method to 
induce the destruction of cancer cells. Human cancer cells expressing 
«Gal epitopes on their cell surface would appear as xenoantigens and 
induce a strong immune response that destroys them. A murine colon 
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S S 
Group 1 
"•"Group 2 
Croup? 
11 13 15 17 19 21 23 25 27 29 31 33 35 37 
Days Post Tumor Ceil Challenge 
-•-Group 1 | 
Groups | 
Broup3 
11 13 16 17 19 21 23 25 27 28 31 33 35 37 
Days Post Tumor Cell ChaBenge 
E 2 
Group 1 
-•"Group 2 
Group 3 
31 33 35 37 
humans (5). aGT KO mice produce little or no «Gal-specific antibody 
(25. 26) but are able to develop an immune response to «Gal when 
immunized with RRBCs. These mice can produce «Gal-specitic an­
tibody with high titers and specificity in some animals similar to those 
observed in humans (27). The RRBC immunization protocol we used 
with the aGT KO mice resulted in high titers of anti-aGal antisera 
that could be detected by indirect ELISA at a 1:16,000 dilution. 
Previously, LaTemple et al (34) demonstrated a partially protective 
immune response when aGT KO mice are vaccinated with «Gal-
expressing B16 cells (after stable transfection of «Gal-negative B16 
cells with «GT cDNA) and challenged with parental B16 cells, 
MC38 murine colon carcinoma cells have a functional «GT en­
zyme and express aGal on their cell surface glycoproteins. Fig. 1 
shows the difference in aGal expression between MC38 colon carci­
noma and B16.BL6-2 melanoma cells used in this study. The aGal 
moiety expressed on the surface of MC38 cells is labeled brightly with 
1 3 6 7 9 11 13 15 17 19 21 23 25 27 2S 31 33 36 
Days Post Tumor CeB Challenge 
Fig. 6, Mice immunized with RRBC were noi protected after tumor challenge with 
«Gal-negative B16.BL6-2 melanoma cells. Survival curve for immunized «GT KO mice 
after challenge with B16.BL6-2 cells shows that an immune response to «Gal epitopes 
does not prevent tumor growth and death. Mice were immunized one time with 107 RRBC 
and challenged 14 days later with 1.0 X KPBl 6.BL6-2 melanoma cells. Mone of the mice 
survived tumor challenge despite immunization with aGal antigen because the BI6BL6-2 
tmnor cell line is a non-oGal-expressing cell. 
1 3 6 7 9 11 13 16 17 19 21 23 26 27 
Days Post Tumor Call Challenge 
Fig. 5, Mice immunized with RRBC showed superior protection to tmnor challenge 
with aGal-positive MC38 colon carcinoma cells compared with mock-immunized mice. 
Survival curves for immunized aGT KO mice and mock-immunized «GT KO mice and 
C57BL/6 mice after MC38 tumor cell challenge demonstrate thai an immune response to 
aGal epitopes can increase the survival of immunized mice in comparison to mice that are 
uot immunized with aGal. Group 1 consisted of aGT KO mice that were immunized one 
time with 107 RRBC before challenge 14 days later with MC3S cells. Group 2 consisted 
of «GT KO mice that were mock immunized and challenged 14 days later. Group 3 
consisted of C57BL/6 mice that were mock immunized and challenged 14 days later. 
Three dilutions of MC38 cells were used to challenge mice (A) 2.5 X I04 MC38 cells, (B) 
5.OX !04 MC3S cells, or (€7) 1.0 X j 05 MC38 cells. Mock-immunized C57BL/6 mice all 
died or were euthanized within IS days. Mock-immunized aGT KO mice showed 
49—60% survival. Immunized cxGT KO mice sliowed 80-100% survival (P = 0.031). 
cancer cell line was chosen for (Ms study. Colon cancer is the third 
most common fonn of cancer and third leading cause of death (4). 
The «GT KO mouse is an ideal small animal model to study our 
hypothesis. The loss of the aGT gene by these mice mimics the 
evolutionary loss of this gene by ancestral Old World primates and 
i "*™OreuB$ 
OT» flarvivaf 
1 3 5 7 S 11 13 18 17 19 21 23 25 27 26 31 
Deys Post Tumor Cefl Challenge 
Fig. 7. Mice immunized twice with RRBC showed superior protection to tumor 
challenge with aGal-positive MC38 colon carcinoma cells compared with mock-immu-
nized tnice. Survival curves for immunized «GT KO mice (group 1) mid mock-inmnuiized 
aGT KO mice (group 2) and C57BL/6 mice (group 3) after MC38 tumor cell challenge. 
Mice were immunized or mock immunized twice with 107 RRBC, 28 and 14 days before 
tumor cell challenge. .411 mice were challenged with 2.5 X I O4 MC38 cells. Group 1 aGT 
KO mice were immunized with RRBC and demonstrated 100% survival to tumor cell 
challenge (P < 0.0069) in comparison to group 2 moek-immuuized aGT KO mice (60% 
survival) mid group 3 mock-immunized C57BL'6 mice (0% survival). 
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IB4 lectin-FITC conjugates, whereas B16.BL6-2 melanoma cells lack 
aGal expression on their surface and do not bind the IB4 lectin. A 
serum exposure assay showed the complement-mediated destruction 
of aGal-positive MC38 colon carcinoma cells. Cells were incubated 
with media that contained 50% human serum with active complement 
or media that contained 50% heat-inactivated human serum (Fig. 2). 
After incubation with the test media, PI uptake measured by flow 
cytometry was used to estimate the percentage of cells killed. A total 
of 98% of MC38 cells was killed when exposed to untreated human 
serum. Control cells that were untreated or treated with lieat-inactivated 
serum (devoid of active complement) showed PI uptake of 22 and 30%. 
respectively). Therefore, the presence of active human complement in­
duced dramatically higher killing as expected (22). Takeuchi et al (18) 
demonstrated similar results using human cells. Transfected cells that 
express porcine aGT are lysed by human serum with complement (18). 
The titer of anti-aGal antibody in immunized «GT KO mice was 
measured by indirect ELISA. Mice immunized twice with RRBC 
developed an average titer of 1:8000 (Fig. 3B) that is comparable with 
measured serum titers from patients receiving VPC treatment (data 
not shown). Mice that were immunized twice with RRBC developed 
an anamnestic immune response to the aGal antigen (Fig. 4-1). The 
titer of anti-aGal peaked 7 days after the second immunization, and 
IgGl, IgG3, and IgM are the dominant anti-aGal heavy chain isotypes 
(Fig. 43). 
Tumor challenge studies were designed to determine whether im­
munity to aGal epitopes could provide protection from challenge with 
«Gal-expressing MC38 murine colon carcinoma cells. In the first 
experiment, «GT KO mice were immunized a single time with 107 
RRBC and challenged with different dilutions (2.5 X 104, 5.0 X 104, 
or 1.0 X 105) of MC38 cells. A total of 13 of 15 «GT KO mice 
survived tumor challenge, whereas only 7 of 15 mock-immunized 
aGT KO mice survived challenge with the same dilutions of MC38 
cells (P = 0.031). Despite our evidence that mice immunized a single 
time with RKBC do not develop high titers of anti-agal antibody, 87% 
of immunized mice were protected and survived. None of the mock-
immunized control C57BL/6 mice survived the tumor challenge, and 
all were euthanized by day 18. Although anti-aGal antibody could not 
be detected by ELISA in sera from mock-immunized control mice, 
others have suggested that aGT KO mice have a low natural titer of 
anti-agal antibody (25, 26). This natural antibody in the transgenic 
knockout mouse may, as hypothesized in humans, arise from stimu­
lation of environmental antigens. The combination of preexisting low 
antibody titers and stimulation by aGal-positive MC38 cells may have 
allowed 47% of the mock-immunized aGT KO mice to survive 
challenge with the MC.38 cell dilutions. In a separate experiment, 
«GT KO mice were immunized a single time with 107 RRBC and 
challenged xvith 1.0 X 105 «Gal-negative B16.BL6-2 murine mela­
noma cells. None of these mice survived beyond day 25 of the tumor 
challenge (Fig. 6), and results of this experiment provide evidence that 
anti-aGal antibodies do not provide protection against tumors that do 
not express the aGT gene. The potential cellular differences (besides 
the expression of aGal epitopes) between MC38 and B16.BL-2 cells 
have been addressed by additional experiments in which immunized 
mice were challenged with B16.BL-2 cells transduced with a vector 
carrying the aGT gene. Results show a significant difference in tmnor 
development and kinetics of tumor growth between immunized mice 
challenged with aGal-expressing B16.BL-2 cells and mice challenged 
with aGal-negative B16.BL-2 cells.4 These findings are similar to 
those reported by LaTemple (34). A second MC38 challenge exper­
iment incorporated two RRBC immunizations of «GT KO mice to 
4 G. Rossi, personal communication. 
generate higher titers of anti-Gal antibodies. Immunized and mock-
immunized control mice were challenged with 2.5 x 1Q4 of MC3S 
tumor cells. All 15 immunized aGT KO mice survived MC38 chal­
lenge, whereas only 9 of 15 mock-hmnunized aGT KO mice survived 
(P = 0.0069 by ANOV'A). Again, all mock-immunized C57BL/6 
control mice developed tumors rapidly and were euthanized by day 
17. After the challenge, mice were observed and palpated daily. 
Observations included slower development of tumors and smaller 
tumors in immunized aGT KO mice compared with mock-immunized 
mice (data not shown). The survival of 60% of the control mock-
immunized «GT KO mice may again be attributable to a combination 
of low-titer natural antibody and immune stimulation by the MC38 
cells. These data provide a first step toward the development of 
aGal-based colon cancer vaccines for lnimans. 
Colorectal cancer vaccines are as yet in the experimental stage of 
development Potential vaccines based upon 17-1A, 791Tgp, carcino-
embryonic antigen (35), and the SART3 peptide antigens (36) are 
currently being tested with marginal but encouraging results. Colon 
cancer cells expressing a functional aGT gene will be readily identi­
fied by the high percentage of innate circulating human antibodies. 
This, in mm, would lead to hyperacute rejection of such genetically 
modified cells. Hyperacute rejection of porcine xenotransplants oc­
curs after recognition and binding of multiple glycoprotein epitopes 
by human serum (13,37). At least five major cell surface glycoprotein 
groups on porcine cells express aGal epitopes and are detected by 
human IgM and IgG antibodies and also bind IB4 lectin (38). Simi­
larly, the MC38 colon carcinoma cells used in this study can also be 
assumed to present multiple epitopes to the aGT KO murine immune 
system. 
We have developed an in vivo animal model to demonstrate that 
immunity to aGal can protect aGT KO mice against challenge with 
colon cancer cells that express aGal. These results demonstrate the 
potential for a cancer gene therapy that uses the innate immunity to 
«Gal antibody in humans. Direct gene transfer of aGT to in vivo 
tumors will be the key next step in determining whether aGT gene 
therapy for colon cancer- will be successful. Gene delivery to tumor 
cells and expression of the aGT gene will present multiple targets for 
the immune system. Because both opsonization and complement 
fixation are dependent upon epitope density, the potential for a pro­
tective immune response directed against human tumor cells that 
express aGal is great. 
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Abstract 
Ataxia-telangiectasia (AT) is an autosomal recessive disorder characterized by genomic instability, chronic oxidative 
damage, and increased cancer incidence. Compared to normal cells, AT cells exhibit unusual sensitivity to exogenous oxidants, 
including r-butyl hydroperoxide (/-BOOII). Since ferritin releases labile iron under oxidative stress (which is chronic in AT) 
and labile iron mediates the toxic effects of /-butyl hydroperoxide, we hypothesized that chelation of intracellular labile 
iron would increase the genomic stability of AT cells, with and without exogenous oxidative stress. Here we report that 
desferoxamine treatment increases the plating efficiency of AT, but not noimal cells, in the colony forming-efficiency assay 
(a method often used to measure genomic stability). Additionally, desferoxamine increases AT, but not normal cell resistance, 
to /-butyl hydroperoxide in this assay. Last, AT cells exhibit increased sensitivity to the toxic effects of FeCl2 in the colony 
forming-efficiency assay and fail to demonstrate a FeCl2-induced G2 checkpoint response when compared to normal cells. 
Our data indicates that: (1) chelation of labile iron increases genomic stability in AT cells, but not normal cells; and (2) AT 
cells exhibit deficits in their responses to iron toxicity. While preliminary, our findings suggest that AT might be, in part, a 
disorder of iron metabolism and treatment of individuals with AT with desferoxamine might have clinical efficacy. 
© 2003 Elsevier Science B.V. All rights reserved. 
Keywords: Ataxia-telangiectasia; Desferoxamine; Oxidative stress; Genomic stability 
1. Introduction 
Ataxia-telangiectasia (AT) is an autosomal reces­
sive disorder characterized by immune dysfunction, 
premature aging, increased ionizing radiation (IR) 
Abbreviations: AT, Ataxia-telangiectasia; pAIM, protein AT-
mutated; FCS, fetal calf semm; 1R, ionizing radiation; r-BOOH, 
/-butyl hydroperoxide: DTPA, diethylenetriansinepeiitoacetic acid; 
DAPI, 4'.6-diamidino-2-phenylindole 
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E-mail address: wangsm@iiis.org (S. Wang). 
sensitivity, cerebellar degeneration accompanied by 
Ataxia-telangiectasias, and elevated cancer inci­
dence [1], In culture, cells from individuals with 
AT exhibit multiple defects when compared to nor­
mal cells, including increased genomic instability, 
increased serum growth factor requirements, pre­
mature senescence, and failure to exhibit Gi, S, or 
Gz checkpoint responses, or p53 induction follow­
ing IR [1], The gene product mutated in AT, pATM 
(for protein AT-mutated), has been cloned and its 
product found to have IR-inducible kinase activity 
[1-3]. 
1568-7864'$ - see front matter © 2003 Elsevier Science B.V. All rights reserved 
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Considerable data indicates that AT is, in part, a 
disorder of chronic oxidative stress and decreased 
antioxidant capacity [4], Individuals with AT exhibit 
increased markers of oxidative stress, including lipid 
peroxidation and oxidative damage to DNA [5], ATM 
knockout mice similarly show increased markers of 
oxidative damage, particularly in the cerebellum [6,7], 
Cells from individuals with AT show increased lipid 
peroxide levels, lowered catalase activity, lowered mi­
tochondrial manganese superoxide dismutase levels, 
and diminished ability to resynthesize glutathione fol­
lowing depletion with diethylpyrocarbonate [8-10]. 
In vitro, AT cells are unusually sensitive to the toxic 
effects of hydrogen peroxide, /-butyl hydroperoxide 
(/-BOOH), nitric oxide, and superoxide in colony 
forming-efficiency assays. AT cells also fail to exhibit 
Gi and G% checkpoint responses or p53 induction 
following /-BOOH exposure [11-14], Last, pATM 
exhibits /-BOOH-inducible kinase activity [11]. 
Since oxidative stress (which is chronic in AT) 
can cause labile or "free" iron release from ferritin 
[15-17], we hypothesized that labile intracellular iron 
acts as a powerful Fenton oxidant within AT cells (for 
review see [ 18]) and chelation of labile iron in AT cells 
would result in reduced oxidative damage to DNA and 
hence, increased genomic stability. Here we report 
that: (1) desferrioxamine treatment increases AT cell 
colony formation in the colony forming-efficiency 
assay (a method often used to measure genomic sta­
bility [11]), both with and without the addition of 
/-BOOH: (2) aspirin, a ferritin inducer [19], also in­
creases the resistance of AT cells to the toxic effects 
/-BOOH: (3) AT cells show increased sensitivity to 
the toxic effects of FeClz; and (4) pATM is required 
for the FeCl2-induced checkpoint response. Our 
data suggests that AT is, in part, a disorder of iron 
metabolism. Therefore treatment of individuals with 
AT with low concentrations of desferrioxamine and/or 
aspirin may lessen the chronic oxidative stress seen 
in AT and slow its clinical progression. 
2. Methods and materials 
2.1. Materials 
FeClj. aspirin, diethylenetriaminepentaacetic acid 
(DTPA), hygromycin, and desferrioxamine mesylate 
were obtained from Sigma (St. Louis, MO). Fetal 
calf serum (PC'S) and Dulbecco's modified eagle's 
medium (DMEM) were obtained from Invitrogen 
(Rockville, MD). Culture dishes were obtained from 
Becton Dickinson (Franklin Lakes, NJ). 
22 Cdb 
AT22, an SV40-transformed skin fibroblast cell 
line, was obtained from David Cortez at the Bay­
lor Medical School. VA13, an SV40-transformed 
normal fetal lung fibroblast cell line, was obtained 
from ATCC (Rockville, MD, USA). pEBS7 and 
pEBS7-YZ5 tumor cell lines were a generous gift 
from Dr. Yosif Shiloh at the Sackler School of 
Medicine, Tel Aviv University, Israel [20]. The NHF1 
normal foreskin fibroblast primary cell strain was a 
generous gift from Richard Paules at the National 
Institute of Environmental Health Sciences. The pri­
mary dermal AT fibroblast cells strains ATDM-1 and 
ATDM-2 were obtained by skin biopsy from two 
males, ages 10 and 14, diagnosed with AT. The AT22 
and VA 13 cells were cultured in DMEM containing 
5% FCS and 1% penicillin/streptomycin/glutamine. 
The pEBS7, and pEBS7-YZ5 cells lines were grown 
in the same media with hygromycin at 100 jig/ml 
[20]. The primary fibroblast cell strains were grown 
in the same media with 20% FCS plus 1% peni-
cilliM'streptomycin/glutamme. 
2.3. Colony forming-efficiency assay 
Colony forming-efficiency experiments were per­
formed as previously described [11]. In brief, ex­
ponentially growing cells were plated at 2000 cells/ 
100 mm tissue culture dish in 10 ml appropriate me­
dia, allowed to adhere 6h, and treated 15min with 
varying concentrations of /-BOOH or FeCl? Follow­
ing treatment, the plates were washed two times with 
media, the media replaced, and colonies fixed and 
stained after 14 days in culture by water:methanol ad­
dition (1:1) containing crystal violet (1 g/1). Colonies 
consisting of cell clusters containing greater than 50 
cells were counted under a dissecting microscope. Un­
less otherwise noted, where desferrioxamine and/or 
aspirin pretreatment was employed, the cells were 
plated in desferrioxamine, aspirin, or desferrioxamine 
and aspirin, and allowed to adhere for 6 h. The plates 
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were then washed four times with media and treated 
with f-BOOII as above. Data indicates survival as a 
percentage of untreated cells. The AT22 and VA13 
tumor cell lines were used at passages 20-40. The pri­
mary NHF1, ATDM-1, and ATDM-2 cell strains were 
used at passages 6-18. pEBS7 and pEBS7-YZ5 cells 
were used at passages 15-20. All experiments were 
done at least twice in triplicate. Standard deviations 
(error bars) were calculated from each experimental 
data point divided by the mean untreated value and 
averaged between experiments to obtain the mean 
standard deviation. 
2.4. Mitotic delay 
Mitotic delay assays were performed as previ­
ously described [11], In brief, cells were plated onto 
100 mm tissue culture plates and incubated 48-72 h 
(to approximately 50% confluency). The cells were 
then treated with FeCl; for 15min as in the colony 
forming-efficiency assay, washed two times with me­
dia, cultured 2h, and the media was removed. The 
cells were fixed in 5 ml cold methanol for 10 min 
and air-dried. The cells were stained with 0.2 pug/ml 
4',6-diamidmo-2-phenylindole (DAPI) in water and 
examined by fluorescence microscopy. The percent­
age of mitotic cells (mitotic delay) was determined by 
counts of 5000 cells. Mitotic delay experiments were 
performed in triplicate and the standard deviations 
were calculated as in the colony forming-efficiency 
assays. 
2.5. Western blot analysis 
Cells on 100 mm tissue culture plates were washed 
three times with phosphate buffered saline, harvested 
by scraping, and pelleted at 1000 x g for 5 mm. 
The resulting cell pellets were resuspended in 250 jxl 
one time lysis buffer (1% NP-40, 10 mM sodium 
phosphate (dibasic), 1 mM EDTA, 5mM glycerol 
phosphate, 1 mM DTT, 150mM NaCl), with protease 
inhibitors (aprotonin 4.0 |ig/ml, leupeptin 0.75 p-g/ml, 
phenylmathanesulfonyl fluoride 340 p,g/ml) and 
placed into a microcentrifuge tube. The suspension 
was centrifuged at 4°C for 20min at 13,000 x g and 
the supernatant, total cellular protein, was put into a 
microfuge tube for protein quantification. 
Primary antibody N514 (kindly provided by Dr. 
Richard Paules [11]) was added to each protein sam­
ple and tumbled 2 h at 4 °C. Twenty microliter pro­
tein G-Separose beads were added (Gibco BRL) and 
the tubes were tumbled for 30min. The G-Separose 
beads were washed three times with 1 ml lysis buffer 
with quick spins at 10,450 x g for ~5 s. Five times 
loading buffer (10% SDS, 375 mM Tris pH 6.8, 50% 
glycerol, 0.01% bromophenol blue) was then added 
to each sample and boiled 5 min. The samples were 
centrifuged at 13,650 x g for 5 min, the supernatants 
collected, and loaded onto a Novex 3-8% gradient 
gel per manufactures suggested protocol. The gel was 
run 90 min at 150 V. The gel was transferred onto ni­
trocellulose 7 h at 90 V at which time it was turned 
down to 35 V overnight. The blot was rinsed with one 
time TBST (20 mM Tris pH 8.0,150 mM NaCl, 0.05% 
Tween-20) and the nitrocellulose was blocked with 
5% powered milk in one time TBST for 3 h. The blot 
was rinsed with one time TBST and then Gene Tëx 
ATM-2C1 was added at 1:1000 dilution for lh. The 
blot was washed three times for 10 min with one time 
TBST. Amersham NA931 was added for 1 h, 1:4000. 
The blot was washed three times 10 min with one time 
TBST and developed using the Roche ECL kit. 
3. Results 
3.1. Long-term culture of AT cells with 
desferrioxamine increases plating efficiency in the 
colony forming-efficiency assay 
Because labile ferrous iron can act a powerful 
oxidant via Fenton chemistry [16,18], we hypothe­
sized that desferrioxamine treatment would chelate 
intracellular labile iron, reducing genomic oxidative 
damage, and thereby increase the plating efficiency of 
AT cells. As shown in Fig. 1, plating AT cells for 14 
days with increasing desferrioxamine concentrations 
significantly increased colony formation in all three 
AT cell types, but not in the normal cells. A significant 
difference was seen with as little as 1 nM desferriox­
amine. Remarkably, AT cells also formed colonies at 
desferrioxamine concentrations that completely inhib­
ited colony formation in the normal cell types (Fig. 1, 
compare VA 13 and NHF1 cells to AT22, ATDM-1, 
and ATDM-2 cells). Aspirin, a ferritin inducer 
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Fig. 1. Long-term culture with desferrioxamine increases the plating efficiency of AT cells in die colony forming-efficiency assay. The 
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hypothesized to chelate iron [19,21], failed to increase 
the plating efficiency of any of the cell types used 
in Fig. 1 over a 0.01-3.0 mM concentration (data 
not shown). Long-term incubation of AT cells with 
diethylenetriaminepentaacetic acid (DTPA), an iron 
chelator that does not cross cell membranes [22], only 
slightly increased AT cell plating efficiency at very-
high concentrations (above 1 mM, data not shown). 
Hence, we conclude that the AT cell behavior seen in 
Fig. 1 depends heavily upon the chelation of intracel­
lular iron. 
3.2. Long-term culture with desferrioxamine 
increases plating efficiency of pEBS7, but not 
pEBS7-YZ5 cells, in the colony forming-efficiency 
assay 
when compared to the pEBS7 cell line. Recombinant 
pATM expression also restored the previously ab­
sent IR-induced S phase checkpoint [20]. When the 
pEBS7 and pEBS7-YZ5 tumor cells lines were plated 
for 14 days with increasing desferrioxamine concen­
trations, colony formation increased significantly only 
for the pEBS7 cells. The pEBS7-YZ5 cells formed 
fewer colonies with increased desferrioxamine con­
centrations and exhibited no desferrioxamine-induced 
increase in colony formation (Fig. 2). Thus, recom­
binant pATM expression in AT cells blocks the in­
creased colony formation seen with desferrioxamine 
treated AT cells. As previously found [20], Western 
blot analysis demonstrated that the pEBS7-YZ5 cells 
expressed pATM, while the pEBS7 cells did not (data 
not shown). 
pEBS7 and pEBS7-YZ5 tumor cells are derived 
from the AT22 tumor cell line. The pEBS7 cell line 
carries a hygromycin resistance expression vector, 
while the pEBS7-YZ5 cell line carries the same 
hygromycin resistance vector, and a vector for re­
combinant pATM expression [20]. Previous exper­
iments demonstrated that pATM expression in the 
pEBS7-YZ5 cells resulted in an increased resis­
tance to IR in the colony forming-efficiency assay 
3.3. Pretreatment with desferrioxamine and aspirin 
increases the resistance of AT cells to oxidative stress 
in the colony forming-efficiency assay 
Previously, AT cells were demonstrated to be un­
usually sensitive to the toxic effects of /-BOOH in 
the colony forming-efficiency assay [11]. Since labile 
iron mediates (-BOOH toxicity by converting perox­
ides into the toxic hydroxyl radical inducing DNA 
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Fig. 2. Long-term culture with desferrioxamine increases the plating efficiency of pEBS7, but not pEBS7-YZ5, cells in the colony 
forming-efficiency assay. The effect of increasing desferrioxamine concentrations upon the pEBS7 (pATM-deficient) and pEBS7-YZ5 
(recombinant pATM expressing) cell types was examined. Exponentially growing cells were plated at a density of 2000 cells/100 mm 
plate in media with increasing desferrioxamine concentrations and cultured for 14 days. Cell colonies were then stained and counted. Data 
indicates survival as a percentage of untreated cells. 
damage [15,16,19], we hypothesized that pretreatment 
with desferrioxamine or aspirin would increase the 
resistance of AT cells to the toxic effects of /-BOOH. 
We chose to use /-BOOH because catalase activity 
is low in AT cells and /-BOOH is poorly hydrolyzed 
by catalase [9,23]. As shown in Fig. 3A (AT22 and 
VA13 cells), 3B (ATDM-1 and NHF1 cells), and 
3C (ATDM-2 and NHF1 cells), a 6 h pretreatment 
with 100 (iM desferrioxamine, 0.3 mM aspirin, or 
the two combined, increased the number of AT cell 
colonies formed following /-BOOH exposure in all 
three AT cell types. Desferrioxamine pretreatment 
was significantly different at all /-BOOH concentra­
tions (Fig. 3A-C), while aspirin pretreatment was 
significantly different for all three AT cell types only 
at 1 p-M /-BOOH (Fig. 3A-C). The combination of 
desferrioxamine and aspirin was significantly differ­
ent in all cases, with the exception of the AT22 cells 
treated with 1 |xM /-BOOH (Fig. 3A). Pretreatment 
of the VA 13 and NHF1 cells (Fig. 3A-C) with same 
concentrations of desferrioxamine, aspirin, or the 
two combined, did not significantly increase colony 
formation at any /-BOOH concentration (data not 
shown). The ability of desferrioxamine pretreatment 
to decrease the toxic effects of /-BOOH appears to 
require an iron chelator that can cross the cell mem­
brane, as pretreatment of AT22 cells with DTPA failed 
to lessen colony forming inhibitory effects of /-BOOH 
under the conditions employed here (data not shown). 
To further evaluate this effect of desferrioxamine 
and aspirin, dose-response curves and time courses 
were performed for each agent on AT22 cells. Fig. 4 
demonstrates that longer pretreatment times with 
100 |j,M desferrioxamine or 0.3 mM aspirin resulted in 
an increased resistance to the toxic effects of /-BOOH 
in the colony forming-efficiency assay until 9 h where 
the protective effects plateaued. Dose-response curves 
for desferrioxamine demonstrated that maximal pro­
tective effects occurred at 30 nM (Fig. 5A). The pro­
tective effect of aspirin peaked at 1 mM and declined at 
3 mM (Fig. 5B). Similar results were attained with the 
ATDM-1 and ATDM-2 cells in both the time courses 
and dose-response experiments (data not shown). 
3.4. AT celts exhibit increased sensitivity to 
FeClj in the colony forming-efficiency assay 
Since labile iron can act as a powerful oxidant 
[16,18], we hypothesized that AT cells would exhibit 
unusual sensitivity to the toxic effects of ferrous iron. 
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As shown in Fig. 6, AT cells exhibited greater colony 
formation inhibition in the colony forming-efficiency 
assay following a 15 min exposure to FeCli when 
compared with normal cells. 
3.5. FeCh induces a pATM-dependent checkpoint 
Previously, the Gi checkpoint response following 
/-BOOH treatment was found to be pATM dependent 
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Fig. 3. Desleirioxamiiie and aspirin pretteatmeiit of AT cells results in increased resistance to f-BOOH toxicity in the colony forming-efficiency 
assay. (A) Exponentially growing AT22 cells were plated for 6 h in media with desferrioxamine, aspirin, or both, washed four times, 
treated with increasing concentrations of f-BOOH, washed two times, cultured tor 14 days, and stained. VA13 cells were used as a normal 
control. (B) The effect plating ATDM-1 cells for 6 h in desfenioxaiuine, aspirin, or both, followed by treatment as in Fig. 5A. (C) The 
effect plating ATDM-2 cells for 6 h in desferrioxamine, aspirin, or both, followed by treatment as in (A). NHF1 cells were used as a 
normal cell control in (B) and (€). Data indicates survival as a percentage of untreated cells: desferrioxamine, IOOJJJM: aspirin, 0.3 mM. 
Asp: aspirin; Def: desferrioxamine. 
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[11]. The effects of desferrioxamine on AT cells 
(Figs. 1-3) and their increased sensitivity to FeCl? 
in the colony forming-efficiency assay (Fig. 6) sug­
gested that AT cells might exhibit deficits in re­
sponse to iron exposure. To test this possibility we 
examined FeCb exposure on the G% checkpoint re­
sponse in primary normal and AT cells. As shown 
in Fig. 7, FeCh treatment induced a dose-dependent 
G] checkpoint 2 h post FeC'h exposure in NHF1 
cells, but not in the ATDM-1 or ATDM-2 cells. Time 
AT22-Asp 
AT22-Def 
« 0 2 4 6 9 12 
tr Hours of Aspirin or Desferrioxamine Pretreatment 
Fig. 4. AT22 cellular resistance to the toxic effects of (-BOOH exposure increases with longer exposure to desfemoxamine or aspirin in 
the colony forming-efficiency assay. Exponentially growing AT22 cells were plated at the same time and treated with desfemoxamine or 
aspirin at 12, 9, 6, 4, 2, or Oh and washed four times. The cells were then treated with 10p.M /-BOOH for 15min, washed two times, 
cultured 14 days, stained, and counted. Data indicates survival as a percentage of untreated cells (100 ± 4.31): desfemoxamine. 100 [iM; 
aspirin, 0.3 mM. Asp: aspirin; Def: desferrioxamine. 
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Fig. 5. Increasing concentrations of desferrioxamine and aspirin increase the resistance of AT22 cells to the toxic effects of f-BOOH in 
the colony forming-efficiency assay. (A) Exponentially growing AT22 cells were plated for 6 h in media with increasing concentrations 
of desfemoxamine, washed four times, treated 15 min with 10|iM f-BOOH, washed two times, cultured 14 days, stained, and counted. 
(B) Exponentially growing AT22 cells were plated and treated as in Fig. 4A and with increasing concentrations of aspirin. Data indicates 
survival as a percentage of untreated cells (100 ± 3.21, Asp; 100 ± 2.17, Def). Asp: aspirin; Def: desterrioxamine. 
course analyses indicated that the FeClj-initiated 
0>2 checkpoint was maximal at 2 h post FeCb treat­
ment (data not shown). Primary cells were em­
ployed in the G% checkpoint experiments as these 
cells allow for more accurate assessment of the 
Gz checkpoint response than do transformed cells 
3.6. pATM Western blot 
Last, Western blot analysis was performed on the 
cells employed here. As shown in Fig. 8, the VA 13 
and NHF1 cells expressed pATM. while the AT22, 
ATDM-1, and ATDM-2 cells did not express pATM, 
indicating that these are AT cells. 
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Fig. 7. Feci; induces a pATM-dependent G2 checkpoint. Expo­
nentially growing NHF1, ATDM-1, and ATDM-2 cells were plated 
for 48-72 li, treated with increasing concentrations of FeCl? for 
15 mm, washed two times, cultured for 2 h, fixed in cold methanol, 
and stained with DAPI. The percentage of mitotic cells was counted 
by fluorescence microscopy. The results are expressed as a per­
centage of the mitotic index of the mock-treated population. 
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Fig. 8. pATM Western blot. Weston blot analysis of the VA13, 
NHF1, AT22. ATDM-1, and ATDM-2 cells. Whole cell extracts 
were prepared, incubated with the N514 anti-pATM antibody, 
immunoprecipitated, and subjected to SDS-PAGE followed by 
transblotting onto nitrocellulose. The blots were then probed for 
pATM using the Gene Tex ATM-2C1 antibody. 
4. Discussion 
Here we demonstrate that: (1) long-term cul­
ture with desferrioxamine increases the plating ef­
ficiency of AT, but not normal cells, in the colony 
forming-efficiency assay: (2) pretreatment with des­
ferrioxamine and/or aspirin partially protects AT 
cells, but not normal cells, from the toxic effects of 
f-BOOH exposure; (3) FeC'b exerts preferential toxi­
city towards AT cells when compared to normal cells; 
and (4) FeCl; treatment initiates a pATM-dependent 
G2 checkpoint response. 
Our data indicates that desferrioxamine treatment 
increases the plating efficiency of AT cells, both 
with and without exogenous oxidative stress in the 
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colony-efficiency forming assay. As this assay is 
commonly used to measure genomic stability [11], 
we conclude that desferrioxamine significantly in­
creases the genomic stability of AT, but not normal 
cells. The increased colony formation observed with 
desferrioxamine treatment of AT cells is dependent 
on a lack of pATM expression, since recombinant 
pATM expression in the pATM deficient pEBS7 
tumor cell line (pEBS7-YZ5 cells) completely sup­
pressed desferrioxamine-mediated increases in colony 
formation (Fig. 2). A likely molecular mechanism is 
that within AT cells intracellular labile iron acts as 
an oxidant via Fenton chemistry [16,18], and chela­
tion of this iron by desferrioxamine inhibits Fenton 
chemistry. Thus hydoxyl radical production would be 
lowered and less oxidative genomic damage would 
occur with desferrioxamine present. Support for this 
hypothesis comes from several observations: (1) in­
creased colony formation in AT cells is seen with 
long-term treatment with the intracellular labile iron 
chelation desferrioxamine (Figs. 1-3); (2) DTPA, an 
iron chelator that does not cross cell membranes fails 
to protect AT cells from exogenous oxidative stress; 
(3) long-term culture of AT cells with DTPA increases 
AT cell colony numbers in the colony-efficiency 
forming assay poorly when compared to desferriox­
amine and then only at high concentrations (1 mM 
and above); and (4) numerous studies indicate that 
desferrioxamine has powerful antioxidant capacities 
via its ability to chelate labile iron [16,24], 
Further support for a role of labile iron toxicity in 
AT comes from our observation that AT cells fail to 
initiate a FeCh-induced G% checkpoint response and 
exhibit enhanced toxicity following FeC'h exposure. 
Last, the metal binding protein metallothionine, which 
is induced by /-BOOH in normal cells, is not induced 
by t-BOOH in AT cells, lending some support for dys-
regulated metal metabolism in AT [25], 
We chose to examine the effect of aspirin on AT 
cells as aspirin has been hypothesized to chelate iron, 
crosses cell membranes, induces ferritin (which should 
aid in labile iron sequestration), and has antioxidant 
properties that inhibit DNA damage [19,21,26], Here 
we demonstrate that 0.3 mM aspirin significantly low­
ers the toxic effects of /-BOOH at 1 JAM, but not at 
greater concentrations. While higher aspirin concen­
trations may have a more significant effect, we did not 
examine them in detail as plasma aspirin concentra­
tions above 0.3 mM would exert toxic effects on indi­
viduals receiving it over prolonged periods, as would 
be required to treat AT. Our data does suggest that 
when combined with iron chelation, low dose aspirin 
might provide some enhanced genomic stability to AT 
cells. Aspirin, by itself, however, failed to increase the 
genomic stability of AT cells without exogenous ox­
idative stress. This data indicates that although aspirin 
exhibits some iron chelating abilities and antioxidant 
effects [19,21,26], these effects are insufficient to sig­
nificantly block the pro-oxidant effects of iron unless 
oxidative stress levels are increased by exogenous ox­
idants. 
Our data, although preliminary, suggests that low­
ering intracellular iron concentrations via desfer­
rioxamine treatment might have therapeutic value 
in treating AT. Our data does not directly address 
whether labile iron is elevated in individuals with AT, 
but indicates that this might be a possibility. Our data 
does indicate that AT cells exhibit preferential toxic­
ity following iron exposure and pATM is required for 
at least one iron-initiated cellular protective response 
(the G? checkpoint). Treatment with desferrioxamine 
is often used to lower iron levels in individuals with 
transfusion-dependent anemias (iron toxicity) [27]. 
This suggests that similar treatment could help indi­
viduals with AT. Minimal doses, namely, 1-30 nM 
desferrioxamine has a significant effect on AT cells. 
Therefore our data indicates that relatively little des­
ferrioxamine might be useful in treating AT. Further 
evaluation of the applicability of desferrioxamine 
in the treatment of AT will require examination of 
the effects of this drug on ATM knockout mouse 
survival. 
Taken together, our data suggests for the first time 
that AT is, in part, a disorder of iron metabolism. This 
altered iron metabolism may be due to increased la­
bile iron, altered iron sequestration, increased Fenton 
chemistry, or a combination all of three events. We 
are currently investigating these possibilities in both 
individuals with AT and AT mice. 
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Abstract 
Ataxia telangeictasia (A-T) is an autosomal recessive disorder characterized by immune dysfunction, genomic instability, chronic oxidative 
damage, and increased cancer incidence. Previously, desferal was found to increase the resistance of A-T, but not normal cells to exogenous 
oxidative stress in the colony forming-efficiency assay, suggesting that iron metabolism is dysregulated in A-T. Since desferal both chelates 
iron and modulates gene expression, we tested the effects of apoferritin and the iron chelating flavonoid quercetin on A-T cell colony-forming 
ability. We demonstrate that apoferritin and quercetin increase the ability of A-T cells to form colonies. We also show that labile iron levels 
are significantly elevated in Atm-deficient mouse sera compared to syngeniec wild type mice. Our findings support a role for labile iron acting 
as a Fenton catalyst in A-T, contributing to the chronic oxidative stress seen ih this disease. Our findings fiirther suggest that iron chelators 
might promote the survival of A-T cells and hence, individuals with A-T. 
© 2004 Elsevier B.V. All rights reserved. 
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1. Introduction 
Ataxia telangeictasia (A-T) is an autosomal recessive 
disorder characterized by immune dysfunction, premature 
aging, increased ionizing radiation (IR) sensitivity, oculo­
cutaneous telangiectasias, cerebellar degeneration accom­
panied by ataxia, and increased lymphoreticular cancer 
incidence [1], In culture cells from individuals with A-T 
show multiple defects when compared to normal cells, 
including increased serum growth factor requirements, in­
creased genomic instability, premature senescence, and 
failure to exhibit the Gj, S, or G2 checkpoint responses, 
or p53 induction following IR [1], The gene mutated in 
A-T, ATM (for A-T-mutatec!) has been cloned and its prod­
Abbrexiations: A-T, Ataxia telangeictasia; ATM, A-T-mutated: FBS, 
fetal bovine senrni; IR, ionizing radiation: (-BOOH, tert-butyl hydroperox­
ide; BPS, bathophenantraline disulphonate; SOD, superoxide dismutase; 
DAJPI, 4',6-diamidino-2-phenylindole. 
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E-mail address: suwang@dwx.com (S. Wang). 
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uct exhibits serine/theonine kinase activity induced by IR, 
and oxidants such as /-butyl hydroperoxide (/-BOOH), 
chromium VI, and nitric oxide [2-6]. ATM activation ap­
pears to follow changes in chromatin structure resulting in 
the dissociation of inactive ATM multimers into monomers, 
with concomitant activating autophosphorylation [7], 
Evidence indicates that A-T is in part, a disease of in­
creased oxidative stress, diminished antioxidant capacity, 
and inability to respond appropriately to exogenous ox­
idants [8], For example, A-T cells show increased lipid 
peroxidation, lowered catalase activity, lowered manganese 
superoxide dismutase levels, and delayed glutathione resyn-
thesis after depletion with diethylpyrocarbonate [9,10]. In 
culuture, A-T cells exhibit elevated levels of stress-induced 
proteins which ate lowered by treatment with the antioxidant 
a-lipoic acid, indicating that these cells are under chronic 
oxidative stress [11]. Individuals with A-T exhibit increased 
markers of oxidative stress, including lipid peroxidaton and 
8-hydroxydeoxyguanosine [12]. Atm-deficient mice show 
a similar pathophysiology, particularly in the cerebellum 
[13,14], In vitro, A-T cells are unusually sensitive to the 
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toxic effects of exogenous oxidants, including H2O2-. >~ 
BOOH, nitric oxide, chromium VI, arsenic, and superoxide, 
and fail to exhibit Gi and G2 checkpoint responses, 01 p53 
induction following /-BOOH exposure [4-6,15-18], 
Previously, the importance of oxidative stress in A-T and 
role of labile iron in mediating the toxic effects of «-BOOH 
[19], led us to hypothesize that desferal would increase the 
resistance of A-T cells to this oxidant [20]. We demonstrated 
that desferal pretreatment increased the ability of A-T, but 
not normal cells, to form colonies in the colony-efficiency 
forming assay following /-BOOH exposure [4]. Addition­
ally, A-T cells exhibited increased sensitivity to the toxic 
effect of FeClî in the colony fonning-efficieiicy assay com­
pared to normal cells and failed to exhibit an Fed)-induced 
G2 checkpoint response. The data suggested that labile iron 
is dysregulated in A-T and desferal increases the resistance 
of A-T cells to /-BOOH via labile iron chelation. Such chela­
tion would lessen Fenton chemistry and thereby increase 
A-T cell survival and colony forming ability. 
While deferal is a powerful iron chelator, it also modu­
lates gene activity, such as hypoxia inducible factor [21], 
raising the possibility that altered gene expression and 
not iron chelation explains desferal's effect on A-T cells. 
To further examine iron chelation and labile iron in the 
pathobiochemistry of A-T, we examined the effect of two 
pharmacologically different iron chelators on A-T cells. We 
report that apoferritin and the flavonoid quercetin increase 
the plating efficiency of A-T, but not normal cells in long-
term culture. Apoferritin also increased the resistance of 
A-T, but not normal cells, to the toxic effects of /-BOOH in 
the colony forming-efficiency assay. Quercertin had similar 
effects on both normal and A-T cells, although to a far 
greater extent in A-T cells. These later two observations 
indicate that apoferritin and quercetin also increase the re­
sistance of A-T cells to oxidative stress. Additionally we 
report that labile iron is elevated in the sera of Atm-deficient 
mice compared to syngeneic normal mice. Taken together, 
our data indicates that iron chelation increases the resis­
tance of A-T cells to oxidative stress, an effect probably 
dependent upon dysregulated iron metabolism in A-T. 
2. Materials and methods 
2.1. Materials 
FeClg, CuClz, Pb acetate, NiCl2. (NHOzFe^Ojb, 
C0CI2, bathophenantroline disulphonate (BPS), 4',6-
diamidino-2-phenylindole (DAPI), apoferritin, and hy­
gromycin were obtained from Sigma Chemical Corp. (St. 
Louis, MO). FBS (fetal bovine serum) and Dulbecco's 
Modified Eagle's Medium (DMEM) were obtained from 
Invitrogen (Rockville, MD). Culture dishes were obtained 
from Becton Dickinson (Franklin Lakes, NJ). The Hu­
man Ferritin Quantification ELIS A Kit (Cat. # 1810) 
was purchased from Alpha Diagnostic International, San 
Antonio, TX and used according the manufacturer's 
protocol. 
22. CWb 
VA13, an SV40-immortalized normal fetal lung fibrob­
last cell line, was obtained from ATCC (Rockville, MD, 
USA). AT22IJE-T (AT22) is an SV40-immortalized A-
T fibroblast cell line. AT22IJE-T pEBS7 (pEBS7) and 
AT22IJE-T pEBS7-YZ5 (YZ5) cells are from the parental 
AT22 cell line transduced with either a hygromycin re­
sistance expression vector or the same vector with ATM 
expression, respectively. These three AT22 cell lines were 
generous gifts from Dr. Yosif Shiloh at the Backer School 
of Medicine, Tel Aviv University, Israel [22]. The NHF1 
normal foreskin human fibroblast primary cell strain was 
a generous gift from Dr. Richard Paules at the National 
Institute of Environmental Health Sciences. The primary 
dermal A-T fibroblast strains ATDM-1 and ATDM-2 were 
obtained by skin biopsy from two unrelated males, ages 
10 and 14, diagnosed with A-T and previously demon­
strated to lack ATM expression [20]. The AT22 and VA 13 
cell lines were cultured in DEMEM containing 5% FBS 
and 1% penicillin/streptomycin/glutamate. The pEBS7 and 
pEBS7-YZ5 cell lines were grown in the same media with 
100 p,g/ml hygromycin [22]. The primary fibroblast cell 
strains were grown in DEMEM with 20% FBS and 1% 
penicilhn/streptomycin/ghitamine. 
2.3. A-T and normal seras 
Frozen seras from five individuals with A-T (ages 9, 11, 
13, 22, and 34) and tour age-matched controls (ages 10, 21, 
22, and 36) were kindly provided by Dr. Howard Ledeiinan 
at the John Hopkins A-T Clinic. 
2.4. Colony forming-efficiency assay 
Colony forming-efficiency experiments were performed 
as previously described [4], In brief, exponentially grow­
ing cells were plated at 2000 cells/100 nun tissue culture 
dish in 10ml appropriate media with an iron chelator and 
cultured for 14 days. The resulting colonies were fixed 
and stained by water :methanol addition (1:1) containing 
crystal violet (1 g/L). "Colonies" consisted of cell clus­
ters containing greater than 50 cells when counted under 
a dissecting microscope. For experiments involving apo­
ferritin or quercetin pre-exposure on /-BOOH resistance, 
the cells were allowed to adhere 6 li in increasing apo­
ferritin or quercetin concentrations, washed 4x with 5 ml 
media, treated with 10 jxM /-BOOH for 15 min in appro­
priate media, washed 1 X with 5 ml media, and allowed 
to grow for 14 days in 10ml of media. Data indicates 
survival as a percentage of untreated cells. The AT22 and 
VA 13 immortalized fibroblast lines were used at passages 
20-40. The primary NHF1, ATDM-1, and ATDM-2 cell 
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strains were used at passages 6-19. All experiments were 
done at least twice in triplicate. Standard deviations (error 
bars) were calculated from each experimental data point 
divided by the mean untreated value and averaged between 
triplicate experiments to obtain the mean standard devia­
tion. 
2.5. Mitotic delay 
Mitotic delay assays were performed as previoulsy de­
scribed [4], In brief, cells were plated onto 100 mm tissue 
culture plates and incubated 72 h (to approximately 50% 
confluency). The cells were treated with 100 p.M CuClg, Pb 
acetate, NiClz, or CoCk for 15min, washed 2x with 5 ml 
media, cultured 2 li, and the media was removed. The cells 
were fixed with 5 ml cold methanol for 10 mill and air-dried. 
The cells were stained with 0.2 p,g/ml DAPI in water and ex­
amined by fluorescence microscopy. The percentage of mi­
totic cells (miotic index) was determined by counts of 5000 
cells. Mitotic delay experiments were performed in tripli­
cate and the standard deviations calculated as in the colony 
forming-efficiency assay. 
2.6. Atm-deficient mouse status typing 
Atm-heterozygous mice were obtained from The Jackson 
Laboratory (Bar Harbor. ME) and were cared for under ap­
proval of an animal protocol using American Association 
for Laboratory Animal Science guidelines. ATM genotyp-
ing was performed as previously described [23]. In brief, 
heterozygous mice pairs were bred and Atm-deficient and 
wild type mice were identified by extracting 35-70 p.1 of 
blood from the Saphenous vein with heparinzed microcap-
illary tubes. The blood was transferred to a inicrofuge tube 
with 20 p.1 of lOmM EDTA, mixed, and stored on ice. Two 
hundred |xl lysis buffer (0.32 M Sucrose, 10 mM Tris-HCl 
pH 7.5, 5mM MgCl%, 1% v/v Triton X-100) was added 
to each tube. The tubes were vortexed and centrifuged at 
16,000 g to pellet. The samples were washed 3x with ly­
sis buffer and centrifuged as before. The pellets were re-
supsended in 25-50 (xl of digestion buffer (50 mM KC1, 
lOmM Tris-HCl pH 8.3,2.5 mM MgClz, 0.1 mg/ml gelatin, 
0.45% [v/v] Nonidet P40, 0.45% [v/v] Tween 20). The so­
lution was autoclaved to sterilize and dissolve the gelatin. 
Proteinase K, was added at a final working concentration of 
60 ng/ml, to the digestion buffer immediately prior to use. 
The resulting solution was incubated at 55 °C overnight, 
heated to 97 °C for 10min to inactivate the protenase K, 
and PCR was performed on 2 |xl of the samples using four 
primers designed to amplify either the Neo genetic mark­
ers or the ATM gene. The PCR reactions were run into a 
1.5% argarose gel. The wild type mice had only one band 
at 147 bp utilizing the A-T primers. The Atm-deficient mice 
mice had only one band at 280 bp utilizing the Neo primers 
[23] 
2.7. Atm-deficient and norma! murine seras 
The Atm-deficient and normal murine seras were obtained 
via cardiac puncture of deeply anesthesia mice which were 
then sacrificed. The blood from each mouse was allowed to 
clot in a 1.5 nil eppindorf tube for 30 min at room temp. After 
30 min the blood was centrifuged with a quick spin (~30 s) 
at 9000 x g and the upper sera layer was removed. The 
sera was immediately used to quantify labile ferrous iron. 
All mice were litennates between 20 and 35 days old and 
all mice were the same age when labile iron concentrations 
were quantified. The sera from each mouse was measured 
separately. Hie seras of five normal and five Atm-deficient 
mice were quantified in two separate experiments. 
2.S. Quantification of labile ferrous iron 
The concentration of labile ferrous iron in normal 
and Atm-deficient mouse sera was quantified as previ­
ously described [24]. In brief, a 50 mM stock solution of 
bathophenantroline disulphonate (BPS) was prepared by 
dissolving 28.2 mg BPS in 1 ml of deionized pyrogen free 
water. A standard curve for ferrous iron was constructed 
by dissolving 196 mg (NH^hFefSOj): in 500 ml deionized 
pyrogen free water. The solution was then diluted to make 
0.1-30 pM (NH4)2Fe(S04)2 solutions. Ten microliters of 
BPS stock solution was added to 490 p,l of water or each 
(NH4)2Fe(SC>4)2 solution, mixed, and left for 15 min to in­
sure complete complex formation. Fifty microliters of each 
sample was then transferred to a 96 well plate and the ab-
sorbance was read at 535 nm against a 50 pi water blank. For 
serum labile ferrous iron measurements 49 jxl of each sera 
sample received either 1 pJ of BPS stock solution or 1 p.1 
water and was gently mixed a 96 plate well. After 15 min, 
the absorbance was read at 535 nm with the standard curve. 
The value of each respective blank was subtracted from 
each of the samples containing the BPS complex. Data was 
analyzed using a student's one-tailed /-test demonstrating a 
significant difference between the means of wild-type and 
Atm-deficient mouse sera (P = 0.013). 
3. Results 
3.1. Apopferritin and quercetin increase the plating 
efficiency of A-T, but riot normal cells, in the colony 
forming-efficiency assay 
Previously we found that the iron chelator desferal in­
creased the colony formation in A-T, but not normal cells 
in the colony forming-efficiency assay [20]. While desferal 
chelates iron, it also modulates gene activity [21], raising 
the possibility that gene modulation and not iron chelation 
caused the increased colony formation seen in A-T cells. 
To differentiate between these two possibilities we cultured 
normal and A-T cells for 14 days with either apoferritin 
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Fig. 1. (A) and (B) Long-tenu culture with aixifenitin increases the plating 
efficiency of A-T cells iu the colony forming-efficiency assay. (A) the 
effect of increasing apoferritin concentrations upon two nonnal and three 
A-T cell types was examined. (B) the effect of increasing apoferritin 
concentrations upon the pEBS7 and pEBS7-YZ5 cell lines was examined. 
Exponentially growing cells were plated at a density of 2000 cells '100 mm 
plate in media with increasing apoferritin concentrations and cultured for 
14 days Cell colonies were then stained and counted Data indicates 
survival as a percentage of untreated cells. 
or quercetin. Culturing the VA13, NHF1, AT22, ATDM-1, 
and ATDM-2 cells with increasing concentrations of apo­
ferritin increased A-T cell colony formation, but not normal 
cell colony formation up to 30 jig/inl apoferritin (Fig. 1 A). 
In culture apoferritin is taken up by cells and binds labile 
iron, acting as an iron sequestrant and antioxidant [25,26], 
Thus apoferritin. a protein iron chelator pharmacologically 
unlike desferal, lias similar effects to desferal on A-T colony 
formation. Interestingly, apoferritn at higher concentrations 
was more toxic to the immortalized cell lines than to the 
primary cells (Fig. 1A). 
To ascertain if this phenomenology was ATM depen­
dent, similar experiments were carried out with the pEBS7 
and pEBS7-YZ5 cell lines. The pEBS7 cell line carries a 
hygromycin resistance expression vector, while the pEBS7-
YZ5 cell line carries a vector for pATM expression and 
hygromycin resistance. When the pEBS7 and pEBS7-YZ5 
cells lines were plated for 14 days with increasing apofer­
ritin, colony formation increased only in the pEBS7 cells 
(Fig. IB). High concentrations of apoferritin ( 100 (jugml) 
however, inhibited colony formation in both cell types 
(Fig. IB). Thus, ATM expression in A-T cells blocks the 
increased colony formation seen with apoferritin treated 
A-T cells. As previously found [22], Western blot analysis 
demonstrated that the pEBS7-YZ5 cells expressed ATM, 
while the pEBS7 cells did not (data not shown). 
Quercetin is a flavonoid with multiple activities, includ­
ing antioxidant and iron and copper chelating activities [27]. 
Although not specifically an iron chelator, we examined the 
effect of quercetin as it has low toxicity, powerful antiox­
idant effects, and chelates iron, making it a possible phar­
macological agent for treating A-T. As shown in Fig. 2A. 
quercetin treatment resulted in a moderate, but significant 
increase in the plating efficiency of A-T, but not normal 
cells, over a 1-10 nM range. Similar results were obtained 
with tlie pEBS7 cell line, but not the pEBS7-YZ5 cell line 
(Fig. 2B), indicating that this phenomenon was dependent 
upon a lack of ATM expression. 
3.2. Apoferritin pretreatment increases the resistance of 
A-T, but not normal cells, to the toxic effects t-BOOH in 
the colony forming-efficiency assay 
Our finding that apoferritin, quercetin. and desferal all 
increase the plating efficiency of A-T, but not normal cells, in 
the colony forming-efficiency assay demonstrates that iron 
chelators have colony formation-promoting effects specific 
to A-T cells [20]. These experiments do not demonstrate that 
these agents increase the resistance of A-T cells to oxidative 
stress, an important factor in the pathobiochemistiy of A-
T. To examine whether or not apoferritin could increase 
the resistance of A-T cells to oxidative stress the "VA13, 
AT22, NHF1, ATDM-1, and ATDM-2 cells were plated into 
media containing increasing apoferritin concentrations for 6 
h. The plates were washed 4x with media, the media was 
replaced, and the cells were treated 15 min with 10|juM t-
BOOH and allowed to form colonies. As shown in Fig. 3, 
increasing apoferritin concentrations increased the colony 
formation of A-T, but not normal cells in the colony forming-
efficiency assay. We used f-BOOH, as catalase activity has 
been reported to be low in A-T cells and /-BOOH is poorly 
hydrolyzed by catalase [9.28]. 
3.3. Quercetin increases the ability of A-T and normal 
cells to form colonies following t-BOOH exposure 
To examine the effect of quercetin on resistance to oxida­
tive stress in A-T and nonnal cells, the cells used in Fig. 4 
were preheated 6 h with increasing quercetin concentrations. 
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Fig. 2. (A) and (B) Long-term culture with quercetin increases the plating 
efficiency of A-T cells in the colony forming-efficiency assay. (A) the 
effect of increasing quercetin concentrations upon two normal and three 
A-T cell types was examined. (B) the effect of increasing quercetin 
concentrations upon the pEBS7 and pEBS7-YZ5 cell lines was examined. 
Data indicates survival as a percentage of untreated cells. 
exposed to 10 p,M /-BOOH, and colony formation was 
quantified. As shown in Fig. 4 quercetin concentrations up 
to 30 nM increased cellular resistance to /-BOOH in all cell 
types. The percentage increase in colony formation was 
much higher for the A-T cells than the normal cells. 
Cell type/treatment pEBS7 b) ± S.D. pEBS7-YZ5 (%) ± S.D. 
Untreated 100.00 7.3* 100.0 ± 3.35 
CuCl, 102.62 ± 3.47 32.90 ± 0.74 
Pb acetate 101.45 ± 10.67 40.0 ± 1.70 
NiCl; 101.45 ± 8.Z3 22.58 ± 5.08 
CoCk 104.36 ± 3.06 35.73 ± 1.78 
CuCli. Pb acetate. NiCl2. and CoCl2 induce an ATM dependent G-
clieckpoint. pEBS7 and pEBS7-YZ5 cell lines were plated 72 li. treated 
15imn with 100|AM CuCb, Pb acetate. NiCk. or CoClj. washed twice, 
cultured for 21i_ fixed in cold methanol, and stained with DAPI. Hie 
percentage of mitotic cells was counted by fluorescence microscopy. The 
results are expressed as a precentage of the mitotic index of the mock-
treated population. 
cells exliibited au increased sensitivity to the toxic effects 
of CuC'h exposure when compared to normal cells. Inter­
estingly, the immortalized cell lines were more sensitive to 
the toxic effects of copper exposure than were the primary 
cells. However, within each cell type (i.e., immortalized 
and primary cells), the A-T cells were more sensitive to the 
toxic effect of copper. 
3.5. CuC'h, Pb acetate, NiCh, and CoCh induce an ATM 
dependent Ch checkpoint response 
Our finding that A-T cells exhibit preferential sensitivity 
to the colony-inhibiting effects of CuCl? exposure, com­
bined with previous data demonstrating that FeClj induced 
an ATM dependent G; checkpoint [20], lead us to hypothe­
size that other toxic metals would also elicit an ATM depen­
dent G] checkpoint response. To test this hypothesis pEBS7 
and pEBS7-YZ5 cells were exposed to 100 (xM CuCl?, Pb 
acetate, NiCK or C0CI2 for 15 min and the G% checkpoint 
response was examined 2 h later. As shown in Table 1, 
CuClz, Pb acetate, N1CI2. and C0CI2 all induced an ATM 
dependent G% checkpoint. Thus toxic metals other than 
iron induce an ATM dependent G? checkpoint response. 
Time course experiments demonstrated that the G% check­
point response was maximal at 2 h for each metal (data not 
shown). 
3.6. Atm-deficient mice exhibit increased serum feirous 
labile iron compaivd to syngeneic normal mice 
3.4. A-T cells exhibit increased sensitivity to the toxic 
effects of copper exposure 
The observation that quercetin, a flavonoid that chelates 
both iron and copper [27], increased the plating efficiency 
and ability of A-T cells to form colonies after /-BOOH 
exposure (Figs. 2A, B, and 4) indicated that A-T cells 
might show increased sensitivity to copper exposure in the 
colony forming-efficiency assay. As shown in Fig. 5, A-T 
While quercetin, apoferritin. and desferal are structurally 
quite different and have different pharmacological proper­
ties, they all chelate iron. Based on this data, we hypoth­
esized that labile iron would be elevated in Atm-deficient 
compared to syngeneic normal mice. When the concentra­
tion of plasma serum labile ferrous iron in Atm-deficient 
mice was compared to that of syngeuiec normal mice, the 
Atm-deficient mice exhibited significantly elevated levels of 
ferrous iron (Fig. 6). 
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ATDM-2 
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Concentration of Apoferritin (ixg/ml) 
Fig. 3. Pretreatment of A-T and normal cells with apofenitin results in increased resistance to /-BOOH toxicity in the colony fonning-efficieucy assay. 
Exponentially growing NHF1. VA13. ATDM-1. ATDM-2. and AT22 cells were plated for 6h with increasing concentrations of apoferritin, washed 4x, 
treated with 10|iM /-BOOH 15 min, washed lx, cultured for 14 days, and stained. Data indicates survival as a percentage of untreated cells. Untreated 
rallies were VA13 cells, 100 ±7.36; AT22. 100 ±9.94; NHF1. 100 ±4.34: ATDM-1. 100 ±12.46; ATDM-2. 100 ±5.24. 
3.7. Ferritin is not dysregulated in A-T cells 
No differences in ferritin induction by 10p,M FeCh in 
the pEBS7 and pEBS7-YZ5 could be detected by enzyme 
linked immunosorbent assay (Human Ferritin Quantification 
ELIS A Kit, data not shown). Similarly, ferritin levels in the 
frozen seras from five individuals with A-T were not sig­
nificantly different than ferritin levels in four age-matched 
control individuals. The ferritin levels in the five A-T serum 
samples were also well within the normal range for serum 
ferritin (data not shown). Based on this data we conclude 
that ferritin is not dysregulated in A-T. 
! 
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NHF1 
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AT22 
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Fig. 4. Pretreatment of A-T and nonnal cells with quercetin results in increased resistance to r-BOOH toxicity in the colony forming-efficiency assay. 
Exponentially growing NHF1. VA13. ATDM-1. ATDM-2, and AT22 cells were plated for 6h with increasing concentrations of quercetin. washed 4x, 
treated with IOJAM F-BOOH 15 min. washed lx, cultured for 14 days, and stained. Data indicates survival as a percentage of untreated cells. Untreated 
values were VA13 cells. 100 ± 5.92: AT22, 100 ± 3.56; NHF1, 100 ± 2.92: ATDM-1. 100 ± 6.43: ATDM-2. 100 ± 6.34. 
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Fig. 5. A-T cells exhibit increased sensitivity to CuCk in the colony forming-efficiency assay. Exponentially growing NHF1. VA13, ATDM-1. ATDM-2. 
and AT22 cells were plated for 6h and treated 15 min with increasing concentrations of CuCK washed 2x. cultured 14 days, stained, and counted. Data 
indicates survival as a percentage of untreated cells. 
4. Discussion 
1.25 
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Fig. 6. A-T mice exhibit increase labile serum ferrous iron compared to 
syngeneic normal mice Senun labile ferrous ir on in syngeneic normal and 
A-T mice were measured against a iNRi hFcvSO; )• standard curve via 
calometnc assay [24], Data was analyzed using a student's one-tailed r-test 
demonstrating a significant difference between the means of wild-type 
and A-T mouse sera (P — 0.013). 
Previously we found that the iron chelator desferal in­
creased the plating efficiency of A-T, but not nonnal cells, in 
the colony tbnuing-efficiency assay. Desferal also increased 
the resistance of A-T, but not nonnal cells, to the toxic effects 
of r-BOOH in the colony fonning-efficiency assay. Desferal 
has multiple pharmacological effects including iron chela­
tion and modulation of gene expression [21]. Thus gene 
modulation and not iron chelation could be responsible for 
the effects of desferal on A-T cells. To address this issue we 
treated nonnal and A-T cells with apoferritin and quercetin. 
Long-term culture with apofenitin and quercetin increased 
colony formation in A-T, but not nonnal cells, in the colony 
fonning-efficiency assay. Apofenitin pretreatment also in­
creased the resistance of A-T, but not nonnal cells, to the 
toxic effects of r-BOOH in the colony fonning-efficiency 
assay. Based on the similar effects of apofenitin, quercetin, 
and desferal on A-T cells and their different structures and 
phannacological activities, we conclude that iron chelation 
and not the gene-modulating effects of desferal are respon­
sible for the effect of these agents on A-T cells. 
Iron is known to mediate the toxic effects of peroxides 
via events such as the Fenton reaction [29]. Based on this 
and previous observations [20], we hypothesized that la­
bile iron would be elevated in A-T. To investigate this we 
compared syngeneic Atm-deficient and nonnal mice and 
found significantly elevated labile fenous iron in the sera 
of the Atm-deficient mice by calonnetric assay [24]. Since 
Atm-deficient mice share much of the same patliobiology 
as individuals with A-T [13,14], we conclude it likely that 
labile iron is dyregulated in individuals with A-T. Although 
we attempted to measure labile ferrous iron in the seras of 
several nonnal individuals and individuals with A-T, our 
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attempts failed as only frozen seras were available and the 
calormetric assay of Nilsson et al. [24] works only with flesh 
.serum. 
Apoferritin and desferal have properties that make them 
difficult to use as a pharmacological treatment for A-T: To 
our knowledge, apoferritin-based therapy in not available 
and desferal is limited in its usefulness due to its extremely 
short (10 min) plasma half life and oral ineffectiveness [30]. 
For this reason we investigated the effects of the flavonoid 
quercetin on A-T cells. Quercetin chelates iron and copper 
and is a powerful antioxidant [27]. Flavonoids also have 
comparatively long serum half lives, low toxicity, and epi­
demiological data indicates that high flavonoid intake cor­
relates with a reduction in diseases associated with chronic 
oxidative stress [31,32]. 
In the colony fonning-efficiency assay quercetin increased 
A-T cell resistance to /-BOOH as measured by the ability to 
form colonies (Fig. 4). Quercetin had a similar effect on nor­
mal cells, although to a lesser degree. The reason for this dif­
ference probably lies in the lower sensitivity of nonnal cells 
to oxidative stress compared to A-T cells and iron chelat­
ing effect of quercetin which appears to preferentially effect 
A-T cells (20, above). Analysis of efficacy of quercetin or 
other flavonoids as orally active pharmacological agents to 
treat A-T must await such analyses in Atm-deficient mice. 
Since quercetin is also a copper chelator, we examined the 
relative toxicity of copper exposure on A-T and normal cells 
(Fig. 5). Copper was preferentially toxic to A-T cells, in­
dicating that a Fenton catalyst other than iron is toxic to 
A-T cells. However at high copper concentrations (30 and 
100 (JLM) the VA 13 cells exliibited greater colony formation 
inhibition than did the primary A-T cells (Fig. 5). This data 
and the observation that the Fed) elicited G% checkpoint 
response is AIM dependent [20] led us to examine the ef­
fects of other toxic metals on A-T cells. Here we demon­
strate that CuCl2, Pb acetate, NiCK and C'oCli also induce 
an ATM dependent G% checkpoint (Table 1). Thus, ATM is 
required for the checkpoint following exposure to toxic 
level of multiple metals. 
Interestingly, we observed a large amount of response 
variation between cell types used here. Currently we have 
no explanation for this variation. However, we found two 
general patterns of cellular behavior. First, the immortalized 
cells lines exliibited greater sensitivity to oxidative stress 
than did the corresponding wild type cells (i.e., AT22 vs. 
ATDM-1 and ATDM-2, and VA13 compared NHF1 cells). 
Also the VA13 cells exhibited greater colony formation in­
hibition at higher copper concentrations than was observed 
with the primary A-T cells (Fig. 5). Second, higher cellular 
sensitivity to /-BOOH correlated with a greater response iron 
chelators. Thus the AT22 cells, which exhibited high sen-
tivity to f-BOOH (Figs. 3 and 4), also exhibited the greatest 
response to iron chelators (Figs. 1-4). The molecular basis 
of this correlation is poorly understood, but appears to in­
volve an increased sensitivity to oxidative stress that follows 
cellular immortalization [34]. 
The molecular mechanism describing the effect of iron 
chelators on A-T could involve several factors. One of them 
could be dysregulated ferritin induction comparable to the 
p53 dysregulation seen in A-T [1], We think this is unlikely 
as in our hands induction of ferritin by FeClj was the same 
in pEBS7 and pEBS7-YZ5 cell lines and the sera of five 
individuals with A-T did not show altered ferritin levels. 
Additionally, the relatively modest increase in labile fenous 
iron seen in the plasma of the A-T mice (~1.05 p.M in 
Atm-deficient versus 50 nM in wild type mice), is too low 
to significantly impinge upon ferritin regulation. Another 
possibility is that while ferritin levels are comparatively 
normal in A-T, the chronic oxidative stress seen in A-T 
[11,12] may cause the release of labile iron from ferritin as 
has been previously seen for superoxide treated ferritin [33]. 
A simple model of the possible biochemical defect in A-T 
is shown in Fig. 7. Mitochondrial superoxide is catalyzed 
by superoxide dismutase to produce H2O2. Since catalase 
activity is often lower in A-T cells [9], this could lead to 
a relative increase in the H2O2 pool. H2O2 in the presence 
of the Fenton catalyst ferrous iron, would be converted to 
the highly toxic hydroxyl radical, causing cellular damage. 
Superoxide could also act to reduce ferric iron back to it 
ferrous form, thus allowing for a continuous supply of cat­
alyst. Thus a relatively small amount of labile iron could 
have a significant biological effect. Iron chelators would 
sequester labile iron and thereby block Fenton chemistry. 
Z X 
Mitochondrial 
Superoxide 
\ / 
W 
Superoxide 
Dismutase 
Hydroxyl Radical + Ferric Iron (Fc3<) 
Ferrous Iron (Fe2 
Catalase 
(often lower 
activity in A-T) 
Fig. 7. Model of possible ferrous iron activity and subsequent redox 
reactions in A-T cells. Mitochondrial function produces superoxide, which 
becomes H1O2 via superoxide dismutase (SOD) activity. Lowered catalase 
activity (often seen in A-T [9]X results in an increased pool of H2O2. 
which in turn becomes the toxic hydroxyl radical via the presence of 
ferrous iron acting as a Fenton catalyst (bold arrow). The ferric iron that 
results from the Fenton chemistry may be regenerated to fenous iron via 
reduction from superoxide. 
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Support for this model comes from the previous observa­
tion that increased Cu/Zn-superoxide dismutase expression 
in Atm-deficient mice actually exacerbated radiation sen­
sitivity and hematopoietic abnormalities [35]. Lastly, iron 
toxity has been linked to several nem ogenerative disorders, 
including Hallervorden-Spatz syndrome and Parkinson's, 
Alzheimer's, and Huntington's diseases, raising the possi­
bility that iron chelation may be used to treat these diseases 
[36]. Since oxidative stress plays an important role in Purk-
inje cell death in Atm-deficient mice [37] and labile iron 
is dysregulation in these mice, our data also suggests that 
blood-brain barrier crossing iron chelators may slow Purk-
inje cell death in A-T. 
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